WO2013165606A1 - Modulators of the relaxin receptor 1 - Google Patents
Modulators of the relaxin receptor 1 Download PDFInfo
- Publication number
- WO2013165606A1 WO2013165606A1 PCT/US2013/032231 US2013032231W WO2013165606A1 WO 2013165606 A1 WO2013165606 A1 WO 2013165606A1 US 2013032231 W US2013032231 W US 2013032231W WO 2013165606 A1 WO2013165606 A1 WO 2013165606A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- phenyl
- salt
- substituted
- Prior art date
Links
- 102100032444 Relaxin receptor 1 Human genes 0.000 title claims abstract description 31
- 101710095754 Relaxin receptor 1 Proteins 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 388
- 238000000034 method Methods 0.000 claims abstract description 272
- 230000036541 health Effects 0.000 claims abstract description 64
- 241000282414 Homo sapiens Species 0.000 claims abstract description 23
- 101000869643 Homo sapiens Relaxin receptor 1 Proteins 0.000 claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 197
- 150000003839 salts Chemical class 0.000 claims description 115
- 125000001424 substituent group Chemical group 0.000 claims description 115
- -1 tricycloalkyl Chemical group 0.000 claims description 109
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- 125000003545 alkoxy group Chemical group 0.000 claims description 66
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 53
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 45
- 239000007787 solid Substances 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 26
- 125000001188 haloalkyl group Chemical group 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 206010063837 Reperfusion injury Diseases 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 206010020772 Hypertension Diseases 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 230000004761 fibrosis Effects 0.000 claims description 11
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 9
- 230000035935 pregnancy Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 206010039710 Scleroderma Diseases 0.000 claims description 7
- 230000033115 angiogenesis Effects 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 230000029663 wound healing Effects 0.000 claims description 7
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 6
- 208000000059 Dyspnea Diseases 0.000 claims description 6
- 206010013975 Dyspnoeas Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 5
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 5
- 125000005605 benzo group Chemical group 0.000 claims description 5
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000004720 fertilization Effects 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 206010025135 lupus erythematosus Diseases 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 201000011461 pre-eclampsia Diseases 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010062553 Scleroderma renal crisis Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 208000021328 arterial occlusion Diseases 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 4
- 231100000517 death Toxicity 0.000 claims description 4
- 230000002357 endometrial effect Effects 0.000 claims description 4
- 230000001076 estrogenic effect Effects 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 125000006492 halo alkyl aryl group Chemical group 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 230000001631 hypertensive effect Effects 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000037805 labour Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 claims description 3
- 238000007634 remodeling Methods 0.000 claims description 3
- 230000005070 ripening Effects 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 206010001029 Acute pulmonary oedema Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000014181 Bronchial disease Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000027932 Collagen disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 2
- 208000005168 Intussusception Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000019395 Lactation disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 2
- 208000036622 Mesenteric occlusion Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 208000029549 Muscle injury Diseases 0.000 claims description 2
- 206010064584 Myosclerosis Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010028665 Myxoedema Diseases 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 208000008826 Obstetric Labor Complications Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 206010053159 Organ failure Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 206010034464 Periarthritis Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 208000004880 Polyuria Diseases 0.000 claims description 2
- 208000005107 Premature Birth Diseases 0.000 claims description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 206010062237 Renal impairment Diseases 0.000 claims description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 206010043647 Thrombotic Stroke Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- 206010054880 Vascular insufficiency Diseases 0.000 claims description 2
- 206010053648 Vascular occlusion Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 201000006449 West Nile encephalitis Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 238000002583 angiography Methods 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 2
- 230000003542 behavioural effect Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 238000007675 cardiac surgery Methods 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 claims description 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 230000035619 diuresis Effects 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 230000003073 embolic effect Effects 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 206010016629 fibroma Diseases 0.000 claims description 2
- 206010049444 fibromatosis Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 230000000004 hemodynamic effect Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 230000004410 intraocular pressure Effects 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 230000033001 locomotion Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 206010025482 malaise Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000001758 mesenteric vein Anatomy 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 208000003786 myxedema Diseases 0.000 claims description 2
- 230000015277 nipple development Effects 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 208000002865 osteopetrosis Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 230000028742 placenta development Effects 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000007232 portal hypertension Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 206010038464 renal hypertension Diseases 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 230000004263 retinal angiogenesis Effects 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 208000037905 systemic hypertension Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 230000009092 tissue dysfunction Effects 0.000 claims description 2
- 230000007838 tissue remodeling Effects 0.000 claims description 2
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 208000023577 vascular insufficiency disease Diseases 0.000 claims description 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000006485 halo alkoxy phenyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 71
- 230000015572 biosynthetic process Effects 0.000 description 204
- 238000003786 synthesis reaction Methods 0.000 description 204
- 230000014759 maintenance of location Effects 0.000 description 190
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 180
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 176
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 166
- 238000005160 1H NMR spectroscopy Methods 0.000 description 133
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 128
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 92
- 239000011541 reaction mixture Substances 0.000 description 91
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 84
- 238000004293 19F NMR spectroscopy Methods 0.000 description 81
- 125000004432 carbon atom Chemical group C* 0.000 description 77
- 239000000243 solution Substances 0.000 description 73
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
- 238000006243 chemical reaction Methods 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- 239000002904 solvent Substances 0.000 description 39
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 38
- 108090000103 Relaxin Proteins 0.000 description 27
- 102000003743 Relaxin Human genes 0.000 description 27
- 239000000047 product Substances 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- 239000002585 base Substances 0.000 description 25
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 238000004007 reversed phase HPLC Methods 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000012467 final product Substances 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 238000000746 purification Methods 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 17
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 239000002502 liposome Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 13
- MDKAAWDKKBFSTK-UHFFFAOYSA-N 2-ethoxybenzoyl chloride Chemical compound CCOC1=CC=CC=C1C(Cl)=O MDKAAWDKKBFSTK-UHFFFAOYSA-N 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 0 *C(NC(C(C(Nc1cccc(*)c1)=O)=CC=C1)=C*1O*)=O Chemical compound *C(NC(C(C(Nc1cccc(*)c1)=O)=CC=C1)=C*1O*)=O 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000012139 lysis buffer Substances 0.000 description 8
- 238000006722 reduction reaction Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- TVONCUQFOOJSCC-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 TVONCUQFOOJSCC-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 5
- LZYNHEOVZMLXIO-UHFFFAOYSA-N 3-(trifluoromethylsulfonyl)aniline Chemical compound NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 LZYNHEOVZMLXIO-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 101000869654 Homo sapiens Relaxin receptor 2 Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 102100032445 Relaxin receptor 2 Human genes 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000004982 aromatic amines Chemical class 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000013262 cAMP assay Methods 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- BKPKEVGJQMLUGA-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 BKPKEVGJQMLUGA-UHFFFAOYSA-N 0.000 description 3
- LNDWWXVPADKTJP-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-nitrophenyl)benzamide Chemical compound [O-][N+](=O)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 LNDWWXVPADKTJP-UHFFFAOYSA-N 0.000 description 3
- RIBAFLVCCDRKED-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-(3-iodophenyl)benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(I)=C1 RIBAFLVCCDRKED-UHFFFAOYSA-N 0.000 description 3
- RSYHJSDOGMSLDH-UHFFFAOYSA-N 2-[(2-propan-2-yloxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound CC(C)OC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 RSYHJSDOGMSLDH-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- RUHBCAVHAVRLGK-UHFFFAOYSA-N 2-amino-n-(furan-2-ylmethyl)benzamide Chemical compound NC1=CC=CC=C1C(=O)NCC1=CC=CO1 RUHBCAVHAVRLGK-UHFFFAOYSA-N 0.000 description 3
- OAEMTEMEJOQHES-UHFFFAOYSA-N 2-amino-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 OAEMTEMEJOQHES-UHFFFAOYSA-N 0.000 description 3
- GMQLXAUNKDGYKY-UHFFFAOYSA-N 2-amino-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 GMQLXAUNKDGYKY-UHFFFAOYSA-N 0.000 description 3
- MVIVDSWUOGNODP-UHFFFAOYSA-N 2-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1I MVIVDSWUOGNODP-UHFFFAOYSA-N 0.000 description 3
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 229910014263 BrF3 Inorganic materials 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000008378 aryl ethers Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 102000054524 human RXFP1 Human genes 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- QPAWIFTXULFVHM-UHFFFAOYSA-N methyl 2-[(2-iodobenzoyl)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=CC=C1I QPAWIFTXULFVHM-UHFFFAOYSA-N 0.000 description 3
- LDWIBUXEMKKIJJ-UHFFFAOYSA-N n-(3-bromophenyl)-2-(cyclohexanecarbonylamino)benzamide Chemical compound BrC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 LDWIBUXEMKKIJJ-UHFFFAOYSA-N 0.000 description 3
- IUCYEPWYFXUHHK-UHFFFAOYSA-N n-(3-cyanophenyl)-2-[(2-ethoxybenzoyl)amino]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C#N)=C1 IUCYEPWYFXUHHK-UHFFFAOYSA-N 0.000 description 3
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 3
- UVSAWKHRZLALIR-UHFFFAOYSA-N n-[2-amino-5-(trifluoromethyl)phenyl]-2-[(2-ethoxybenzoyl)amino]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC(C(F)(F)F)=CC=C1N UVSAWKHRZLALIR-UHFFFAOYSA-N 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FDHIJDLIJYNPPA-UHFFFAOYSA-N tert-butyl 4-[2-[2-[[3-(trifluoromethyl)phenyl]carbamoyl]phenoxy]ethyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CCOC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FDHIJDLIJYNPPA-UHFFFAOYSA-N 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 2
- BEKURLQQHGYDEB-UHFFFAOYSA-N 2-(2-ethoxyphenyl)-3-[4-(2h-tetrazol-5-yl)phenyl]quinazolin-4-one Chemical compound CCOC1=CC=CC=C1C1=NC2=CC=CC=C2C(=O)N1C1=CC=C(C2=NNN=N2)C=C1 BEKURLQQHGYDEB-UHFFFAOYSA-N 0.000 description 2
- NZNCPPMZUDTQKE-UHFFFAOYSA-N 2-(2-ethoxyphenyl)-n-[3-(trifluoromethylsulfonyl)phenyl]-1h-benzimidazole-4-carboxamide Chemical compound CCOC1=CC=CC=C1C1=NC2=C(C(=O)NC=3C=C(C=CC=3)S(=O)(=O)C(F)(F)F)C=CC=C2N1 NZNCPPMZUDTQKE-UHFFFAOYSA-N 0.000 description 2
- PGVVAPDKWDNFEU-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(2-methylphenyl)benzamide Chemical compound CC1=CC=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 PGVVAPDKWDNFEU-UHFFFAOYSA-N 0.000 description 2
- DCWHKHHRIOPSRX-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-ethynylphenyl)benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C#C)=C1 DCWHKHHRIOPSRX-UHFFFAOYSA-N 0.000 description 2
- MWYBCJUJEFNNHK-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-methoxyphenyl)benzamide Chemical compound COC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 MWYBCJUJEFNNHK-UHFFFAOYSA-N 0.000 description 2
- NHKINKUGDMROHT-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-methylsulfanylphenyl)benzamide Chemical compound CSC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 NHKINKUGDMROHT-UHFFFAOYSA-N 0.000 description 2
- LXNJJXKYVGMXQS-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-phenylphenyl)benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 LXNJJXKYVGMXQS-UHFFFAOYSA-N 0.000 description 2
- IFOLPHJXCLBTKP-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-thiophen-2-ylphenyl)benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NC(C=1)=CC=CC=1C1=CC=CS1 IFOLPHJXCLBTKP-UHFFFAOYSA-N 0.000 description 2
- RQHMBOSMNJPRFL-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(4-methylphenyl)benzamide Chemical compound C1=CC(C)=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 RQHMBOSMNJPRFL-UHFFFAOYSA-N 0.000 description 2
- JHZJADQGVUCBMO-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[2-(furan-2-ylmethylcarbamoyl)phenyl]benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NCC1=CC=CO1 JHZJADQGVUCBMO-UHFFFAOYSA-N 0.000 description 2
- WWKYBCSINPENOG-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-phenylbenzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WWKYBCSINPENOG-UHFFFAOYSA-N 0.000 description 2
- GEOVSWWZZYXULY-UHFFFAOYSA-N 2-[(2-but-3-enoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C=2C(=CC=CC=2)OCCC=C)=C1 GEOVSWWZZYXULY-UHFFFAOYSA-N 0.000 description 2
- ZSBZZBQUCHBLKN-UHFFFAOYSA-N 2-[(2-butoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound CCCCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 ZSBZZBQUCHBLKN-UHFFFAOYSA-N 0.000 description 2
- OFZSZTDSDMQFKK-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-(5-iodopyridin-3-yl)benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CN=CC(I)=C1 OFZSZTDSDMQFKK-UHFFFAOYSA-N 0.000 description 2
- XITBEQMXRBXUFN-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-(2h-tetrazol-5-yl)phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XITBEQMXRBXUFN-UHFFFAOYSA-N 0.000 description 2
- ZINWPUFMQUFWBV-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 ZINWPUFMQUFWBV-UHFFFAOYSA-N 0.000 description 2
- AESAYYDMRAGIAF-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]pyridine-3-carboxamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=NC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 AESAYYDMRAGIAF-UHFFFAOYSA-N 0.000 description 2
- PJKHPLDJDHQEAC-XCVCLJGOSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-[(e)-prop-1-enyl]phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(\C=C\C)=C1 PJKHPLDJDHQEAC-XCVCLJGOSA-N 0.000 description 2
- QXEFABXNOOOUHO-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-pyridin-4-ylbenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=NC=C1 QXEFABXNOOOUHO-UHFFFAOYSA-N 0.000 description 2
- XYPPDWVHCXDHKJ-UHFFFAOYSA-N 2-[(2-ethylsulfanylbenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound CCSC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 XYPPDWVHCXDHKJ-UHFFFAOYSA-N 0.000 description 2
- LIJPVQZEFXCHRY-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-(3-methylsulfonylphenyl)benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(C)(=O)=O)=C1 LIJPVQZEFXCHRY-UHFFFAOYSA-N 0.000 description 2
- ARGWKCNXOVDSJY-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 ARGWKCNXOVDSJY-UHFFFAOYSA-N 0.000 description 2
- HKYGEYKIJGMDPZ-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 HKYGEYKIJGMDPZ-UHFFFAOYSA-N 0.000 description 2
- CRPYCUOWNPLURT-UHFFFAOYSA-N 2-[(2-propoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound CCCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 CRPYCUOWNPLURT-UHFFFAOYSA-N 0.000 description 2
- IJPVGGQIVOIEAF-UHFFFAOYSA-N 2-[[2-(2,2,2-trifluoroethoxy)benzoyl]amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound FC(F)(F)COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 IJPVGGQIVOIEAF-UHFFFAOYSA-N 0.000 description 2
- RTFQXLGSOALNDT-UHFFFAOYSA-N 2-[[3-(trifluoromethylsulfonyl)anilino]methyl]aniline Chemical compound NC1=CC=CC=C1CNC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 RTFQXLGSOALNDT-UHFFFAOYSA-N 0.000 description 2
- DORHQWBAPHXLJL-UHFFFAOYSA-N 2-benzamido-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C=2C=CC=CC=2)=C1 DORHQWBAPHXLJL-UHFFFAOYSA-N 0.000 description 2
- NZCKTGCKFJDGFD-UHFFFAOYSA-N 2-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Br NZCKTGCKFJDGFD-UHFFFAOYSA-N 0.000 description 2
- BIFZMIPCHICOOS-UHFFFAOYSA-N 2-but-3-enoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OCCC=C BIFZMIPCHICOOS-UHFFFAOYSA-N 0.000 description 2
- DSOQQJJRBWCBHZ-UHFFFAOYSA-N 2-ethoxy-n-[2-[[3-(trifluoromethylsulfonyl)anilino]methyl]phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1CNC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 DSOQQJJRBWCBHZ-UHFFFAOYSA-N 0.000 description 2
- RDZQJHJGFJTREC-UHFFFAOYSA-N 2-methoxy-n-[3-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 RDZQJHJGFJTREC-UHFFFAOYSA-N 0.000 description 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 2
- IASBMUIXBJNMDW-UHFFFAOYSA-N 4-aminonicotinic acid Chemical compound NC1=CC=NC=C1C(O)=O IASBMUIXBJNMDW-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N Cc1cccnc1C Chemical compound Cc1cccnc1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229910020323 ClF3 Inorganic materials 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101100476455 Mus musculus Rxfp1 gene Proteins 0.000 description 2
- 101100115713 Mus musculus Stfa3 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001503 aryl iodides Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- CJYQQUPRURWLOW-YDLUHMIOSA-M dmsc Chemical compound [Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O CJYQQUPRURWLOW-YDLUHMIOSA-M 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- PMJPOAPHRLHWHJ-UHFFFAOYSA-N ethyl 2-but-3-enoxybenzoate Chemical compound CCOC(=O)C1=CC=CC=C1OCCC=C PMJPOAPHRLHWHJ-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XLYUKWSGXILQAP-UHFFFAOYSA-N methyl 2-[(2-methoxybenzoyl)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=CC=C1OC XLYUKWSGXILQAP-UHFFFAOYSA-N 0.000 description 2
- QVVSWCFFYNYALO-UHFFFAOYSA-N methyl 2-[(2-propan-2-yloxybenzoyl)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=CC=C1OC(C)C QVVSWCFFYNYALO-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- CWZZSRWZIBKKOY-UHFFFAOYSA-N n-(3-chlorophenyl)-2-(cyclohexanecarbonylamino)benzamide Chemical compound ClC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 CWZZSRWZIBKKOY-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000008327 renal blood flow Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- VEQVMIVTFODWSW-UHFFFAOYSA-N tert-butyl N-[2-[[3-(trifluoromethylsulfanyl)phenyl]carbamoyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)Nc1ccccc1C(=O)Nc1cccc(SC(F)(F)F)c1 VEQVMIVTFODWSW-UHFFFAOYSA-N 0.000 description 2
- KCWUAYRGXBSECV-UHFFFAOYSA-N tert-butyl N-[2-[[3-(trifluoromethylsulfonyl)phenyl]carbamoyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)Nc1ccccc1C(=O)Nc1cccc(c1)S(=O)(=O)C(F)(F)F KCWUAYRGXBSECV-UHFFFAOYSA-N 0.000 description 2
- DHALMIBUKCNMLD-UHFFFAOYSA-N tert-butyl n-(2-formylphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C=O DHALMIBUKCNMLD-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 2
- 230000006492 vascular dysfunction Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- PHNQGEQNNUOSNH-UHFFFAOYSA-N 1,2,4-trifluoro-3-iodobenzene Chemical compound FC1=CC=C(F)C(I)=C1F PHNQGEQNNUOSNH-UHFFFAOYSA-N 0.000 description 1
- DSIBSRXKQRYPJP-UHFFFAOYSA-N 1,2-oxazole-5-carboxamide Chemical compound NC(=O)C1=CC=NO1 DSIBSRXKQRYPJP-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KKTUQAYCCLMNOA-UHFFFAOYSA-M 2,3-diaminobenzoate Chemical compound NC1=CC=CC(C([O-])=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-M 0.000 description 1
- FWABSMRBOKADMR-UHFFFAOYSA-N 2,6-dimethoxy-n-[2-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]benzamide Chemical compound COC1=CC=CC(OC)=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FWABSMRBOKADMR-UHFFFAOYSA-N 0.000 description 1
- TVOTZIGTEZBARS-UHFFFAOYSA-N 2-(2-ethylbutanoylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CCC(CC)C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 TVOTZIGTEZBARS-UHFFFAOYSA-N 0.000 description 1
- ITTXELWEQXTYBP-UHFFFAOYSA-N 2-(2-methoxyanilino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 ITTXELWEQXTYBP-UHFFFAOYSA-N 0.000 description 1
- OSIPEROMDOYCCO-UHFFFAOYSA-N 2-(2-methoxyethoxy)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COCCOC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 OSIPEROMDOYCCO-UHFFFAOYSA-N 0.000 description 1
- GGPKGBYGOWNVIC-UHFFFAOYSA-N 2-(2-methoxyethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COCCNC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 GGPKGBYGOWNVIC-UHFFFAOYSA-N 0.000 description 1
- WKTRNQDYHNQMDX-UHFFFAOYSA-N 2-(cyclobutanecarbonylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCC2)=C1 WKTRNQDYHNQMDX-UHFFFAOYSA-N 0.000 description 1
- ZIJYNENFPVRHKA-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(1h-indol-5-yl)benzamide Chemical compound C=1C=CC=C(C(=O)NC=2C=C3C=CNC3=CC=2)C=1NC(=O)C1CCCCC1 ZIJYNENFPVRHKA-UHFFFAOYSA-N 0.000 description 1
- YTCMGDQCZVSTII-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(2,3-dihydro-1h-inden-5-yl)benzamide Chemical compound C=1C=CC=C(C(=O)NC=2C=C3CCCC3=CC=2)C=1NC(=O)C1CCCCC1 YTCMGDQCZVSTII-UHFFFAOYSA-N 0.000 description 1
- BGMWOQMILDJTIN-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(2-nitrophenyl)benzamide Chemical compound [O-][N+](=O)C1=CC=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 BGMWOQMILDJTIN-UHFFFAOYSA-N 0.000 description 1
- WEINUQXTFVPWAY-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-fluorophenyl)benzamide Chemical compound FC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 WEINUQXTFVPWAY-UHFFFAOYSA-N 0.000 description 1
- JCZMZWBTSUFZAD-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-iodophenyl)benzamide Chemical compound IC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 JCZMZWBTSUFZAD-UHFFFAOYSA-N 0.000 description 1
- BMWMGZYVMLAKPI-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-methylsulfonylphenyl)benzamide Chemical compound CS(=O)(=O)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 BMWMGZYVMLAKPI-UHFFFAOYSA-N 0.000 description 1
- GTQKCHJYBYNNAR-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-piperidin-1-ylphenyl)benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NC(C=1)=CC=CC=1N1CCCCC1 GTQKCHJYBYNNAR-UHFFFAOYSA-N 0.000 description 1
- APGOHRPTJLNZEH-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(3-propan-2-ylphenyl)benzamide Chemical compound CC(C)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 APGOHRPTJLNZEH-UHFFFAOYSA-N 0.000 description 1
- DKCDCNHMGHPACV-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 DKCDCNHMGHPACV-UHFFFAOYSA-N 0.000 description 1
- BIJIXDFAKGOEML-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(4-methoxyphenyl)benzamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 BIJIXDFAKGOEML-UHFFFAOYSA-N 0.000 description 1
- XLMBIGKMXAKTMS-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(4-nitrophenyl)benzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 XLMBIGKMXAKTMS-UHFFFAOYSA-N 0.000 description 1
- TUPODPRJKNTXCJ-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(furan-2-ylmethyl)benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NCC1=CC=CO1 TUPODPRJKNTXCJ-UHFFFAOYSA-N 0.000 description 1
- BNZOKFJIZHNIAD-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-(thiophen-2-ylmethyl)benzamide Chemical compound C1CCCCC1C(=O)NC1=CC=CC=C1C(=O)NCC1=CC=CS1 BNZOKFJIZHNIAD-UHFFFAOYSA-N 0.000 description 1
- VNIILJHKBSLKCO-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[(5-methylfuran-2-yl)methyl]benzamide Chemical compound O1C(C)=CC=C1CNC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 VNIILJHKBSLKCO-UHFFFAOYSA-N 0.000 description 1
- VULKPKSAGRKXDW-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 VULKPKSAGRKXDW-UHFFFAOYSA-N 0.000 description 1
- ZGULDRFPHZVIGF-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[3-(trifluoromethylsulfanyl)phenyl]benzamide Chemical compound FC(F)(F)SC1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 ZGULDRFPHZVIGF-UHFFFAOYSA-N 0.000 description 1
- JCCHAOMTEAVGSL-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 JCCHAOMTEAVGSL-UHFFFAOYSA-N 0.000 description 1
- VNXLCRZLATUWJC-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[3-[2-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC=C1C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 VNXLCRZLATUWJC-UHFFFAOYSA-N 0.000 description 1
- AOCJPMMPZBUYOG-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[3-[3-(trifluoromethyl)phenyl]phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(C=2C=C(NC(=O)C=3C(=CC=CC=3)NC(=O)C3CCCCC3)C=CC=2)=C1 AOCJPMMPZBUYOG-UHFFFAOYSA-N 0.000 description 1
- KASDOQIVMVIPKZ-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 KASDOQIVMVIPKZ-UHFFFAOYSA-N 0.000 description 1
- PVWASZAUCMLNNR-UHFFFAOYSA-N 2-(cyclohexanecarbonylamino)-n-[[3-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CNC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 PVWASZAUCMLNNR-UHFFFAOYSA-N 0.000 description 1
- JYEJTVKTNKWOTM-UHFFFAOYSA-N 2-(cyclopentanecarbonylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCC2)=C1 JYEJTVKTNKWOTM-UHFFFAOYSA-N 0.000 description 1
- KGUJFARQLOGYHU-UHFFFAOYSA-N 2-(furan-2-carbonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC(=O)C1=CC=CO1 KGUJFARQLOGYHU-UHFFFAOYSA-N 0.000 description 1
- MLWQRRGIZDDKQR-UHFFFAOYSA-N 2-(pentanoylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CCCCC(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 MLWQRRGIZDDKQR-UHFFFAOYSA-N 0.000 description 1
- SSZGFAXEFRIGMM-UHFFFAOYSA-N 2-[(2-chlorobenzoyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C=2C(=CC=CC=2)Cl)=C1 SSZGFAXEFRIGMM-UHFFFAOYSA-N 0.000 description 1
- HMUUFDCCBCUQAV-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 HMUUFDCCBCUQAV-UHFFFAOYSA-N 0.000 description 1
- RKKFLQWZFINRIZ-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]thiophene-3-carboxamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=C(C(=O)NC=2C=C(C=CC=2)S(=O)(=O)C(F)(F)F)C=CS1 RKKFLQWZFINRIZ-UHFFFAOYSA-N 0.000 description 1
- PJKHPLDJDHQEAC-KMKOMSMNSA-N 2-[(2-ethoxybenzoyl)amino]-n-[3-[(z)-prop-1-enyl]phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(\C=C/C)=C1 PJKHPLDJDHQEAC-KMKOMSMNSA-N 0.000 description 1
- DQUXVVWCJGWORL-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-pyridin-2-ylbenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC=N1 DQUXVVWCJGWORL-UHFFFAOYSA-N 0.000 description 1
- GDBOFDPYYUABPK-UHFFFAOYSA-N 2-[(2-ethoxybenzoyl)amino]-n-pyridin-3-ylbenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CN=C1 GDBOFDPYYUABPK-UHFFFAOYSA-N 0.000 description 1
- GXVNJYCNFDGQPG-UHFFFAOYSA-N 2-[(2-ethoxyphenyl)sulfonylamino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound CCOC1=CC=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 GXVNJYCNFDGQPG-UHFFFAOYSA-N 0.000 description 1
- LDCQQZUEHIHAPV-UHFFFAOYSA-N 2-[(2-iodobenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]benzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C=2C(=CC=CC=2)I)=C1 LDCQQZUEHIHAPV-UHFFFAOYSA-N 0.000 description 1
- VPFSPGAKTAETCS-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)-methylamino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)N(C)C1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 VPFSPGAKTAETCS-UHFFFAOYSA-N 0.000 description 1
- YYVKYTJHQVRFHP-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)-methylamino]-n-methyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)N(C)C1=CC=CC=C1C(=O)N(C)C1=CC=CC(C(F)(F)F)=C1 YYVKYTJHQVRFHP-UHFFFAOYSA-N 0.000 description 1
- BGBUREGPNUSDAF-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-(3-methylsulfanylphenyl)benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(SC)=C1 BGBUREGPNUSDAF-UHFFFAOYSA-N 0.000 description 1
- OGVANAALBWFWBB-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-(3-piperidin-1-ylphenyl)benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(N2CCCCC2)=C1 OGVANAALBWFWBB-UHFFFAOYSA-N 0.000 description 1
- AJOKZAOFKVFHJQ-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-(3-thiophen-2-ylphenyl)benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C=2SC=CC=2)=C1 AJOKZAOFKVFHJQ-UHFFFAOYSA-N 0.000 description 1
- WKMAMLDILPQFKC-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-[3-(trifluoromethylsulfanyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(SC(F)(F)F)=C1 WKMAMLDILPQFKC-UHFFFAOYSA-N 0.000 description 1
- MEWLWAUKTRIWNA-UHFFFAOYSA-N 2-[(2-methoxybenzoyl)amino]-n-methyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)N(C)C1=CC=CC(C(F)(F)F)=C1 MEWLWAUKTRIWNA-UHFFFAOYSA-N 0.000 description 1
- OWTGUVUPCCNKCM-UHFFFAOYSA-N 2-[(2-methoxyphenyl)methylamino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC=C1CNC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 OWTGUVUPCCNKCM-UHFFFAOYSA-N 0.000 description 1
- UNYRSFZLRLCZHD-UHFFFAOYSA-N 2-[(2-phenylacetyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)CC=2C=CC=CC=2)=C1 UNYRSFZLRLCZHD-UHFFFAOYSA-N 0.000 description 1
- GBOROWPKNUMZDL-UHFFFAOYSA-N 2-[(2-propan-2-yloxybenzoyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CC(C)OC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 GBOROWPKNUMZDL-UHFFFAOYSA-N 0.000 description 1
- MHMUKLZACPVPGL-UHFFFAOYSA-N 2-[(3-methoxybenzoyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 MHMUKLZACPVPGL-UHFFFAOYSA-N 0.000 description 1
- PQZVYXIEAFYJOW-UHFFFAOYSA-N 2-[(4-methoxybenzoyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 PQZVYXIEAFYJOW-UHFFFAOYSA-N 0.000 description 1
- JHZCRMBSMXIHFD-UHFFFAOYSA-N 2-[(4-methylcyclohexanecarbonyl)amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1CC(C)CCC1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 JHZCRMBSMXIHFD-UHFFFAOYSA-N 0.000 description 1
- JOBVMXATFOWLBC-UHFFFAOYSA-N 2-[[2-(2-methoxyethoxy)benzoyl]amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound COCCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 JOBVMXATFOWLBC-UHFFFAOYSA-N 0.000 description 1
- LAYCDJVGDJWSGO-UHFFFAOYSA-N 2-[[2-(trifluoromethoxy)benzoyl]amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)OC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 LAYCDJVGDJWSGO-UHFFFAOYSA-N 0.000 description 1
- URLHCOVSCABDQW-UHFFFAOYSA-N 2-[[2-[2-(dimethylamino)ethoxy]benzoyl]amino]-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CN(C)CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 URLHCOVSCABDQW-UHFFFAOYSA-N 0.000 description 1
- POAWRLMAPXTHNV-UHFFFAOYSA-N 2-amino-3-[(2-ethoxybenzoyl)amino]benzoic acid Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC(C(O)=O)=C1N POAWRLMAPXTHNV-UHFFFAOYSA-N 0.000 description 1
- CICQVRULEXWWCJ-UHFFFAOYSA-N 2-bromo-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)Br)=C1 CICQVRULEXWWCJ-UHFFFAOYSA-N 0.000 description 1
- IQYRWZAYIWGNRM-UHFFFAOYSA-N 2-ethoxy-n-[2-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]phenyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C1=NC2=CC=C(C(F)(F)F)C=C2N1 IQYRWZAYIWGNRM-UHFFFAOYSA-N 0.000 description 1
- DUQHXONJPUNVQL-UHFFFAOYSA-N 2-ethoxy-n-[3-oxo-3-[3-(trifluoromethylsulfonyl)anilino]propyl]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NCCC(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 DUQHXONJPUNVQL-UHFFFAOYSA-N 0.000 description 1
- RWURYJNJYODVAL-UHFFFAOYSA-N 2-ethoxybenzenesulfonyl chloride Chemical compound CCOC1=CC=CC=C1S(Cl)(=O)=O RWURYJNJYODVAL-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- DRSKOQLOPZOSTH-UHFFFAOYSA-N 2-methoxy-n-[4-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CC=C(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)C=C1 DRSKOQLOPZOSTH-UHFFFAOYSA-N 0.000 description 1
- RGDYELOMVIBUPS-UHFFFAOYSA-N 2-methyl-n-[2-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]benzamide Chemical compound CC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 RGDYELOMVIBUPS-UHFFFAOYSA-N 0.000 description 1
- XPWMIGFSEWFXEZ-UHFFFAOYSA-N 2-prop-2-enoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OCC=C XPWMIGFSEWFXEZ-UHFFFAOYSA-N 0.000 description 1
- CIYMDTDRZWFTTL-UHFFFAOYSA-N 2-propan-2-yloxybenzoyl chloride Chemical compound CC(C)OC1=CC=CC=C1C(Cl)=O CIYMDTDRZWFTTL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SFDGJDBLYNJMFI-UHFFFAOYSA-N 3,1-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)OC=NC2=C1 SFDGJDBLYNJMFI-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- DENPAKQJZNDKEL-UHFFFAOYSA-N 3-(trifluoromethylsulfanyl)aniline Chemical compound NC1=CC=CC(SC(F)(F)F)=C1 DENPAKQJZNDKEL-UHFFFAOYSA-N 0.000 description 1
- FRUFALLSBQQWOU-UHFFFAOYSA-N 3-[(2-ethoxybenzoyl)amino]-N-[3-(trifluoromethylsulfonyl)phenyl]pyridine-2-carboxamide Chemical compound CCOc1ccccc1C(=O)Nc1cccnc1C(=O)Nc1cccc(c1)S(=O)(=O)C(F)(F)F FRUFALLSBQQWOU-UHFFFAOYSA-N 0.000 description 1
- LUHLWDKNIPZDPF-UHFFFAOYSA-N 3-[(2-ethoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]pyridine-4-carboxamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CN=CC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 LUHLWDKNIPZDPF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MOQVHOPVBREXLY-UHFFFAOYSA-N 3h-dioxol-4-ylmethanol Chemical compound OCC1=COOC1 MOQVHOPVBREXLY-UHFFFAOYSA-N 0.000 description 1
- LWIJLQNVGBWKFD-UHFFFAOYSA-N 4-[(2-ethoxybenzoyl)amino]-n-[3-(trifluoromethylsulfonyl)phenyl]pyridine-3-carboxamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=NC=C1C(=O)NC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 LWIJLQNVGBWKFD-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- AOKZYKXOUXQPJD-UHFFFAOYSA-N 4-bromobenzoyl bromide Chemical compound BrC(=O)C1=CC=C(Br)C=C1 AOKZYKXOUXQPJD-UHFFFAOYSA-N 0.000 description 1
- DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- VKELSQNRSVJHGR-UHFFFAOYSA-N 4-oxo-4-sulfooxybutanoic acid Chemical class OC(=O)CCC(=O)OS(O)(=O)=O VKELSQNRSVJHGR-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KOQRHYYPTOZFGC-UHFFFAOYSA-N 6-(2-ethoxyphenyl)-10-(trifluoromethyl)benzimidazolo[1,2-c]quinazoline Chemical compound CCOC1=CC=CC=C1C1=NC2=CC=CC=C2C2=NC3=CC(C(F)(F)F)=CC=C3N12 KOQRHYYPTOZFGC-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ZPJBSWJZELXZKA-UHFFFAOYSA-N 7-amino-2,3-dihydroisoindol-1-one Chemical compound NC1=CC=CC2=C1C(=O)NC2 ZPJBSWJZELXZKA-UHFFFAOYSA-N 0.000 description 1
- YPUYHGBUEFDFTA-UHFFFAOYSA-N 7-amino-2-[3-(trifluoromethyl)phenyl]-3h-isoindol-1-one Chemical compound O=C1C=2C(N)=CC=CC=2CN1C1=CC=CC(C(F)(F)F)=C1 YPUYHGBUEFDFTA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical compound C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- YDGQFXXVXYOGKH-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(CCOC)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCOC)CC1)=O YDGQFXXVXYOGKH-UHFFFAOYSA-N 0.000 description 1
- KNCALNRRKAXEBE-UHFFFAOYSA-N CCOC(c1cc(NC(c2ccccc2OC)=O)ccc1)=O Chemical compound CCOC(c1cc(NC(c2ccccc2OC)=O)ccc1)=O KNCALNRRKAXEBE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- PIGNSYZNAFHAAD-UHFFFAOYSA-N Cc1cc(C(Nc(cccc2)c2C(Nc2cccc(C(F)(F)F)c2)=O)=O)ccc1 Chemical compound Cc1cc(C(Nc(cccc2)c2C(Nc2cccc(C(F)(F)F)c2)=O)=O)ccc1 PIGNSYZNAFHAAD-UHFFFAOYSA-N 0.000 description 1
- NURQLCJSMXZBPC-UHFFFAOYSA-N Cc1ccncc1C Chemical compound Cc1ccncc1C NURQLCJSMXZBPC-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101001091094 Homo sapiens Prorelaxin H1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102100033262 Insulin-like 3 Human genes 0.000 description 1
- 108091012778 Insulin-like 3 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- JRQZGOAGCBXTOB-UHFFFAOYSA-N O=C(C1(CC(C2)C3)CC3CC2C1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O Chemical compound O=C(C1(CC(C2)C3)CC3CC2C1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O JRQZGOAGCBXTOB-UHFFFAOYSA-N 0.000 description 1
- DLHYBJOKFUWQFK-UHFFFAOYSA-N O=C(C1CC1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O Chemical compound O=C(C1CC1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O DLHYBJOKFUWQFK-UHFFFAOYSA-N 0.000 description 1
- DCPSZYAYVXUKLL-UHFFFAOYSA-N O=C(C1CCCCC1)Nc(cccc1)c1C(Nc1ccc2OCOc2c1)=O Chemical compound O=C(C1CCCCC1)Nc(cccc1)c1C(Nc1ccc2OCOc2c1)=O DCPSZYAYVXUKLL-UHFFFAOYSA-N 0.000 description 1
- UIGYPEKKGRVRLM-UHFFFAOYSA-N O=C(c1ccc[o]1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O Chemical compound O=C(c1ccc[o]1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O UIGYPEKKGRVRLM-UHFFFAOYSA-N 0.000 description 1
- AYJGMYMIIVLLRL-UHFFFAOYSA-N O=C(c1ccncc1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O Chemical compound O=C(c1ccncc1)Nc1ccccc1C(Nc1cccc(C(F)(F)F)c1)=O AYJGMYMIIVLLRL-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102100034945 Prorelaxin H1 Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000004215 Relaxin receptors Human genes 0.000 description 1
- 108090000728 Relaxin receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910019891 RuCl3 Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Chemical group 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- CBMCZKMIOZYAHS-NSCUHMNNSA-N [(e)-prop-1-enyl]boronic acid Chemical compound C\C=C\B(O)O CBMCZKMIOZYAHS-NSCUHMNNSA-N 0.000 description 1
- CBMCZKMIOZYAHS-IHWYPQMZSA-N [(z)-prop-1-enyl]boronic acid Chemical compound C\C=C/B(O)O CBMCZKMIOZYAHS-IHWYPQMZSA-N 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- NVQMLNHOFAMSPZ-UHFFFAOYSA-N adamantane-1-carboxamide Chemical compound C1C(C2)CC3CC2CC1(C(=O)N)C3.C1C(C2)CC3CC2CC1(C(=O)N)C3 NVQMLNHOFAMSPZ-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003206 anti-remodeling effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- QJVFPOMUIKCQED-UHFFFAOYSA-N cycloheptanecarboxamide Chemical compound NC(=O)C1CCCCCC1 QJVFPOMUIKCQED-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MKJQYFVTEPGXIE-UHFFFAOYSA-N ethyl 2-aminothiophene-3-carboxylate Chemical compound CCOC(=O)C=1C=CSC=1N MKJQYFVTEPGXIE-UHFFFAOYSA-N 0.000 description 1
- JZJINEBAULMTGE-UHFFFAOYSA-N ethyl 3-[(2-ethoxybenzoyl)amino]propanoate Chemical compound CCOC(=O)CCNC(=O)C1=CC=CC=C1OCC JZJINEBAULMTGE-UHFFFAOYSA-N 0.000 description 1
- NJMHKZSCCRDZAP-UHFFFAOYSA-N ethyl 4-[(2-methoxybenzoyl)amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)C1=CC=CC=C1OC NJMHKZSCCRDZAP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940063699 lanoxin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 description 1
- 229960002248 meradimate Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- NRHLZBZGTWXJSJ-UHFFFAOYSA-N methyl 2-(2-ethoxyphenyl)-1h-benzimidazole-4-carboxylate Chemical compound CCOC1=CC=CC=C1C1=NC2=C(C(=O)OC)C=CC=C2N1 NRHLZBZGTWXJSJ-UHFFFAOYSA-N 0.000 description 1
- JLNLMMVZLYNRSB-UHFFFAOYSA-N methyl 2-(cyclohexanecarbonylamino)benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 JLNLMMVZLYNRSB-UHFFFAOYSA-N 0.000 description 1
- KDYJZZRGSCMQNQ-UHFFFAOYSA-N methyl 2-(furan-2-carbonylamino)benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C1=CC=CO1 KDYJZZRGSCMQNQ-UHFFFAOYSA-N 0.000 description 1
- GWANJQJHFQHVAP-UHFFFAOYSA-N methyl 2-[(2-ethoxybenzoyl)amino]benzoate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)OC GWANJQJHFQHVAP-UHFFFAOYSA-N 0.000 description 1
- YZWLPNMAFVTZMZ-UHFFFAOYSA-N methyl 2-[(2-ethoxybenzoyl)amino]pyridine-3-carboxylate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=NC=CC=C1C(=O)OC YZWLPNMAFVTZMZ-UHFFFAOYSA-N 0.000 description 1
- VDMUPXLTEMZULX-UHFFFAOYSA-N methyl 2-[(2-ethoxybenzoyl)amino]thiophene-3-carboxylate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=C(C(=O)OC)C=CS1 VDMUPXLTEMZULX-UHFFFAOYSA-N 0.000 description 1
- TWTMZNWXKANWBW-UHFFFAOYSA-N methyl 2-[(2-ethoxyphenyl)sulfonylamino]benzoate Chemical compound CCOC1=CC=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)OC TWTMZNWXKANWBW-UHFFFAOYSA-N 0.000 description 1
- ZNXSHWAMGDNJJV-UHFFFAOYSA-N methyl 2-[(2-methoxybenzoyl)-methylamino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N(C)C(=O)C1=CC=CC=C1OC ZNXSHWAMGDNJJV-UHFFFAOYSA-N 0.000 description 1
- UAABTYHDQGBHLJ-UHFFFAOYSA-N methyl 2-amino-3-[(2-ethoxybenzoyl)amino]benzoate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC(C(=O)OC)=C1N UAABTYHDQGBHLJ-UHFFFAOYSA-N 0.000 description 1
- KBOHJWZDJFMNMJ-UHFFFAOYSA-N methyl 3-[(2-ethoxybenzoyl)amino]pyridine-2-carboxylate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CN=C1C(=O)OC KBOHJWZDJFMNMJ-UHFFFAOYSA-N 0.000 description 1
- PZVZPDAUAUADOA-UHFFFAOYSA-N methyl 3-[(2-ethoxybenzoyl)amino]pyridine-4-carboxylate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CN=CC=C1C(=O)OC PZVZPDAUAUADOA-UHFFFAOYSA-N 0.000 description 1
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 1
- YQKTYFNLRUWQFV-UHFFFAOYSA-N methyl 3-aminopyridine-2-carboxylate Chemical compound COC(=O)C1=NC=CC=C1N YQKTYFNLRUWQFV-UHFFFAOYSA-N 0.000 description 1
- XLQIGLBALJNHKR-UHFFFAOYSA-N methyl 3-aminopyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1N XLQIGLBALJNHKR-UHFFFAOYSA-N 0.000 description 1
- AXLLDIAPHDWTRH-UHFFFAOYSA-N methyl 4-[(2-ethoxybenzoyl)amino]pyridine-3-carboxylate Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=NC=C1C(=O)OC AXLLDIAPHDWTRH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- RYJPRHANKQDROH-UHFFFAOYSA-N n-(2-bromophenyl)-2-(cyclohexanecarbonylamino)benzamide Chemical compound BrC1=CC=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 RYJPRHANKQDROH-UHFFFAOYSA-N 0.000 description 1
- BCLONUXXYULIDN-UHFFFAOYSA-N n-(3-carbamimidoylphenyl)-2-[(2-ethoxybenzoyl)amino]benzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(N)=N)=C1 BCLONUXXYULIDN-UHFFFAOYSA-N 0.000 description 1
- MBQHKCIVBQDLMD-UHFFFAOYSA-N n-(3-tert-butylphenyl)-2-(cyclohexanecarbonylamino)benzamide Chemical compound CC(C)(C)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCC2)=C1 MBQHKCIVBQDLMD-UHFFFAOYSA-N 0.000 description 1
- HFKJIUZNICBOTK-UHFFFAOYSA-N n-(4-bromophenyl)-2-(cyclohexanecarbonylamino)benzamide Chemical compound C1=CC(Br)=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 HFKJIUZNICBOTK-UHFFFAOYSA-N 0.000 description 1
- JIHJJSAEROQZIB-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(cyclohexanecarbonylamino)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CC=C1NC(=O)C1CCCCC1 JIHJJSAEROQZIB-UHFFFAOYSA-N 0.000 description 1
- IGBGUJLKLDHVJU-UHFFFAOYSA-N n-[2-[[2-(furan-2-ylmethylcarbamoyl)phenyl]carbamoyl]phenyl]furan-2-carboxamide Chemical compound C=1C=COC=1C(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC=C1C(=O)NCC1=CC=CO1 IGBGUJLKLDHVJU-UHFFFAOYSA-N 0.000 description 1
- IIWZJZLNNDCNKN-UHFFFAOYSA-N n-[2-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]cycloheptanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C2CCCCCC2)=C1 IIWZJZLNNDCNKN-UHFFFAOYSA-N 0.000 description 1
- CABLZLANVVFNQB-UHFFFAOYSA-N n-[2-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NC(=O)C=2C=NC=CC=2)=C1 CABLZLANVVFNQB-UHFFFAOYSA-N 0.000 description 1
- BYYDJJPFOMWFLW-UHFFFAOYSA-N n-[3-(trifluoromethyl)phenyl]-2-[[3-(trifluoromethyl)phenyl]methylamino]benzamide Chemical compound FC(F)(F)C1=CC=CC(CNC=2C(=CC=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 BYYDJJPFOMWFLW-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- QQAMZZFIHGASEX-UHFFFAOYSA-N tert-butyl n-[2-(hydroxymethyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1CO QQAMZZFIHGASEX-UHFFFAOYSA-N 0.000 description 1
- QZZGHRJQYFJJOS-UHFFFAOYSA-N tert-butyl n-[2-[[3-(trifluoromethyl)phenyl]carbamoyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 QZZGHRJQYFJJOS-UHFFFAOYSA-N 0.000 description 1
- LJEJHRFPKLIIHD-UHFFFAOYSA-N tert-butyl n-[2-[[3-(trifluoromethylsulfonyl)anilino]methyl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1CNC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 LJEJHRFPKLIIHD-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- GSQBIOQCECCMOQ-UHFFFAOYSA-N β-alanine ethyl ester Chemical class CCOC(=O)CCN GSQBIOQCECCMOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/04—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/42—Y being a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- the peptide hormone relaxin was discovered in 1926 as a hormone of pregnancy, due to its effects to relax pubic ligaments and soften the cervix to facilitate parturition (Hisaw, F ., Proc. Soc. Exp. Biol. Med. 1926, 23(8), 661-663; Fevold. H.L. et al, J. Am. Chem. Soc. 1930, 52(8), 3340-3348). Since then, it has been shown that blood concentrations of relaxin rise during the first trimester of pregnancy, promoting cardiovascular and renal adjustments to meet the increased nutritional demands of the growing fetus, and the elevated requirements for renal clearance of metabolic wastes (Baylis. C, Am. J. Kidney Dis.
- Relaxin induces a 20% increase in cardiac output, 30% decrease in systemic vascular resistance, 30% increase in global arterial compliance, and 45% increase in renal blood flow during pregnancy (Schrier, R. W. et al, Am. J. Kidney Dis. 1987, 9, 284-9).
- ICDs implantable cardioverter- defibrillators
- LVADs left ventricular assist devices
- ACE angiotensin-converting enzyme
- ARBs angiotensin II receptor blockers
- lanoxin lanoxin
- beta blockers aldosterone antagonists.
- relaxin relieves systemic and renal vasoconstriction and increases vascular compliance, including normalization of high blood pressure, reduction of pulmonary capillary wedge pressure, increase of cardiac output, increase renal blood flow, natriuresis, and decongestion.
- animal pharmacology data indicate that relaxin hormone has anti-inflammatory and cardiac protection effects, including reduction of myocardial ischemia, reduction of reperfusion injury, increase of wound healing, and reduction of ventricular fibrosis.
- A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH 2 CH 2 -, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, and 1,2-heterocyclyl are optionally substituted with one or more substituents independently selected from halo, CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and S0 2 CF 3 ,
- Ri is -NHCOR 3 , R 4 , -NHR 5 , or -OR 6 ,
- R 2 is alkyl, cycloalkyl, heteroarylalkyl, orphenyl, which are optionally substituted with one or more substituents independently selected from halo, CF 3 , C1-C10 alkyl, C 2 -Cio alkenyl, C1-C10 alkyloxy, trihalo C1-C10 alkyl, perhalo C1-C10 alkyl, trihalo C1-C10 alkyloxy, perhalo C1-C10 alkyloxy, aryl, trihalo alky laryl, perhaloalkylaryl, heterocyclylalkyl, - SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , -N0 2 , -CN, and -S0 2 CF 3 ,
- R 3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from t halo, CF 3 , C1-C10 alkyl, C 2 -Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohalo alkyl,
- Ci-Ciohaloalkoxy -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , -N0 2 ,-CN, and -S0 2 CF 3 ,
- R 4 is phenyl optionally substituted with alkyloxy, haloalkoxy,, arylalkyl, or arylalkyloxy
- R 5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl
- alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
- R7 IS C1-C10 alkyl, Ci-Cio haloalkyl, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy.
- the disclosure also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound or salt of the invention and a pharmaceutically acceptable carrier.
- the disclosure further provides a method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1 , comprising administering an effective amount of the compound on the disclosure to a mammal afflicted therewith.
- the mammal is a human and the mammalian relaxin receptor 1 is a human relaxin 1 receptor.
- Figure 1 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figure 2 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figure 3 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figure 4 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figure 5 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figure 6 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figure 7 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
- Figures 1-7 depict synthetic schemes for the preparation of embodiments of the disclosure.
- Figure 8 depicts the cell impedence observed for representative embodiments of the disclosure.
- Figure 9 depicts the results of substitution of mouse sequence with human sequence on activation of cAMP in accordance with an embodiment of the disclosure.
- Figure 10 depicts the activiation of relaxin receptors from human, monkey, pig, and mouse by compound 178.
- Figure 11 depicts the identification of a human RXFP1 region responsible for activation by compound 178.
- A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH 2 CH 2 -, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, and 1,2-heterocyclyl are optionally substituted with one or more substituents independently selected from halo, CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and S0 2 CF 3 ,
- Ri is -NHCOR 3 , R 4 , -NHR 5 , or -OR 6 ,
- R 2 is alkyl, cycloalkyl, heteroarylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF 3 , C1-C10 alkyl, C 2 -Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, aryl, halo alky laryl, heterocyclylalkyl, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , -N0 2 , -CN, and -S0 2 CF 3 ,
- R 3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, each of which are optionally substituted with one or more substituents independently selected from halo, CF 3 , C1-C10 alkyl, C 2 -Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy favor -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , -N0 2 ,-CN, and -S0 2 CF 3 ,
- R 4 is phenyl optionally substituted with alkyloxy, haloalkyloxy, arylalkyl, or arylalkyloxy,
- R 5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl, Re is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
- R 7 is C 1 -C 10 alkyl, C 1 -C 10 haloalkyl, Ci-Ciohaloalkyl or Ci-Ciohaloalkoxy, with the provisos that:
- R 3 when R 3 is methyl, chloromethyl, or dichloromethyl, and A is 1 ,2-phenylenyl, then R 2 is not methyl, phenyl, 2-methylphenyl, 2-methoxyphenyl, or 4-methoxyphenyl;
- R 3 when R 3 is phenyl, and A is 1 ,2-phenylenyl, then R 2 is not halophenyl, methoxyphenyl, 2,6-dimethylphenyl, or 2,4,6-trimethylphenyl;
- R 3 when R 3 is phenyl substituted with alkyl, and A is 1 ,2-phenylenyl, then R 2 is not methoxyphenyl;
- R 2 is phenyl substituted with a substituent selected from -S0 2 CF 3 , -SCF 3 , and -CF3.
- A is 1 ,2-phenylene optionally substituted with one or more substituents selected from hydrogen, halo, -CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- Rl is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF 3 , Ci-Cioalkyl, C 1 -C 10 alkyloxy,
- R 3 is
- R2 is phenyl substituted with a substituent selected from -CF 3 , Ci-Cioalkyl, C 1 -C 10 alkyloxy, Ci-Ciohaloalkyl,
- the compound is selected from the group consisting of:
- Ri is R4, wherein R4 is
- Ri is -NHR 5 , wherein R5 is aryl optionally substituted with one or more substituents selected from alkyloxy and trifluoromethyl.
- Ri is -OR 6 , wherein R ⁇ is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl.
- A is 1 ,2-heteroarylenyl optionally substituted with one or more subsitutents independently selected from halo, -CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- A is selected from
- Ri is -NHCOR 3 , wherein R 3 is phenyl substituted with a substituent selected from the group consisting of -CF 3 , Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- R 3 is
- A is tCH 2 CH 2 -.
- Ri is -NHCOR3, wherein R 3 is phenyl substituted with a substituent independently selected from -CF 3 , C 1 -C 1 0 alkyl, C 1 -C 1 0 alkyloxy, Ci-Ciohalo alkyl, Ci-Ciohaloalkoxy confront -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- R 3 is 2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
- the compound is:
- a ring and 3 Qo 8--membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with R 10 ;
- p are integers independently chosen from 0, 1, and 2 and each n , , and P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C 2 alkyl, and Ci-C 2 alkoxy;
- X and Y are independently chosen from O and S;
- R9 are independently chosen from hydrogen and Ci-C 4 alkyl
- Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy;
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
- R30 is hydrogen or R 30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C 4 alkyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes a compound or salt of Formula X
- the disclosure includes compounds or salts for Formula X where is a group of formula each of which is substituted with R 10 .
- the disclosure includes compounds or salts for Formula X, wherein m, n, o, and p are all 0 and X and Y are both O.
- the disclosure includes compounds or pharmaceutically salts for Formula XI
- R 21 , and R 3 i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, d-Gtalkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, d-C 2 haloalkyl, and Ci-C 2 haloalkoxy;
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Cioalkyl or Ci-Ciohaloalkyl; R30 is hydrogen or R 30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C 4 alkyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XI, wherein R 2 o is Ci- Cehaloalkyl, -S(Ci-C 6 haloalkyl), or SO 2 (Ci-C 6 haloalkyl).
- the disclosure includes compounds and salts of Formula XI, wherein Rio, R 21 , and R31 are each 0 substituents.
- the disclosure includes compounds and salts of Formula XI, wherein Rio, R 21 , and R31 are each 0 substituents; R 20 is CF 3 , SCF 3 , or S0 2 CF 3i and R30 is C 2 -C 6 alkoxy or C 2 - Cealkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and STF 3.
- the disclosure includes compounds and salts of Formula XI, wherein R 2 o is
- the disclosure includes compounds and salts of Formula XII
- Rio and R 31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy; and
- R 2 is (phenyl)Co-C 2 alkyl- or (5- or 6-membered heteroaryl)Co-C 2 alkyl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 3 -C 7 Cycloalkyl)Co-C 2 alkyl, 5- and 6-membered heterocycloalkyl, thienyl, phenyl, phenyl substituted with CF 3 , mono- and di-Ci-Cealkylamino, Ci -Cealkylthio, Ci-Cealkylsulfonyl Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy, -SR7, -SOR 7 , and -SO 2 R 7 , where R
- R 2 is dihydroindenyl, benzo[ ⁇ i][l,3]dioxolyl, or indolyl, each of which is substituted with 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- or di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and - C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XII, wherein R 10 and R31 are both 0 substituents.
- the disclosure includes compounds and salts of Formula XII, wherein
- R 2 is phenyl substituted with one or two substituents independently chosen from hydroxyl, halogen, nitro, SCF 3 , SO 2 CF 3 , Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, 5- and 6- membered heterocycloalkyl, thienyl, phenyl, phenyl substituted with CF 3 , mono- and di-Ci- Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci- C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XII, wherein R 2 is phenyl substituted in the meta position with CF 3 , SCF 3 , or S0 2 CF 3 .
- the disclosure includes compounds and salts of Formula XII, wherein
- R 2 is 2,3-dihydro-lH-indenyl, benzo[ ⁇ i][l,3]dioxolyl, or indolyl, each of which is unsubstituted.
- the disclosure includes compounds and pharmaceutically acceptable salts of Formulf
- Rio and R 21 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy;
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Ciocarbhydryl or Ci-Ciohaloalkyl; ; and
- R 3 is cyclohexyl
- R 3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF 3 , SC> 2 CF 3 , Ci-Cealkyl, C 2 -Cealkenyl, C 2 - Cealkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci- C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XIII, wherein R 10 and
- R21 are both 0 substituents and R 3 is phenyl substituted with one meta-position substituent.
- the disclosure includes compounds and salts of Formula XIII, wherein R 10 and
- R21 are both 0 substituents and R20 is CF 3 , SCF 3 , or S0 2 CF 3 .
- the disclosure includes compounds and salts of Formula XIII, wherein R 2 o is
- R 3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF 3 , S0 2 CF 3 , Ci-Cealkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-C 6 alkylthio, Ci-Cealkylsulfonyl Ci- C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XIII, wherein R 2 o is
- R 3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF 3 , SC> 2 CF 3 , Ci-Cealkyl, C 2 -Cealkenyl, C 2 - Cealkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci- C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- A-ring is a thienyl or pyridyl
- the disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein each of m, n, o, and p are 0 and X and Y are both O.
- the disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Cioalkyl or Ci-Ciohaloalkyl; and R30 is hydrogen or R 30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C 4 alkyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein R 2 o is Ci-Cehaloalkyl, -S(Ci-C 6 haloalkyl), or SO 2 (Ci-C 6 haloalkyl).
- the disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein R 10 , R21 , and R31 are each 0 substituents; R 2 o is CF 3 , SCF 3 , or S0 2 CF 3i and R30 is C 2 -C 6 alkoxy or C 2 -C 6 alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and HEF 3.
- the disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein R 2 o is S0 2 CF 3 .
- the disclosure further includes compounds and salts of Formula XIV
- n, o, and p are integers independently chosen from 0, 1, and 2 and each of V / n , V / o , and ; P P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C 2 alkyl, and Ci-C 2 alkoxy;
- X and Y are independently chosen from O and S;
- R8 and R9 are independently chosnen from hydrogen and Ci-C 4 alkyl
- Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy;
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
- R30 is hydrogen or R 30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C 4 alkyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XIV, wherein m, n, o, and p are all 0 and X and Y are both O.
- the disclosure includes compounds and salts of Formula XV
- R 21 , and R 3 i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy;
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
- R 3 o is hydrogen or R 30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C 4 alkyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes compounds and salts of Formula XVI
- R 21 , and R 3 i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C 4 alkyl, Ci-C 4 alkoxy, mono- and di-(Ci-C 2 alkyl)amino-, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy;
- R 20 is N0 2 , CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , or -S0 2 R 7 , where R 7 is Ci-Cioalkyl or Ci-Ciohaloalkyl; R30 is hydrogen or R 30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C 4 alkyl, Ci-C 4 alkoxy, Ci-C 2 haloalkyl, and Ci-C 2 haloalkoxy.
- the disclosure includes compounds of Formula XV and XVI, wherein R 2 o is
- Ci-Cehaloalkyl -S(d-C 6 haloalkyl), or SO 2 (Ci-C 6 haloalkyl).
- the disclosure includes compounds of Formula XV and XVI, wherein R 21 , and
- R31 are both 0 substituents.
- the disclosure includes compounds of Formula XV and XVI, wherein R 2 i and
- R31 are both 0 substituents;
- R 2 o is CF 3 , SCF 3 , or S0 2 CF 3i and
- R30 is C 2 -C 6 alkoxy or C 2 - C 6 alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and STF 3.
- the disclosure includes compounds of Formula XV and XVI, wherein R 20 is S0 2 CF 3 .
- variable definitions set forth herein e.g. Rio, R 2 o, R 2 i, R30, R31, Rs, R9, X, Y, m, n, o, and p
- any of the genuses, subgenuses, and compounds in the scope of the disclosure, including compounds and salts of Formula X to Formula XVI, can be used for treating any of the conditions, disorders, diseases, or other facets of mammalian health listed in this application.
- any of the genuses, subgenuses, and compounds of the disclosure, including compounds and salts of Formula X to XI can be used for the manufacture of a medicament for any of the conditions, disorders, diseases, or other facets of mammalian health listed in this application.
- HlkylChie ans a straight-chain or branched alkyl substituent containing from, for example, 1 to about 10 carbon atoms, preferably from 1 to about 4 carbon atoms, more preferably from 1 to 2 carbon atoms.
- substituents include methyl, ethyl, propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, pentyl, isoamyl, hexyl, and the like.
- alkenyl means a linear or branched alkenyl substituent containing at least one carbon-carbon double bond and from, for example, linear alkenyl of about 2 to about 10 carbon atoms (branched alkenyls are about 3 to about 6 carbons atoms), preferably from about 2 to about 5 carbon atoms (branched alkenyls are preferably from about 3 to about 5 carbon atoms), more preferably linear alkenyl of about 3 to about 4 carbon atoms.
- substituents examples include vinyl, propenyl, isopropenyl, n-butenyl, sec- butenyl, isobutenyl, tert-butenyl, pentenyl, isopentenyl, hexenyl, and the like.
- alkynyl means a linear or branched alkynyl substituent containing at least one carbon-carbon triple bond and from, for example, linear alkynyl of 2 to about 10 carbon atoms (branched alkynyls are about 3 to about 6 carbons atoms), preferably from 2 to about 5 carbon atoms (branched alkynyls are preferably from about 3 to about 5 carbon atoms), more preferably linear alkynyl of about 3 to about 4 carbon atoms.
- substituents include ethynyl, propynyl, isopropynyl, n-butynyl, sec- butynyl, isobutynyl, tert-butynyl, pentynyl, isopentynyl, hexynyl, and the like.
- Carbhydryl Os a hydrocarbon group that is straight, branched or cyclic (including (cycloalkyl)alkyl) and contains any combination of single, double, and triple covalent bonds.
- a carbhydryl group may be an alkyl, alkenyl, or alkynyl group.
- carbhydryl is used in conjuction with BxyCcarbhydryl is a group as defined covalently bound to the group it substitutes through an oxygen, -0-, bridge.
- carbhydrylthio is a carbhydryl group as defined covalently bound to the group it substitutes through a sulfur, - S-, bridge.
- BycloalkyLCas used herein means a cyclic alkyl substituent containing from, for example, about 3 to about 8 carbon atoms, preferably from about 4 to about 7 carbon atoms, and more preferably from about 4 to about 6 carbon atoms.
- substituents include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
- the cyclic alkyl groups may be unsubstituted or further substituted with alkyl groups such as methyl groups, ethyl groups, and the like.
- fbicycloalkyl ⁇ as used herein means a bicyclic alkyl substituent containing from, for example, about 4 to about 12 carbon atoms, preferably from about 4 to about 7 carbon atoms, and more preferably from about 6 to about 10 carbon atoms.
- substituents examples include bicyclo[3.2.0]heptyl, bicyclo[3.3.0]octyl,
- the bicyclic alkyl groups may be unsubstituted or further substituted with alkyl groups such as methyl groups, ethyl groups, and the like.
- tricycloalkylQas used herein means a tricyclic alkyl substituent containing from, for example, about 6 to about 18 carbon atoms, preferably from about 8 to about 16 carbon atoms. Examples of such substituents include adamantyl and the like.
- the tricyclic alkyl groups may be unsubstituted or further substituted with alkyl groups such as methyl groups, ethyl groups, and the like.
- Halo alkyl indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms.
- haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
- Halo alkoxy indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
- the heterocyclyl group can be any suitable heterocyclyl group and can be an aliphatic heterocyclyl group, an aromatic heterocyclyl group, or a combination thereof.
- the heterocyclyl group can be a monocyclic heterocyclyl group or a bicyclic heterocyclyl group.
- Suitable bicyclic heterocyclyl groups include monocylic heterocyclyl rings fused to a C 6 -Cio aryl ring.
- the heterocyclyl group is a bicyclic heterocyclyl group, both ring systems can be aliphatic or aromatic, or one ring system can be aromatic and the other ring system can be aliphatic as in, for example, dihydrobenzofuran.
- the heterocyclyl group is an aromatic heterocyclyl group.
- Non-limiting examples of suitable heterocyclyl groups include furanyl, thiopheneyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, l,3,4-oxadiazol-2-yl, l,2,4-oxadiazol-2-yl, 5-methyl-l,3,4- oxadiazole, 3-methyl-l,2,4-oxadiazole, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, benzothiopheneyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolinyl, benzothiazolinyl, and quinazolinyl.
- the heterocyclyl group is optionally substituted with 1, 2, 3, 4, or 5 substituents as recited herein such as with alkyl groups such as methyl groups, ethyl groups, and the like, or with aryl groups such as phenyl groups, naphthyl groups and the like, wherein the aryl groups can be further substituted with, for example halo, dihaloalkyl, trihaloalkyl, nitro, hydroxy, alkoxy, aryloxy, amino, substituted amino, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, thio, alkylthio, arylthio, and the like, wherein the optional substituent can be present at any open position on the heterocyclyl group.
- substituents as recited herein such as with alkyl groups such as methyl groups, ethyl groups, and the like, or with aryl groups such as phenyl groups, naphthyl
- heteroaryl, Cas used herein refers to a monocyclic or bicyclic 5- or 6-membered ring system containing one or more heteroatoms selected from O, N, S, and combinations thereof.
- the heteroaryl group can be any suitable heteroaryl.
- the heteroaryl group can be a monocyclic heteroaryl group or a bicyclic heteroaryl group.
- Suitable bicyclic heteroaryl groups include monocylic heteroaryl rings fused to a C 6 -Cio aryl ring. When the heteroaryl group is a bicyclic heteroaryl group, both ring systems are preferably aryl.
- Non-limiting examples of suitable heteroaryl groups include furanyl, thiopheneyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, benzo furanyl, benzo thiopheneyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolinyl, benzo thiazolinyl, and quinazolinyl.
- the heteroaryl group is optionally substituted with 1, 2, 3, 4, or 5 substituents as recited herein, wherein the optional substituent can be present at any open position on the heteroaryl group.
- fieteroarylalkylCand Iheterocyclylalkyl, Cas used herein refers to a heteroaryl or heterocyclyl group as defined herein having an alkyl linker group attached thereto, wherein the heteroarylalkyl and heterocyclylalkyl groups are attached to the rest of the molecule via the alkyl linker group.
- [1,2-phenylenylCand] refer to a phenyl group or a heteroaryl group having attached to the ring two groups positioned at adjacent positions on the phenyl or heteroaryl group, i.e., forming an ortho substitution on the phenyl or heteroaryl group.
- Hrylalkyl refers to an alkyl group linked to a C 6 -Cio aryl ring and further linked to a molecule via the alkyl group.
- Hlkylaryl, Cas used herein refers to a C 6 -Cio aryl ring linked to an alkyl group and further linked to a molecule via the aryl group.
- a range of the number of atoms in a structure is indicated (e.g., a C1-C12, Ci-C 8 , Ci-C 6 , C1-C4, or C2-C12, C 2 -C 8 , C 2 -C 6 , C 2 -C 4 alkyl, alkenyl, alkynyl, etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used.
- any chemical group e.g., alkyl, alkylamino, etc.
- any chemical group e.g., alkyl, alkylamino, etc.
- any sub-range thereof e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 1-9 carbon atoms, 1-10 carbon atoms, 1-11 carbon atoms, 1-12 carbon atom
- 6-10 carbon atoms e.g., C 6 -Cio
- any chemical group e.g., aryl
- 6-10 carbon atoms 6-9 carbon atoms, 6-8 carbon atoms, 6-7 carbon atoms, 7-10 carbon atoms, 7-9 carbon atoms, 7-8 carbon atoms, 8-10 carbon atoms, and/or 8-9 carbon atoms, etc., as appropriate).
- Halo Cor means a substituent selected from Group VIIA, such as, for example, fluorine, bromine, chlorine, and iodine.
- Hryl refers to an unsubstituted or substituted aromatic carbocyclic substituent, as commonly understood in the art, and the term HE 6-Cio arylOncludes phenyl and naphthyl. It is understood that the term aryl applies to cyclic substituents that are planar and comprise 4n+2 ⁇ electrons, according to HuckelH Rule.
- saltOs intended to include nontoxic salts synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
- nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ⁇ Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445, and Journal of ' Pharmaceutical Science, 66, 2-19 (1977).
- Suitable bases include inorganic bases such as alkali and alkaline earth metal bases, e.g., those containing metallic cations such as sodium, potassium, magnesium, calcium and the like.
- suitable bases include sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate.
- Suitable acids include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, maleic acid, tartaric acid, fatty acids, long chain fatty acids, and the like.
- Preferred pharmaceutically acceptable salts of inventive compounds having an acidic moiety include sodium and potassium salts.
- Preferred pharmaceutically acceptable salts of inventive compounds having a basic moiety include hydrochloride and hydrobromide salts.
- the compounds of the present disclosure containing an acidic or basic moiety are useful in the form of the free base or acid or in the form of a pharmaceutically acceptable salt thereof.
- solvates refers to a molecular complex wherein the solvent molecule, such as the crystallizing solvent, is incorporated into the crystal lattice.
- the solvent incorporated in the solvate is water, the molecular complex is called a hydrate.
- Pharmaceutically acceptable solvates include hydrates, alcoholates such as methanolates and ethanolates, acetonitrilates and the like. These compounds can also exist in polymorphic forms.
- the compounds of the disclosure can be synthesized using any suitable synthetic route. Referring to Figure 1, methyl 2-aminobenzoate 500 can be reacted with an acid chloride in the presence of a base such as triethylamine in a solvent such as
- amide 501 can be reacted with an amine in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene to provide bis-amide 502.
- Compound 503 can be reacted with a boronic acid in the presence of a catalyst such as Pd(PPh 3 ) 4 , a base such as sodium carbonate, in a solvent such as
- Arylthiol compound 505 can be oxidized with an agent such as m-chloroperoxybenzoic acid in a solvent such as dichloromethane to give sulfone 506.
- the cyano compound 507 can be reacted with ammonium chloride in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene to give amidine 508.
- Reaction of amidine 508 with an azide such as sodium azide in the presence of a catalyst such as zinc bromide in a solvent such as water gives tetrazole 510.
- carboxylic acid 511 can be reacted with an amine such as
- 1,3-trilfuoromethylaniline in the presence of a coupling agent such as EDC and a basic catalyst such as dimethylaminopyridine in a solvent such as dichloromethane, followed by deprotection with an agent such as trifluoro acetic acid in a solvent such as dichloromethane to give free amine 513.
- a coupling agent such as EDC and a basic catalyst such as dimethylaminopyridine
- an agent such as trifluoro acetic acid in a solvent such as dichloromethane
- reaction of amine 513 with an acid chloride or an acid bromide in the presence of a base such as triethylamine in a solvent such as dichloromethane provides amide 514.
- reaction of aryl iodide 515 with an alcohol in the presence of a catalyst such as 1,10-phenanthroline and a base such as cesium carbonate in a solvent such as toluene gives aryl ether 516.
- a catalyst such as 1,10-phenanthroline
- a base such as cesium carbonate
- a solvent such as toluene
- 2-bromobenzoyl chloride or 2-iodobenzoyl chloride 517 with 3-trifluoromethylaniline in the presence of a base such as triethylamine in a solvent such as dichloromethane provides amide 518.
- Amide 518 reacts with a boronic acid in the presence of a catalyst such as Pd(PPh 3 ) 4 , a base such as sodium carbonate, in a solvent such as dimethylformamide under microwave irradiation gives alkylated/arylated compound
- Reaction of compound 518 with a primary amine in the presence of a catalyst such as cuprous chloride in a solvent such as dimethylformanide provides arylamine 520.
- Reaction of 518 with an alcohol in the presence of catalysts such as copper (I) iodide and 1,10-phenanthroline in the presence of a base such as cesium carbonate in a solvent such as toluene gives aryl ether 521.
- reaction of amide 522 with an alkylating agent such as iodomethane in the presence of a base such as NaH in a solvent such as dimethylformamide gives N-methylamide 523.
- Compound 523 reacts with an arylamine such as compound 524 in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene to give bis-amide 525.
- Oxidation of alcohol 526 with an oxidant such as Dess-Martin periodinane in a solvent such as dichloromethane gives aldehyde 527.
- arylamine 530 Coupling of arylamine 530 with an acyl chloride such as 531 in the presence of a base such as triethylamine in a solvent such as dichloromethane gives amine-amide 532.
- Sulfonamides can be prepared by reaction of methyl 2-aminobenzoate 533 with sulfonyl chloride 534 in the presence of a base such as triethylamine in a solvent such as dichloromethane to give sulfonamide 535. Reaction of 535 with 3-trifluoromethylsulfonylaniline in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene gives compound 536.
- aniline derivative 537 can be reacted with an acyl chloride in the presence of a base such as triethylamine in a solvent such as dichloromethane to provide amide 538.
- Reaction of 538 with 3-trifluoromethylaniline in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene gives bis-amide 539.
- a catalyst such as trimethylaluminum in a solvent such as toluene gives bis-amide 539.
- the same chemistry can be performed substituting hetero eye lic/hetero aryl analogs of compound 537.
- 3-trifluoromethylsulfonylaniline in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene gives compound 550.
- Reaction of amine 551 with 3-iodotrifluorobenzene in the presence of a catalyst such as 1,2-methylaminocyclohexane in the presence of a catalyst such as copper (I) iodide and a base such as potassium carbonate in a solvent such as toluene gives the coupled product 553.
- the present disclosure is further directed to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound or salt described herein.
- the pharmaceutically acceptable carrier be one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of use.
- compositions of the present disclosure The following formulations for oral, aerosol, nasal, pulmonary, parenteral, subcutaneous, intravenous, intramuscular,
- intraperitoneal, intrathecal, intratumoral, topical, rectal, and vaginal administration are merely exemplary and are in no way limiting.
- compositions for parenteral administration that comprise a solution or suspension of the inventive compound or salt dissolved or suspended in an acceptable carrier suitable for parenteral administration, including aqueous and non-aqueous isotonic sterile injection solutions.
- Such solutions can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the compound or salt of the present disclosure may be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose,
- a pharmaceutically acceptable surfactant such
- hydro xypropylmethylcellulose or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
- Oils useful in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
- Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
- suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfo succinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-beta-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.
- the parenteral formulations can contain preservatives and buffers.
- such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17.
- HLB hydrophile-lipophile balance
- the quantity of surfactant in such formulations will typically range from about 5 to about 15% by weight.
- Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- sterile liquid excipient for example, water
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- Topical formulations including those that are useful for transdermal drug release, are well-known to those of skill in the art and are suitable in the context of the disclosure for application to skin.
- Topically applied compositions are generally in the form of liquids, creams, pastes, lotions and gels. Topical administration includes application to the oral mucosa, which includes the oral cavity, oral epithelium, palate, gingival, and the nasal mucosa.
- the composition contains at least one active component and a suitable vehicle or carrier. It may also contain other components, such as an anti-irritant.
- the carrier can be a liquid, solid or semi-solid.
- the composition is an aqueous solution.
- the composition can be a dispersion, emulsion, gel, lotion or cream vehicle for the various components.
- the primary vehicle is water or a biocompatible solvent that is substantially neutral or that has been rendered substantially neutral.
- the liquid vehicle can include other materials, such as buffers, alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired pH, consistency and viscosity.
- the compositions can be produced as solids, such as powders or granules. The solids can be applied directly or dissolved in water or a biocompatible solvent prior to use to form a solution that is substantially neutral or that has been rendered substantially neutral and that can then be applied to the target site.
- the vehicle for topical application to the skin can include water, buffered solutions, various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as a therapeutically effective amount of the inventive compound dissolved in diluents, such as water, saline, or orange juice, (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules, (c) powders, (d) suspensions in an appropriate liquid, and (e) suitable emulsions.
- Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a
- Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch.
- Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, micro crystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
- Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- a flavor usually sucrose and acacia or tragacanth
- pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- the compound or salt of the present disclosure can be made into aerosol formulations to be administered via inhalation.
- the compounds are preferably supplied in finely divided form along with a surfactant and propellant.
- Typical percentages of active compound are 0.01%-20% by weight, preferably
- the surfactant must, of course, be nontoxic, and preferably soluble in the propellant.
- Representative of such surfactants are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
- Mixed esters such as mixed or natural glycerides may be employed.
- the surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25%-5%.
- the balance of the composition is ordinarily propellant.
- a carrier can also be included as desired, e.g., lecithin for intranasal delivery.
- aerosol formulations can be placed into acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations may be used to spray mucosa.
- the compound or salt of the present disclosure may be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases.
- bases such as emulsifying bases or water-soluble bases.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
- the compound or salt of the present disclosure may be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes.
- inclusion complexes such as cyclodextrin inclusion complexes, or liposomes.
- Liposomes serve to target the compounds to a particular tissue, such as lymphoid tissue or cancerous hepatic cells. Liposomes can also be used to increase the half-life of the inventive compound.
- Liposomes useful in the present disclosure include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like.
- the active agent to be delivered is incorporated as part of a liposome, alone or in conjunction with a suitable chemotherapeutic agent.
- liposomes filled with a desired inventive compound or salt thereof can be directed to the site of a specific tissue type, hepatic cells, for example, where the liposomes then deliver the selected compositions.
- Liposomes for use in the disclosure are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, for example, liposome size and stability of the liposomes in the blood stream.
- a liposome suspension containing a compound or salt of the present disclosure may be administered intravenously, locally, topically, etc. in a dose that varies according to the mode of administration, the agent being delivered, and the stage of disease being treated.
- the disclosure further provides a method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1 comprising
- A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH 2 CH 2 -, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, or 1,2-heterocyclyl are optionally substituted with one or more substituents independently selected from halo, CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and S0 2 CF 3 ,
- Ri is -NHCOR 3 , R 4 , -NHR 5 , or -OR 6 ,
- R 2 is alkyl, cycloalkyl, heteroarylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF 3 , C 1 -C 10 alkyl, C 2 -Cio alkenyl, C 1 -C 10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy aryl, , halo alky laryl, heterocyclylalkyl, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , -N0 2 , -CN, and -S0 2 CF 3 ,
- R 3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, which are optionally substituted with one or more substituents selected from halo, CF 3 , C 1 -C 10 alkyl, C 2 -Cio alkenyl, C 1 -C 10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , -N0 2 ,-CN, and -S0 2 CF 3 ,
- R 4 is phenyl optionally substituted with alkyloxy, haloalkyloxy, arylalkyl, or arylalkyloxy,
- R 5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl,
- Re is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
- R 7 is C 1 -C 10 alkyl, C 1 -C 10 haloalkyl, Ci-Ciohaloalkyl, or Ci-Ciohaloalkoxy.
- R 2 is phenyl substituted
- A is 1 ,2-phenylene optionally substituted with one or more substituents independently selected from halo, -CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- Ri is -NHCOR 3 , wherein R 3 is phenyl substituted with a substituent selected from -CF 3 , C 1 -C 10 alkyl, C 1 -C 10 alkyloxy,
- Ci-Ciohaloalkyl Ci-Ciohaloalkoxy, alkyloxyalkyloxy, dimethylaminoalkyloxy, -
- R 3 is
- R 2 is phenyl substituted with a substituent selected from -CF 3 , Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Ciohaloalkyl,
- the compound is selected from the group consisting of:
- Ri is R4, wherein R4 is
- Ri is -NHR 5 , wherein R5 is aryl optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl.
- Ri is -OR 6 , wherein R ⁇ is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl.
- A is 1 ,2-heteroarylenyl optionally substituted with one or more subsitutents independently selected from halo, -CF 3 , alkyl, alkyloxy, haloalkyl, haloalkoxy -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- A is selected from
- Ri is -NHCOR 3 , wherein R 3 is phenyl substituted with a substituent selected from independently -CF3, C 1 -C 10 alkyl, C 1 -C 10 alkyloxy, Ci-Ciohalo alkyl, Cl-Ciohaloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- R3 is
- A is [CH 2 CH 2 -.
- Ri is -NHCOR3, wherein R 3 is phenyl substituted with a substituent selected from -CF 3 , C 1 -C 1 0 alkyl, C 1 -C 1 0 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR 7 , -SOR 7 , -S0 2 R 7 , -SCF 3 , and -S0 2 CF 3 .
- R3 is 2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
- the compound is:
- the facet of mammalian health can be any disease, disorder, or aspect of mammalian health that is mediated by a mammalian relaxin receptor 1.
- facets of mammalian health wherein the mammal is a human, that are mediated by a mammalian relaxin receptor 1, wherein the mammalian relaxin receptor 1 is a human relaxin receptor 1, are disclosed in, e.g., E.T. Van Der Westhuizen et al, Current Drug Targets 2007, 8, 91-104; U.S. Patent 8,053,411; and U.S. Patent Application Publication 2011/0177998, the discloses of which are incorporated herein.
- the mammal can be any suitable mammal.
- suitable mammals include, but are not limited to, the order Rodentia, such as mice, and the order Logomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is more preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). It is most preferred that the mammals are of the order Primates, Ceboids, or Simioids (monkeys) or of the order Anthropoids (humans and apes). An especially preferred mammal is the human.
- the subject can be the unborn offspring of any of the forgoing hosts, especially mammals (e.g., humans), in which case any screening of the subject or cells of the subject, or administration of compounds to the subject or cells of the subject, can be performed in utero.
- mammals e.g., humans
- any screening of the subject or cells of the subject, or administration of compounds to the subject or cells of the subject can be performed in utero.
- the mammalian relaxin receptor 1 can be any suitable mammalian relaxin receptor 1.
- the mammalian relaxin receptor 1 is a relaxin receptor 1 that exists in the particular mammal being treated.
- the facet of mammalian health is a facet of human health.
- the mammalian relaxin receptor 1 is a human relaxin receptor 1.
- the facet of mammalian health is cardiovascular disease.
- cardiovascular disease include acute heart failure, myocardial ischemia-reperfusion injury, cardiac fibrosis, acute congestive heart failure, cerebrovascular disease and stroke, post-infarction heart, cardiac anaphylaxis, cerebral ischemia (stroke), intestinal ischemia-reperfusion injury, systemic and pulmonary hypertension, vascular inflammation, hypertension, high blood pressure; left ventricular hypertrophy (LVH);
- vasodilation renal hypertension; diuresis; nephritis; natriuresis; scleroderma renal crisis; angina pectoris (stable and unstable); myocardial infarction; heart attack; coronary artery disease; coronary heart disease; cardiac arrhythmias; atrial fibrillation; portal hypertension; raised intraocular pressure; vascular restenosis; chronic hypertension; valvular disease;
- the facet of mammalian health is dyspnea associated with acute heart failure in a human subject, wherein said subject has dyspnea associated with acute heart failure and is in a hypertensive or normotensive state at the onset of said administering.
- the facet of mammalian health is acute decompensated heart failure, wherein the method is effective to reduce in-hospital worsening of said acute decompensated heart failure in said subject.
- the in-hospital worsening of said acute decompensated heart failure comprises one or more of worsening dyspnea, need for additional therapy to treat said heart failure, need for mechanical support of breathing, and need for mechanical support of blood pressure.
- the method further comprises a reduction in the risk of death or
- the facet of mammalian health is fibrotic disease.
- the fibrotic disease is selected from the group of but not limited to pulmonary fibrosis, renal tubulo interstitial fibrosis, mesangial proliferative nephritis, hepatic fibrosis (cirrhosis) alcohol and non-alcohol related (including viral infection such as HAV, HBV and HCV); fibromatosis; granulomatous lung disease; glomerulonephritis, myocardial scarring following infarction; endometrial fibrosis and endometriosis, polycystic kidney disease, scleroderma and systemic sclerosis, keloids, arthritis, autoimmune disorder, inflammatory condition associated with infection, skeletal muscle injuries, conditions involving tissue remodeling following inflammation or ischemia-reperfusion injury and is selected from endomyocardial and cardiac fibrosis; mediastinal fibrosis; retroperitoneal
- the facet of mammalian health is respiratory disease selected from asthma, bronchial disease, lung diseases, chronic obstructive pulmonary disease (COPD), Acute Respiratory Distress Syndrome (ARDS), severe acute respiratory syndrome (SARS), Fibrosis related Asthma, and cystic fibrosis.
- COPD chronic obstructive pulmonary disease
- ARDS Acute Respiratory Distress Syndrome
- SARS severe acute respiratory syndrome
- Fibrosis related Asthma and cystic fibrosis.
- the facet of mammalian health is skin disease selected from dermal repair, wound healing; burns, erythemas, lesions, wound healing following surgical procedures; skin or tissue lesions including lesions induced by Psoriasis, Lupus and Kaposhi Sarcoma; Scleroderma, and collagenous diseases of the skin and skin tumors.
- the facet of mammalian health is female reproduction.
- the facet of female reproduction is selected from in vitro fertilization, abnormal implantation, pre-term birth and induction of labor, mammary functions and lactation disorders;, plasma osmolarity during pregnancy, uterine fibroids, abnormal endometrial angiogenesis; placental development defects; cervical ripening (softening); nipple development and disfunction; pregnancy related remodeling of the uterine tissue; endometriosis; preeclampsia; estrogenic and non-estrogenic related hormonal disorders; preterm labor; post term labor; and labor complications.
- the facet of mammalian health is male reproduction.
- the facet of male reproduction is selected from sperm functions and fertilization.
- the facet of mammalian health is surgical transplantation of a liver.
- the facet of mammalian health is a cancer selected from colon cancer, lung cancer, breast cancer, prostate cancer, brain cancer, pancreatic cancer, ovarian cancer, kidney cancer, testicular cancer, bone cancer, osteosarcoma, liver cancer, melanoma, glioma, sarcoma, leukemia, or lymphoma, and wherein the cancer is invasive or metastatic.
- the facet of mammalian health is enhancement of drug delivery in the treatment of a solid cancer, in combination with a chemotherapeutic treatment or radiation treatment of the cancer.
- the facet of mammalian health is orthodontic tooth movement.
- the facet of mammalian health is bone joint disease.
- the facet of mammalian health is selected from osteoporosis; osteoarthritis; osteopetrosis; bone inconsistency; osteosarcoma; and cancer metastasis to the bone.
- the facet of mammalian health is diabetes mellitus.
- the facet of mammalian health is ischemia-reperfusion injury associated with ischemic and post-ischemic events in organs and tissues and in a group of patients with thrombotic stroke; myocardial infarction; angina pectoris; embolic vascular occlusions; peripheral vascular insufficiency; splanchnic artery occlusion; arterial occlusion by thrombi or embolisms, arterial occlusion by non-occlusive processes such as following low mesenteric flow or sepsis; mesenteric arterial occlusion; mesenteric vein occlusion; ischemia-reperfusion injury to the mesenteric microcirculation; ischemic acute renal failure; ischemia-reperfusion injury to the cerebral tissue; intestinal intussusception; hemodynamic shock; tissue dysfunction; organ failure; restenosis; atherosclerosis; thrombosis; platelet aggregation, ischemia-reperfusion injury following cardiac surgery; organ
- the facet of mammalian health is an inflammatory condition associated with an infection, wherein the infection is selected from a viral infection caused by human immunodeficiency virus I (HIV-1) or HIV-2, acquired immune deficiency (AIDS), West Nile encephalitis virus, coronavirus, rhinovirus, influenza virus, dengue virus, HCV, HBV, HAV, hemorrhagic fever; an otological infection; severe acute respiratory syndrome (SARS), sepsis and sinusitis.
- HIV-1 human immunodeficiency virus I
- HIV-2 acquired immune deficiency
- AIDS acquired immune deficiency
- AIDS acquired immune deficiency
- coronavirus coronavirus
- rhinovirus influenza virus
- dengue virus HCV
- HBV HBV
- HAV hemorrhagic fever
- SARS severe acute respiratory syndrome
- the facet of mammalian health is kidney diseases selected from diabetic nephropathy; glomerulosclerosis; nephropathies; renal impairment; scleroderma renal crisis and chronic renal failure.
- the facet of mammalian health is an angiogenesis related condition selected from retinal angiogenesis in a number of mammalian ocular diseases such as diabetes mellitus, retinopathy of prematury, and age-related macular degeneration, or cancer associated angiogenesis in primary or metastatic cancer, including but not limited to cancer of the prostate, brain, breast, colorectal, lung, ovarian, pancreatic, renal, cervical, melanoma, soft tissue sarcomas, lymphomas, head-and-neck, and glioblastomas.
- mammalian ocular diseases such as diabetes mellitus, retinopathy of prematury, and age-related macular degeneration
- cancer associated angiogenesis in primary or metastatic cancer including but not limited to cancer of the prostate, brain, breast, colorectal, lung, ovarian, pancreatic, renal, cervical, melanoma, soft tissue sarcomas, lymphomas, head-and-neck, and glioblast
- the facet of mammalian health is an inflammatory disorder selected from gastritis, gout, gouty arthritis, arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ulcers, chronic bronchitis, asthma, allergy, acute lung injury, pulmonary inflammation, airway hyper-responsiveness, vasculitis, septic shock and inflammatory skin disorders, including but not limited to psoriasis, atopic dermatitis, eczema.
- the facet of mammalian health is an autoimmune disorder is selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus
- erythematosus Hashimoto's thyroiditis, primary myxedema, Graves' disease, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, insulin dependent diabetes mellitis, Good pasture's syndrome, myasthenia gravis, pemphigus, sympathetic ophthalmia, autoimmune uveitis, autoimmune hemolytic anemia, idiopathic thrombocytopenia, primary biliary cirrhosis, chronic action hepatitis, ulceratis colitis, Sjogren's syndrome, rheumatic disease, polymyositis, scleroderma, mixed connective tissue disease, inflammatory rheumatism, degenerative rheumatism, extra-articular rheumatism, collagen diseases, chronic polyarthritis, psoriasis arthropathica, ankylosing spondylitis, juvenile rheumatoid arthritis, periarthritis humeroscapular
- the facet of mammalian health is an behavioral abnormality or disease.
- [Therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1 Qefers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop.
- the term ameliorating, Qvith reference to a disease or pathological condition refers to any observable beneficial effect of the treatment.
- the beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease.
- Treatment of cardiovascular disease can be evidenced, for example, by reduction of blood pressure, an enhancement of vascular compliance, a reduction in clinical symptoms resulting from the cardiovascular disease, or other parameters well known in the art that are specific to the cardiovascular disease.
- a disease or condition for example, in a subject who is at risk for a disease such as cardiovascular disease.
- the therapeutic intervention provides an enhancement in a desirable facet of mammalian health.
- the therapeutic intervention provides an enhancement in a desirable facet of human health.
- the therapeutic intervention can lead to improved outcomes in organ transplantation, in improvements in female fertility such as increased success in in vitro fertilization, and the like.
- suitable methods of utilizing a compound and administering it to a mammal for the treatment or prevention of disease states which would be useful in the method of the present disclosure, are available. Although more than one route can be used to administer a particular compound, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described methods are merely exemplary and are in no way limiting.
- the dose administered to a mammal, particularly, a human, in accordance with the present disclosure should be sufficient to effect the desired response. Such responses include reversal or prevention of the bad effects of the disease for which treatment is desired or to elicit the desired benefit.
- dosage will depend upon a variety of factors, including the age, condition, and body weight of the mammal, as well as the source, particular type of the disease, and extent of the disease in the human.
- the size of the dose will also be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular compound and the desired physiological effect. It will be appreciated by one of skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
- Suitable doses and dosage regimens can be determined by conventional range- finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound.
- the present inventive method typically will involve the administration of about 0.1 to about 300 mg of one or more of the compounds described above per kg body weight of the mammal.
- Unit dosage formCas used herein refers to a physically discrete unit of therapeutic agent appropriate for the subject to be treated.
- dosages are calculated based on body surface area and from about 1 mg/m 2 to about 200 mg/m 2 , such as from about 5 mg/m 2 to about 100 mg/m 2 will be administered to the subject per day.
- administration of the therapeutically effective amount of the compound or compounds involves administering to the subject from about 5 mg/m 2 to about 50 mg/m 2 , such as from about 10 mg/m 2 to about 40 mg/m 2 per day. It is currently believed that a single dosage of the compound or compounds is suitable, however a therapeutically effective dosage can be supplied over an extended period of time or in multiple doses per day.
- unit dosage forms also can be calculated using a subjects body surface area based on the suitable ranges recited above and the desired dosing schedule.
- the disclosure further provides a use of a compound or salt of the disclosure in the manufacture of a medicament for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1.
- the medicament typically is a pharmaceutical composition as described herein.
- Method 1 A 7-minute gradient of 4% to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8-minute run time at a flow rate of 1.0 mL/min.
- Method 2 (t 2 ): A 3-minute gradient of 4% to 100% acetonitrile (containing 0.025% trifluoro acetic acid) in water (containing 0.05% trifluoroacetic acid) was used with a 4.5- minute run time at a flow rate of 1.0 mL/min. A Phenomenex Luna C 18 column (3 micron, 3 x 75 mm) was used at a temperature of 50 °C. Purity determination was performed using an Agilent diode array detector for both Method 1 and Method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode.
- reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of dichloromethane in hexanes followed by 10% of EtOAc in dichloromethane to give 2.20 g (46%) of the title product as a white solid.
- This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-002, NCGC00189486-01).
- the title compound was prepared according to general protocol A.
- This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4- (trifiuoromethyl)phenyl)benzamide (XJB06-012, NCGC00189480-01).
- the title compound was prepared according to general protocol A.
- This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4- fluorophenyl)benzamide (XJB06-014, NCGC00189478-01).
- the title compound was prepared according to general protocol A.
- This example illustrates a synthesis of 2-Amino-N-(furan-2-ylmethyl)benzamide (XJB06-052, NCGC00165247-02).
- a solution of methyl 2-aminobenzoate (0.857 mL, 6.62 mmol) and furan-2-ylmethanamine (1.84 mL, 19.9 mmol) in toluene (20.0 mL) was treated at room temperature with AlMe 3 (6.62 mL, 2.0 M in toluene, 13.2 mmol).
- the reaction mixture was stirred at 100 °C for 5 h and then quenched with water after cooling to room temperature.
- This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2-((furan- 2-ylmethyl)carbamoyl)phenyl)benzamide (XJB06-065, NCGC00189449-01).
- a solution of methyl 2-(cyclohexanecarboxamido)benzoate (50.0 mg, 0.191 mmol) and 2-amino-N-(furan- 2-ylmethyl)benzamide (41.4 mg, 0.191 mmol) in toluene (2.00 mL) was treated at room temperature with AlMe3 (0.192 mL, 2.0 M in toluene, 0.384 mmol).
- reaction mixture was stirred at 100 °C for overnight and then quenched with 100 of water.
- the mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C 18 reverse phase HPLC to give the title compound as a white solid.
- This example illustrates a synthesis of Methyl 2-(furan-2-carboxamido)benzoate (XJB06-066, NCGC00026064-02).
- a solution of methyl 2-aminobenzoate (1.71 mL, 13.2 mmol) in dichloro methane (50.0 mL) and TEA (5.53 mL, 39.7 mmol) was treated at room temperature with furan-2-carbonyl chloride (2.62 mL, 26.5 mmol). The reaction mixture was stirred at room temperature for 1 h.
- This example illustrates a synthesis of 2-(3-(Methylsulfonyl)benzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-075, NCGC00238755-01).
- the title compound was prepared according to general protocol D.
- This example illustrates a synthesis of 2-(4-Acetylbenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-076, NCGC00238756-01).
- the title compound was prepared according to general protocol D.
- This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- isopropylphenyl)benzamide (XJB07-080, NCGC00238757-01).
- the title compound was prepared according to general protocol A.
- This example illustrates a synthesis of 2-(3-Methylbenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-093, NCGC00238759-01).
- the title compound was prepared according to general protocol C.
- This example illustrates a synthesis of 2-((2-Methoxybenzyl)amino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-028, NCGC00244511-01).
- the title compound was prepared according to general protocol F.
- This example illustrates a synthesis of 2-(Phenylamino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-029, NCGC00244510-01).
- the title compound was prepared according to general protocol F.
- This example illustrates a synthesis of 2-((Cyclohexylmethyl)amino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-033, NCGC00244473-01).
- the title compound was prepared according to general protocol F.
- This example illustrates a synthesis of 2,6-Dimethoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-056, NCGC00244474-01 , CID-56593296).
- the title compound was prepared according to general protocol C.
- This example illustrates a synthesis of Methyl 2-(2-methoxybenzamido)benzoate (XJB09-051).
- a solution of 2-aminobenzoate (2.57 mL, 19.9 mmol) in dichloro methane (50.0 mL) and TEA (8.30 mL, 59.5 mmol) was treated at 0 °C with 2-methoxybenzoyl chloride (2.67 mL, 19.9 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)benzamide (XJB09-067, NCGC00244477-01).
- the title compound was prepared according to general protocol G.
- This example illustrates a synthesis of Ethyl 4-(2-methoxybenzamido)benzoate (XJB09-077).
- a solution of ethyl 3-aminobenzoate (1.00 g, 6.05 mmol) in dichloromethane (10.0 mL) and triethylamine (2.53 mL, 18.2 mmol) was treated at 0 °C with 2- methoxybenzoyl chloride (0.814 mL, 6.05 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of Methyl 2-(2-methoxy-N- methylbenzamido)benzoate (XJB 10-022).
- the reaction mixture was warmed to room temperature and stirred at room temperature for 1 h.
- a solution of Mel (1.27 mL, 20.3 mmol) in DMF (4.00 mL) was added drop wise.
- the reaction mixture was stirred at room temperature for 1.5 h.
- This example illustrates a synthesis of 2-(2-(Dimethylamino)ethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-028, NCGC00244483-01).
- the title compound was prepared according to general protocol H.
- This example illustrates a synthesis of 2-Phenoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB10-037, NCGC00244517-01).
- the title compound was prepared according to general protocol H.
- This example illustrates a synthesis of 2-(2-(Piperazin-l-yl)ethoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJBlO-043, NCGC00244504-01).
- a solution of tert- butyl 4-(2-(2-(3-(trifluoromethyl)phenylcarbamoyl)phenoxy)ethyl)piperazine-l-carboxylate (0.099 g, 0.200 mmol) in dichloromethane (2.00 mL) was treated at 0 °C with TFA (1.00 mL). The reaction mixture was stirred at 0 °C for 1 h.
- This example illustrates a synthesis of Methyl 4-(2-ethoxybenzamido)nicotinate (XJBl 1-044).
- a solution of 4-aminonicotinate (500 mg, 3.29 mmol) in dichloromethane (25.0 mL) and triethylamine (1.37 mL, 9.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (607 mg, 3.29 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of 4-(2-Ethoxybenzamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)nicotinamide (XJB11-049, NCGC00250117-01).
- the title compound was prepared according to general protocol A.
- This example illustrates a synthesis of Methyl 2-(2-ethoxybenzamido)nicotinate (XJB11-045).
- a solution of 4-aminonicotinate (500 mg, 3.29 mmol) in dichloromethane (25.0 mL) and triethylamine (1.37 mL, 9.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (607 mg, 3.29 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of Methyl 3-(2- ethoxybenzamido)isonicotinate (XJB11-046).
- a solution of methyl 3-aminoisonicotinate (200 mg, 1.31 mmol) in dichloromethane (25.0 mL) and triethylamine (0.550 mL, 3.94 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (243 mg, 1.31 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of Methyl 2-(2-ethoxybenzamido)thiophene- 3-carboxylate (XJB 11-057).
- a solution of 2-aminothiophene-3-carboxylate (500 mg, 3.18 mmol) in dichloromethane (25.0 mL) and triethylamine (1.33 mL, 9.54 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (587 mg, 3.18 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of Methyl 2-(2- ethoxyphenylsulfonamido)benzoate (XJBl 1-060).
- a solution of methyl 2-aminobenzoate (206 mg, 1.359 mmol) in dichloromethane (5.00 mL) and triethylamine (0.568 mL, 4.08 mmol) was treated at 0 °C with 2-ethoxybenzene-l-sulfonyl chloride (300 mg, 1.359 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- This example illustrates a synthesis of Ethyl 3-(2-ethoxybenzamido)propanoate (XJB11-061).
- a solution of ethyl 3-aminopropanoate, HC1 salt (300 mg, 1.95 mmol) in dichloromethane (25.0 mL) and triethylamine (0.817 mL, 5.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (361 mg, 1.95 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h.
- NCGC00250106-01, CID-56593341 A tube was charged with Cul (3.3 mg, 0.017 mmol), 1,10-phenanthroline (6.3 mg, 0.035 mmol), (56.7 mg, 0.174 mmol), 2-iodo-N-(2-(3- (trifiuoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (50.0 mg, 0.087 mmol) and ethanethiol (10.8 mg, 0.174 mmol) in toluene (1.50 mL) under N 2 . The tube was sealed and the reaction mixture was stirred at 110 °C for 24 h.
- the resulting mixture was cooled to room temperature and treated with a small portion of Si-THIOL to get rid of copper.
- the mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C 18 reverse phase HPLC to give the final product.
- This example illustrates a synthesis of Methyl 2-(2- isopropoxybenzamido)benzoate (XJB12-040).
- a solution of methyl 2-aminobenzoate (0.245 mL, 1.89 mmol) in dichloromethane (8.00 mL) and triethylamine (0.53 mL, 3.78 mmol) was treated at 0 °C with 2-isopropoxybenzoyl chloride (250 mg, 1.26 mmol). The reaction mixture was stirred at 0 °C for 2 hours and then at room temperature for another 2 hours.
- This exam le illustrates a synthesis of 2-Isopropoxy-N-(2-(3- (trifluoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (XJB11-073, NCGC00250135- 01, compound 178).
- a ⁇ W tube was charged with copper (I) iodide (3.3 mg, 0.017 mmol), 1,10-phenanthroline (6.3 mg, 0.035 mmol), cesium carbonate (56.7 mg, 0.174 mmol), 2-iodo- N-(2-(3-(trifluoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (50.0 mg, 0.087 mmol), propan-2-ol (10.5 mg, 0.174 mmol), and dry toluene (1.50 mL). The tube was sealed, and the reaction mixture was stirred at 110 °C for overnight. The resulting suspension was cooled to room temperature and treated with Si-Thio.
- This example illustrates a synthesis of Methyl 2-amino-3-(2- ethoxybenzamido)benzoate (XJB 11-082).
- a solution of 2, 3-diaminobenzoate (100 mg, 0.602 mmol) in dichloro methane (5.00 mL) and TEA (0.252 mL, 1.81 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (11 1 mg, 0.602 mmol).
- the reaction mixture was stirred at 0 °C for 1 h.
- the reaction mixture was concentrated in vacuo and the crude material was used directly in the next reaction.
- NCGC00250112-01 A solution of N-(2-aminobenzyl)-3-(trifluoromethylsulfonyl)aniline (0.060 g, 0.181 mmol) in dichloromethane (2.00 mL) and TEA (0.075 mL, 0.535 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (0.033 g, 0.181 mmol). The reaction mixture was stirred overnight at room temperature for 2 h. The mixture was concentrated, re- dissolved in 2.00 mL of DMSO, filtered and purified via C 18 reverse phase HPLC to give the final product.
Abstract
Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
Description
MODULATORS OF THE RELAXIN RECEPTOR 1
CROSS REFERENCE TO RELATED APPLICATION
This application claims priority from U.S. Provisional Application No. 61/642,986 filed May 4, 2012, which is hereby incorporated by reference in its entirety.
STATEMENT OF GOVERNMENT SUPPORT
This invention was made in part with government support from the National Institutes of Health. The government has certain rights in this invention.
BACKGROUND
[0001] The peptide hormone relaxin was discovered in 1926 as a hormone of pregnancy, due to its effects to relax pubic ligaments and soften the cervix to facilitate parturition (Hisaw, F ., Proc. Soc. Exp. Biol. Med. 1926, 23(8), 661-663; Fevold. H.L. et al, J. Am. Chem. Soc. 1930, 52(8), 3340-3348). Since then, it has been shown that blood concentrations of relaxin rise during the first trimester of pregnancy, promoting cardiovascular and renal adjustments to meet the increased nutritional demands of the growing fetus, and the elevated requirements for renal clearance of metabolic wastes (Baylis. C, Am. J. Kidney Dis. 1999, 34, 1142-4). Relaxin induces a 20% increase in cardiac output, 30% decrease in systemic vascular resistance, 30% increase in global arterial compliance, and 45% increase in renal blood flow during pregnancy (Schrier, R. W. et al, Am. J. Kidney Dis. 1987, 9, 284-9).
Numerous clinical and nonclinical studies using this hormone have now recapitulated these cardiovascular effects in both males and females, demonstrating the pharmacological utility of relaxin in modulating cardiovascular and renal functions in humans.
[0002] The X-ray crystal structure of relaxin at 1.5 A resolution was reported for the physiologically active form of the human hormone in 1991. The physiological effects of relaxin are mediated by its interaction with a G protein-coupled receptor (RXFPl) leading to the modulation of several signal transduction pathways. Activation of RXFPl by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2)
extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-β; and 4) angiogenesis by
activating transcription of VEGF. The understanding of the biological effects of RXFP1 activation by relaxin has led to the evaluation of relaxin as a pharmacologic agent for the treatment of patients with acute heart failure (AHF), pre- eclampsia, and hypertensive disease. In addition, several clinical trials studied the therapeutic role of relaxin in treatment of scleroderma, cervical ripening, fibromyalgia, and orthodontics, given its function as antiinflammatory and extracellular matrix remodeler.
[0003] The latest statistics indicate that 1 of every 2.9 deaths in the United States is due to cardiovascular disease (CVD) (Roger, V.L. et al, Circulation 2011, 123(4), 459-463). Each year, ~ 795,000 people experience a new or recurrent stroke, and 1 in 9 death certificates in the United States mention heart failure. In addition, 33.5% of US adults over 20 years of age have hypertension. These statistics clearly illustrate the limitations of current therapies to address CVD in general and acute heart failure (AHF) in particular. The significant contribution of vascular dysfunction to the pathophysiology of AHF has more recently been recognized. These patients are characterized by preserved or elevated systolic blood pressure and increased vascular stiffness with less fluid overload. They are more likely to be elderly and female. Large-scale registry studies suggest that patients with vascular dysfunction causing AHF represent the majority of patients, and that this may have been underappreciated during previous development of new therapies.
[0004] Therapeutically, there is a great medical need for better approaches to treat heart failure. Currently, there are two major methodologies: a) surgery and medical devices:
coronary bypass surgery, heart valve repair or replacement, implantable cardioverter- defibrillators (ICDs), heart pumps (left ventricular assist devices, or LVADs), or heart transplant; b) medications: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), digoxin (lanoxin), beta blockers and aldosterone antagonists. Importantly, none of these approaches are able to address the development of scar heart tissue after severe heart failure, or repair it after damage. In that sense the anti-fibrotic and remodeling properties of relaxin, together with its capacity to normalize blood pressure, increase blood and renal flow, while it promotes decongestion and vascular compliance, seem to be ideal for treating these conditions. Clinical data agrees with this theory (Teichman S.L. et al, Curr. Heart Failure Rep. 2010, 7, 75-82). Relaxin relieves systemic and renal vasoconstriction and increases vascular compliance, including normalization of high blood
pressure, reduction of pulmonary capillary wedge pressure, increase of cardiac output, increase renal blood flow, natriuresis, and decongestion. In addition, animal pharmacology data indicate that relaxin hormone has anti-inflammatory and cardiac protection effects, including reduction of myocardial ischemia, reduction of reperfusion injury, increase of wound healing, and reduction of ventricular fibrosis.
[0005] Recombinant relaxin hormone has produced excellent responses in clinical trials for treatment of heart failure and is about to reach commercialization. However,
administration of the peptide is difficult in chronic settings. In view of the foregoing, there is an unmet need for new small molecule agonists of the RXFP1 receptor.
SUMMARY
wherein A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH2CH2-, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, and 1,2-heterocyclyl are optionally substituted with one or more substituents independently selected from halo, CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and S02CF3,
Ri is -NHCOR3, R4, -NHR5, or -OR6,
R2 is alkyl, cycloalkyl, heteroarylalkyl, orphenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, trihalo C1-C10 alkyl, perhalo C1-C10 alkyl, trihalo C1-C10 alkyloxy, perhalo C1-C10 alkyloxy, aryl, trihalo alky laryl, perhaloalkylaryl, heterocyclylalkyl, - SR7, -SOR7, -S02R7, -SCF3, -N02, -CN, and -S02CF3,
R3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from t halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohalo alkyl,
Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, -N02,-CN, and -S02CF3,
R4 is phenyl optionally substituted with alkyloxy, haloalkoxy,, arylalkyl, or arylalkyloxy,
R5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl,
is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
and R7 IS C1-C10 alkyl, Ci-Cio haloalkyl, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy.
[0007] The disclosure also provides a pharmaceutical composition comprising a compound or salt of the invention and a pharmaceutically acceptable carrier.
[0008] The disclosure further provides a method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1 , comprising administering an effective amount of the compound on the disclosure to a mammal afflicted therewith. In some embodiments the mammal is a human and the mammalian relaxin receptor 1 is a human relaxin 1 receptor.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)
[0009] Figure 1 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0010] Figure 2 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0011] Figure 3 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0012] Figure 4 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0013] Figure 5 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0014] Figure 6 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0015] Figure 7 depicts synthetic schemes for the preparation of compounds in accordance with embodiments of the disclosure.
[0016] Figures 1-7 depict synthetic schemes for the preparation of embodiments of the disclosure.
[0017] Figure 8 depicts the cell impedence observed for representative embodiments of the disclosure.
[0018] Figure 9 depicts the results of substitution of mouse sequence with human sequence on activation of cAMP in accordance with an embodiment of the disclosure.
[0019] Figure 10 depicts the activiation of relaxin receptors from human, monkey, pig, and mouse by compound 178.
[0020] Figure 11 depicts the identification of a human RXFP1 region responsible for activation by compound 178.
DETAILED DESCRIPTION
wherein A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH2CH2-, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, and 1,2-heterocyclyl are optionally substituted with one or more substituents independently selected from halo, CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and S02CF3,
Ri is -NHCOR3, R4, -NHR5, or -OR6,
R2 is alkyl, cycloalkyl, heteroarylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, aryl, halo alky laryl, heterocyclylalkyl, -SR7, -SOR7, -S02R7, -SCF3, -N02, -CN, and -S02CF3,
R3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, each of which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy„ -SR7, -SOR7, -S02R7, -SCF3, -N02,-CN, and -S02CF3,
R4 is phenyl optionally substituted with alkyloxy, haloalkyloxy, arylalkyl, or arylalkyloxy,
R5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl,
Re is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
and R7 is C1-C10 alkyl, C1-C10 haloalkyl, Ci-Ciohaloalkyl or Ci-Ciohaloalkoxy, with the provisos that:
(i) when R3 is methyl, chloromethyl, or dichloromethyl, and A is 1 ,2-phenylenyl, then R2 is not methyl, phenyl, 2-methylphenyl, 2-methoxyphenyl, or 4-methoxyphenyl; and
(ii) when R3 is phenyl, and A is 1 ,2-phenylenyl, then R2 is not halophenyl, methoxyphenyl, 2,6-dimethylphenyl, or 2,4,6-trimethylphenyl; and
(iii) when R3 is phenyl substituted with alkyl, and A is 1 ,2-phenylenyl, then R2 is not methoxyphenyl;
or a pharmaceutically acceptable salt thereof.
[0022] In accordance with certain embodiments, R2 is phenyl substituted with a substituent selected from -S02CF3, -SCF3, and -CF3.
[0023] In accordance with certain embodiments, A is 1 ,2-phenylene optionally substituted with one or more substituents selected from hydrogen, halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0024] In accordance with certain embodiments, Rl is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3, Ci-Cioalkyl, C1-C10 alkyloxy,
Ci-Ciohaloalkyl, Cl-Ciohaloalkoxy, alkyloxyalkyloxy, dimethylamino alkyloxy, - SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0025] In accordance with certain preferred embodiments, R3 is
2-(Ci-Cio)alkyloxyphenyl.
[0026] In accordance with certain preferred embodiments, R2 is phenyl substituted with a substituent selected from -CF3, Ci-Cioalkyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl,
Cl-ClOhaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0027] In certain preferred embodiments, the compound is selected from the group consisting of:
[0028] In accordance with certain embodiments, Ri is R4, wherein R4 is
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio) haloalkyloxyphenyl.
[0029] In accordance with certain preferred embodiments, Ri is -NHR5, wherein R5 is aryl optionally substituted with one or more substituents selected from alkyloxy and trifluoromethyl.
[0030] In accordance with certain embodiments, Ri is -OR6, wherein R^ is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl.
[0031] In accordance with certain embodiments, A is 1 ,2-heteroarylenyl optionally substituted with one or more subsitutents independently selected from halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0033] In accordance with certain preferred embodiments, Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from the group consisting of -CF3, Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0034] In accordance with certain preferred embodiments, R3 is
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
[0035] In certain preferred embodiments, wherein the compound is selected from the group consisting of:
[0036] In accordance with certain embodiments, A is tCH 2CH2-.
[0037] In accordance with certain embodiments, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent independently selected from -CF3, C1-C10 alkyl, C1-C10 alkyloxy, Ci-Ciohalo alkyl, Ci-Ciohaloalkoxy„ -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0038] In accordance with certain embodimenst, R3 is 2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
[0039] In accordance with a particular embodiment, the compound is:
[0040] The disclosure provides compounds and pharmaceutically acceptable thereof, having the formula
(Formula X)
is a 3- to 8-membered carbocyclic ring or a 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, each of which A ring is optionally fused to a 3- to 8-membered carbocyclic ring or a 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, to form a bicylic ring system; and the A ring and 3 Qo 8--membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with R10; , and p are integers independently chosen from 0, 1, and 2 and each
n ,
, and P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy;
X and Y are independently chosen from O and S;
Rs and R9 are independently chosen from hydrogen and Ci-C4alkyl;
Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0041] In another embodiment the disclosure includes a compound or salt of Formula X
where
is a phenyl or 5- or 6-membered heteroaryl group containing 1 to 3 heteroatoms independently chosen from N, O, and S, each of which A ring is optionally fused to 5- or 6-membered carbocyclic or heterocyclic ring to form a bicylic ring system; and the A ring and 5- or 6-membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with R10.
[0042] The disclosure includes compounds or salts for Formula X where
is a group of formula
each of which is substituted with R10.
[0043] The disclosure includes compounds or salts for Formula X, wherein m, n, o, and p are all 0 and X and Y are both O.
The disclosure includes compounds or pharmaceutically salts for Formula XI
Rio, R21, and R3i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, d-Gtalkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, d-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0044] The disclosure includes compounds and salts of Formula XI, wherein R2o is Ci- Cehaloalkyl, -S(Ci-C6haloalkyl), or SO 2(Ci-C6haloalkyl).
[0045] The disclosure includes compounds and salts of Formula XI, wherein Rio, R21, and R31 are each 0 substituents.
[0046] The disclosure includes compounds and salts of Formula XI, wherein Rio, R21, and R31 are each 0 substituents; R20 is CF3, SCF3, or S02CF3i and R30 is C2-C6alkoxy or C2- Cealkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and STF 3.
[0047] The disclosure includes compounds and salts of Formula XI, wherein R2o is
[0048] The disclosure includes compounds and salts of Formula XII
Rio and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy; and
R2 is (phenyl)Co-C2alkyl- or (5- or 6-membered heteroaryl)Co-C2alkyl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7Cycloalkyl)Co-C2alkyl, 5- and 6-membered heterocycloalkyl, thienyl, phenyl, phenyl substituted with CF3, mono- and di-Ci-Cealkylamino, Ci -Cealkylthio, Ci-Cealkylsulfonyl Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy, -SR7, -SOR7, and -SO2R7, where R7 is Ci-Ciocarbhydryl or Ci-Ciohaloalkyl; or
R2 is dihydroindenyl, benzo[<i][l,3]dioxolyl, or indolyl, each of which is substituted with 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino,
Ci-C4alkyl, Ci-C4alkoxy, mono- or di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and - C2haloalkoxy.
[0049] The disclosure includes compounds and salts of Formula XII, wherein R10 and R31 are both 0 substituents.
[0050] The disclosure includes compounds and salts of Formula XII, wherein
R2 is phenyl substituted with one or two substituents independently chosen from hydroxyl, halogen, nitro, SCF3, SO2CF3, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, 5- and 6- membered heterocycloalkyl, thienyl, phenyl, phenyl substituted with CF3, mono- and di-Ci- Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci- C2haloalkoxy.
[0051] The disclosure includes compounds and salts of Formula XII, wherein R2 is phenyl substituted in the meta position with CF3, SCF3, or S02CF3.
[0052] The disclosure includes compounds and salts of Formula XII, wherein
R2 is 2,3-dihydro-lH-indenyl, benzo[<i][l,3]dioxolyl, or indolyl, each of which is unsubstituted.
[0053] The disclosure includes compounds and pharmaceutically acceptable salts of Formul
Rio and R21 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbhydryl or Ci-Ciohaloalkyl;; and
R3 is cyclohexyl; or
R3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF3, SC>2CF3, Ci-Cealkyl, C2-Cealkenyl, C2- Cealkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci- C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0054] The disclosure includes compounds and salts of Formula XIII, wherein R10 and
R21 are both 0 substituents and R3 is phenyl substituted with one meta-position substituent.
[0055] The disclosure includes compounds and salts of Formula XIII, wherein R10 and
R21 are both 0 substituents and R20 is CF3, SCF3, or S02CF3.
[0056] The disclosure includes compounds and salts of Formula XIII, wherein R2o is
CF3; and
R3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF3, S02CF3, Ci-Cealkyl, C2-C6alkenyl, C2- C6alkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-C6alkylthio, Ci-Cealkylsulfonyl Ci- C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0057] The disclosure includes compounds and salts of Formula XIII, wherein R2o is
S02CF3; and
R3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF3, SC>2CF3, Ci-Cealkyl, C2-Cealkenyl, C2- Cealkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci- C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
he disclosure includes compounds and salts of Formula X, wherein
[0058] Additionally in certain embodiments where the A-ring is a thienyl or pyridyl
Rio, R21, and R3i are each 0 substituents.
[0059] The disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein each of m, n, o, and p are 0 and X and Y are both O.
[0060] The disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl; and
R30 is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0061] The disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein R2o is Ci-Cehaloalkyl, -S(Ci-C6haloalkyl), or SO 2(Ci-C6haloalkyl).
[0062] The disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein R10, R21 , and R31 are each 0 substituents; R2o is CF3, SCF3, or S02CF3i and R30 is C2-C6alkoxy or C2-C6alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and HEF 3.
[0063] The disclosure also includes compounds and salts where the A ring is a thienyl or pyridyl, wherein R2o is S02CF3.
[0064] The disclosure further includes compounds and salts of Formula XIV
m, n, o, and p are integers independently chosen from 0, 1, and 2 and each of V / n , V / o , and ; P P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy;
X and Y are independently chosen from O and S;
R8 and R9 are independently chosnen from hydrogen and Ci-C4alkyl;
Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0065] The disclosure includes compounds and salts of Formula XIV, wherein m, n, o, and p are all 0 and X and Y are both O.
[0066] The disclosure includes compounds and salts of Formula XV
Rio, R21, and R3i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
R3o is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
The disclosure includes compounds and salts of Formula XVI
Rio, R21, and R3i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
[0067] The disclosure includes compounds of Formula XV and XVI, wherein R2o is
Ci-Cehaloalkyl, -S(d-C6haloalkyl), or SO 2(Ci-C6haloalkyl).
[0068] The disclosure includes compounds of Formula XV and XVI, wherein R21, and
R31 are both 0 substituents.
[0069] The disclosure includes compounds of Formula XV and XVI, wherein R2i and
R31 are both 0 substituents; R2o is CF3, SCF3, or S02CF3i and R30 is C2-C6alkoxy or C2- C6alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and STF 3.
[0070] The disclosure includes compounds of Formula XV and XVI, wherein R20 is S02CF3.
[0071] Any of the variable definitions set forth herein (e.g. Rio, R2o, R2i, R30, R31, Rs, R9, X, Y, m, n, o, and p) may be combined so long as a stable compound results, and all such combinations which result in a stable compound are included as compounds within the scope of the disclosure.
[0072] Any of the genuses, subgenuses, and compounds in the scope of the disclosure, including compounds and salts of Formula X to Formula XVI, can be used for treating any of the conditions, disorders, diseases, or other facets of mammalian health listed in this application.
[0073] Any of the genuses, subgenuses, and compounds of the disclosure, including compounds and salts of Formula X to XI can be used for the manufacture of a medicament for any of the conditions, disorders, diseases, or other facets of mammalian health listed in this application.
[0074] Referring now to terminology used generically herein, the term HlkylChieans a straight-chain or branched alkyl substituent containing from, for example, 1 to about 10 carbon atoms, preferably from 1 to about 4 carbon atoms, more preferably from 1 to 2 carbon atoms. Examples of such substituents include methyl, ethyl, propyl, isopropyl, n-butyl, sec- butyl, isobutyl, tert-butyl, pentyl, isoamyl, hexyl, and the like.
[0075] The term alkenyl, Cas used herein, means a linear or branched alkenyl substituent containing at least one carbon-carbon double bond and from, for example, linear alkenyl of
about 2 to about 10 carbon atoms (branched alkenyls are about 3 to about 6 carbons atoms), preferably from about 2 to about 5 carbon atoms (branched alkenyls are preferably from about 3 to about 5 carbon atoms), more preferably linear alkenyl of about 3 to about 4 carbon atoms. Examples of such substituents include vinyl, propenyl, isopropenyl, n-butenyl, sec- butenyl, isobutenyl, tert-butenyl, pentenyl, isopentenyl, hexenyl, and the like.
[0076] The term alkynyl, Cas used herein, means a linear or branched alkynyl substituent containing at least one carbon-carbon triple bond and from, for example, linear alkynyl of 2 to about 10 carbon atoms (branched alkynyls are about 3 to about 6 carbons atoms), preferably from 2 to about 5 carbon atoms (branched alkynyls are preferably from about 3 to about 5 carbon atoms), more preferably linear alkynyl of about 3 to about 4 carbon atoms. Examples of such substituents include ethynyl, propynyl, isopropynyl, n-butynyl, sec- butynyl, isobutynyl, tert-butynyl, pentynyl, isopentynyl, hexynyl, and the like.
[0077] [Carbhydryl Os a hydrocarbon group that is straight, branched or cyclic (including (cycloalkyl)alkyl) and contains any combination of single, double, and triple covalent bonds. For example a carbhydryl group may be an alkyl, alkenyl, or alkynyl group. When the term carbhydryl is used in conjuction with BxyCcarbhydryl is a group as defined covalently bound to the group it substitutes through an oxygen, -0-, bridge. Similarly, carbhydrylthio is a carbhydryl group as defined covalently bound to the group it substitutes through a sulfur, - S-, bridge.
[0078] The term BycloalkyLCas used herein, means a cyclic alkyl substituent containing from, for example, about 3 to about 8 carbon atoms, preferably from about 4 to about 7 carbon atoms, and more preferably from about 4 to about 6 carbon atoms. Examples of such substituents include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. The cyclic alkyl groups may be unsubstituted or further substituted with alkyl groups such as methyl groups, ethyl groups, and the like.
[0079] The term fbicycloalkyl^as used herein, means a bicyclic alkyl substituent containing from, for example, about 4 to about 12 carbon atoms, preferably from about 4 to about 7 carbon atoms, and more preferably from about 6 to about 10 carbon atoms.
Examples of such substituents include bicyclo[3.2.0]heptyl, bicyclo[3.3.0]octyl,
bicyclo[4.3.0]nonyl, bicyclo[4.4.0]decyl, and the like. The bicyclic alkyl groups may be unsubstituted or further substituted with alkyl groups such as methyl groups, ethyl groups, and the like.
[0080] The term tricycloalkylQas used herein, means a tricyclic alkyl substituent containing from, for example, about 6 to about 18 carbon atoms, preferably from about 8 to about 16 carbon atoms. Examples of such substituents include adamantyl and the like. The tricyclic alkyl groups may be unsubstituted or further substituted with alkyl groups such as methyl groups, ethyl groups, and the like.
[0081] Halo alkyl indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
[0082] Halo alkoxy indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical). The term [heterocyclyl, Cor [heterocyclic Cas used herein, refers to a monocyclic or bicyclic 3- to 8-membered ring system containing one or more heteroatoms selected from O, N, S, and combinations thereof. The heterocyclyl group can be any suitable heterocyclyl group and can be an aliphatic heterocyclyl group, an aromatic heterocyclyl group, or a combination thereof. The heterocyclyl group can be a monocyclic heterocyclyl group or a bicyclic heterocyclyl group. Suitable bicyclic heterocyclyl groups include monocylic heterocyclyl rings fused to a C6-Cio aryl ring. When the heterocyclyl group is a bicyclic heterocyclyl group, both ring systems can be aliphatic or aromatic, or one ring system can be aromatic and the other ring system can be aliphatic as in, for example, dihydrobenzofuran. Preferably, the heterocyclyl group is an aromatic heterocyclyl group. Non-limiting examples of suitable heterocyclyl groups include furanyl, thiopheneyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, l,3,4-oxadiazol-2-yl, l,2,4-oxadiazol-2-yl, 5-methyl-l,3,4- oxadiazole, 3-methyl-l,2,4-oxadiazole, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, benzothiopheneyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolinyl, benzothiazolinyl, and quinazolinyl. The heterocyclyl group is optionally substituted with 1, 2, 3, 4, or 5 substituents as recited herein such as with alkyl groups such as methyl groups, ethyl groups, and the like, or with aryl groups such as phenyl groups, naphthyl groups and the like, wherein the aryl groups can be further substituted with, for example halo, dihaloalkyl, trihaloalkyl, nitro, hydroxy, alkoxy, aryloxy, amino, substituted amino, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, aryloxycarbonyl, thio, alkylthio,
arylthio, and the like, wherein the optional substituent can be present at any open position on the heterocyclyl group.
[0083] The term [heteroaryl, Cas used herein, refers to a monocyclic or bicyclic 5- or 6-membered ring system containing one or more heteroatoms selected from O, N, S, and combinations thereof. The heteroaryl group can be any suitable heteroaryl. The heteroaryl group can be a monocyclic heteroaryl group or a bicyclic heteroaryl group. Suitable bicyclic heteroaryl groups include monocylic heteroaryl rings fused to a C6-Cio aryl ring. When the heteroaryl group is a bicyclic heteroaryl group, both ring systems are preferably aryl.
Non-limiting examples of suitable heteroaryl groups include furanyl, thiopheneyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, benzo furanyl, benzo thiopheneyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolinyl, benzo thiazolinyl, and quinazolinyl. The heteroaryl group is optionally substituted with 1, 2, 3, 4, or 5 substituents as recited herein, wherein the optional substituent can be present at any open position on the heteroaryl group.
[0084] The terms fieteroarylalkylCand Iheterocyclylalkyl, Cas used herein, refers to a heteroaryl or heterocyclyl group as defined herein having an alkyl linker group attached thereto, wherein the heteroarylalkyl and heterocyclylalkyl groups are attached to the rest of the molecule via the alkyl linker group.
[0085] The terms [1,2-phenylenylCand [[,2-heteroarylenyl, Cas used herein, refer to a phenyl group or a heteroaryl group having attached to the ring two groups positioned at adjacent positions on the phenyl or heteroaryl group, i.e., forming an ortho substitution on the phenyl or heteroaryl group.
[0086] The term Hrylalkyl, as used herein, refers to an alkyl group linked to a C 6-Cio aryl ring and further linked to a molecule via the alkyl group. The term Hlkylaryl, Cas used herein, refers to a C6-Cio aryl ring linked to an alkyl group and further linked to a molecule via the aryl group.
[0087] The term Hlkylcarbonyl, Cas used herein, refers to an alkyl group linked to a carbonyl group and further linked to a molecule via the carbonyl group, e.g., alkyl-C(=0)-. The term Hlkoxycarbonyl, Cas used herein, refers to an alkoxy group linked to a carbonyl group and further linked to a molecule via the carbonyl group, e.g., alkyl-0-C(=0)-.
[0088] Whenever a range of the number of atoms in a structure is indicated (e.g., a C1-C12, Ci-C8, Ci-C6, C1-C4, or C2-C12, C2-C8, C2-C6, C2-C4 alkyl, alkenyl, alkynyl, etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used. Thus, for instance, the recitation of a range of 1- 8 carbon atoms (e.g., Ci-Cs), 1-6 carbon atoms (e.g., Ci-C6), 1-4 carbon atoms (e.g., C1-C4), 1-3 carbon atoms (e.g., C1-C3), or 2-8 carbon atoms (e.g., C2-Cs) as used with respect to any chemical group (e.g., alkyl, alkylamino, etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, and/or 12 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 1-9 carbon atoms, 1-10 carbon atoms, 1-11 carbon atoms, 1-12 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 2-7 carbon atoms, 2-8 carbon atoms, 2-9 carbon atoms, 2-10 carbon atoms, 2-11 carbon atoms, 2-12 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3- 6 carbon atoms, 3-7 carbon atoms, 3-8 carbon atoms, 3-9 carbon atoms, 3-10 carbon atoms, 3-11 carbon atoms, 3-12 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, 4-7 carbon atoms, 4-8 carbon atoms, 4-9 carbon atoms, 4-10 carbon atoms, 4-11 carbon atoms, and/or 4- 12 carbon atoms, etc., as appropriate). Similarly, the recitation of a range of 6-10 carbon atoms (e.g., C6-Cio) as used with respect to any chemical group (e.g., aryl) referenced herein encompasses and specifically describes 6, 7, 8, 9, and/or 10 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 6-10 carbon atoms, 6-9 carbon atoms, 6-8 carbon atoms, 6-7 carbon atoms, 7-10 carbon atoms, 7-9 carbon atoms, 7-8 carbon atoms, 8-10 carbon atoms, and/or 8-9 carbon atoms, etc., as appropriate).
[0089] The term Halo Cor [halogen, as used herein, means a substituent selected from Group VIIA, such as, for example, fluorine, bromine, chlorine, and iodine.
[0090] The term Hryl refers to an unsubstituted or substituted aromatic carbocyclic substituent, as commonly understood in the art, and the term HE 6-Cio arylOncludes phenyl and naphthyl. It is understood that the term aryl applies to cyclic substituents that are planar and comprise 4n+2 π electrons, according to HuckelH Rule. The term BarbocyclicQefers to an aliphatic or aromatic ring containing only carbon ring atoms.
[0091] The phrase pharmaceutically acceptable saltOs intended to include nontoxic salts synthesized from the parent compound which contains a basic or acidic moiety by
conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. Generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington^ Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445, and Journal of 'Pharmaceutical Science, 66, 2-19 (1977).
[0092] Suitable bases include inorganic bases such as alkali and alkaline earth metal bases, e.g., those containing metallic cations such as sodium, potassium, magnesium, calcium and the like. Non-limiting examples of suitable bases include sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate. Suitable acids include inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, benzenesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, maleic acid, tartaric acid, fatty acids, long chain fatty acids, and the like. Preferred pharmaceutically acceptable salts of inventive compounds having an acidic moiety include sodium and potassium salts. Preferred pharmaceutically acceptable salts of inventive compounds having a basic moiety (e.g., a dimethylaminoalkyl group) include hydrochloride and hydrobromide salts. The compounds of the present disclosure containing an acidic or basic moiety are useful in the form of the free base or acid or in the form of a pharmaceutically acceptable salt thereof.
[0093] It should be recognized that the particular counterion forming a part of any salt of this disclosure is usually not of a critical nature, so long as the salt as a whole is
pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.
[0094] It is further understood that the above compounds and salts may form solvates, or exist in a substantially uncomplexed form, such as the anhydrous form. As used herein, the term "solvate" refers to a molecular complex wherein the solvent molecule, such as the crystallizing solvent, is incorporated into the crystal lattice. When the solvent incorporated in the solvate is water, the molecular complex is called a hydrate. Pharmaceutically acceptable solvates include hydrates, alcoholates such as methanolates and ethanolates, acetonitrilates and the like. These compounds can also exist in polymorphic forms.
[0095] The compounds of the disclosure can be synthesized using any suitable synthetic route. Referring to Figure 1, methyl 2-aminobenzoate 500 can be reacted with an acid chloride in the presence of a base such as triethylamine in a solvent such as
dichloromethane to provide amide 501. Amide 501 can be reacted with an amine in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene to provide bis-amide 502. Compound 503 can be reacted with a boronic acid in the presence of a catalyst such as Pd(PPh3)4, a base such as sodium carbonate, in a solvent such as
dimethylformamide under microwave irradiation to give the coupled product 504. Arylthiol compound 505 can be oxidized with an agent such as m-chloroperoxybenzoic acid in a solvent such as dichloromethane to give sulfone 506. The cyano compound 507 can be reacted with ammonium chloride in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene to give amidine 508. Reaction of amidine 508 with an azide such as sodium azide in the presence of a catalyst such as zinc bromide in a solvent such as water gives tetrazole 510.
[0096] Referring to Figure 2, carboxylic acid 511 can be reacted with an amine such as
1,3-trilfuoromethylaniline in the presence of a coupling agent such as EDC and a basic catalyst such as dimethylaminopyridine in a solvent such as dichloromethane, followed by deprotection with an agent such as trifluoro acetic acid in a solvent such as dichloromethane to give free amine 513. Reaction of amine 513 with a carboxylic acid in the presence of coupling agentssuch as EDC or HATU in the presence of a basic catalyst such as
dimethylaminopyridine in a solvent such as dimethylformamide gives amide 514.
Alternatively, reaction of amine 513 with an acid chloride or an acid bromide in the presence of a base such as triethylamine in a solvent such as dichloromethane provides amide 514.
[0097] Referring to Figure 3, reaction of aryl iodide 515 with an alcohol in the presence of a catalyst such as 1,10-phenanthroline and a base such as cesium carbonate in a solvent such as toluene gives aryl ether 516. Reaction of 2-bromobenzoyl chloride or 2-iodobenzoyl chloride 517 with 3-trifluoromethylaniline in the presence of a base such as triethylamine in a solvent such as dichloromethane provides amide 518. Amide 518 reacts with a boronic acid in the presence of a catalyst such as Pd(PPh3)4, a base such as sodium carbonate, in a solvent such as dimethylformamide under microwave irradiation gives alkylated/arylated compound
519. Reaction of compound 518 with a primary amine in the presence of a catalyst such as cuprous chloride in a solvent such as dimethylformanide provides arylamine 520. Reaction
of 518 with an alcohol in the presence of catalysts such as copper (I) iodide and 1,10-phenanthroline in the presence of a base such as cesium carbonate in a solvent such as toluene gives aryl ether 521.
[0098] Referring to Figure 4, reaction of amide 522 with an alkylating agent such as iodomethane in the presence of a base such as NaH in a solvent such as dimethylformamide gives N-methylamide 523. Compound 523 reacts with an arylamine such as compound 524 in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene to give bis-amide 525. Oxidation of alcohol 526 with an oxidant such as Dess-Martin periodinane in a solvent such as dichloromethane gives aldehyde 527. Reductive amination of aldehyde 527 with an amine such as 528 in the presence of a catalyst such as Ti(Oz'Pr)4 and a reductant such as sodium borohydride gives amine 529. Deprotection of Boc compound 529 with an agent such as trifluoro acetic acid in a solvent such as dichloromethane gives arylamine 530.
Coupling of arylamine 530 with an acyl chloride such as 531 in the presence of a base such as triethylamine in a solvent such as dichloromethane gives amine-amide 532. Sulfonamides can be prepared by reaction of methyl 2-aminobenzoate 533 with sulfonyl chloride 534 in the presence of a base such as triethylamine in a solvent such as dichloromethane to give sulfonamide 535. Reaction of 535 with 3-trifluoromethylsulfonylaniline in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene gives compound 536.
[0099] Referring to Figure 5, aniline derivative 537 can be reacted with an acyl chloride in the presence of a base such as triethylamine in a solvent such as dichloromethane to provide amide 538. Reaction of 538 with 3-trifluoromethylaniline in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene gives bis-amide 539. The same chemistry can be performed substituting hetero eye lic/hetero aryl analogs of compound 537.
[0100] Referring to Figure 6, cyclization of amino amide 543 in a solvent such as acetic acid at room temperature provides benzimidazole 544. Cyclization at 70° C gives a mixture of isomeric tetracyclic compounds 545 and 546. Reaction of bis-amine compound 547 with an acid chloride such as 2-ethoxybenzoyl chloride in the presence of a base such as triethylamine in a solvent such as dichloromethane gives amino amide 548. Cyclization of
548 in a solvent such as acetic acid gives benzimidazole 549. Amidation of 549 with
3-trifluoromethylsulfonylaniline in the presence of a catalyst such as trimethylaluminum in a solvent such as toluene gives compound 550. Reaction of amine 551 with
3-iodotrifluorobenzene in the presence of a catalyst such as 1,2-methylaminocyclohexane in the presence of a catalyst such as copper (I) iodide and a base such as potassium carbonate in a solvent such as toluene gives the coupled product 553. Reaction of 553 with
2-ethoxybenzoyl chloride in the presence of a base such as triethylamine in a solvent such as dichloromethane gives amide 554.
[0101] Referring to Figure 7, reaction of aryl iodide 555 with an alcohol or a thiol in the presence of catalysst such as copper (I) iodide chloride and 1,10-phenanthroline in the presence of base such as cesium carbonate in a solvent such as toluene gives aryl ether 556.
[0102] The present disclosure is further directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound or salt described herein.
[0103] It is preferred that the pharmaceutically acceptable carrier be one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of use.
[0104] The choice of carrier will be determined in part by the particular compound of the present disclosure chosen, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of the
pharmaceutical composition of the present disclosure. The following formulations for oral, aerosol, nasal, pulmonary, parenteral, subcutaneous, intravenous, intramuscular,
intraperitoneal, intrathecal, intratumoral, topical, rectal, and vaginal administration are merely exemplary and are in no way limiting.
[0105] The pharmaceutical composition can be administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the disclosure provides compositions for parenteral administration that comprise a solution or suspension of the inventive compound or salt dissolved or suspended in an acceptable carrier suitable for parenteral administration, including aqueous and non-aqueous isotonic sterile injection solutions.
[0106] Overall, the requirements for effective pharmaceutical carriers for parenteral compositions are well known to those of ordinary skill in the art. See, e.g., Banker and
Chalmers, eds., Pharmaceutics and Pharmacy Practice, J. B. Lippincott Company,
Philadelphia, pp. 238-250 (1982), and Toissel, ASHP Handbook on Injectable Drugs, 4th ed., pp. 622-630 (1986). Such solutions can contain anti-oxidants, buffers, bacteriostats, and
solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The compound or salt of the present disclosure may be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose,
hydro xypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
[0107] Oils useful in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
[0108] Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfo succinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-beta-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.
[0109] The parenteral formulations can contain preservatives and buffers. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a
hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
[0110] Topical formulations, including those that are useful for transdermal drug release, are well-known to those of skill in the art and are suitable in the context of the disclosure for application to skin. Topically applied compositions are generally in the form of liquids, creams, pastes, lotions and gels. Topical administration includes application to the oral mucosa, which includes the oral cavity, oral epithelium, palate, gingival, and the nasal mucosa. In some embodiments, the composition contains at least one active component and a suitable vehicle or carrier. It may also contain other components, such as an anti-irritant. The carrier can be a liquid, solid or semi-solid. In embodiments, the composition is an aqueous solution. Alternatively, the composition can be a dispersion, emulsion, gel, lotion or cream vehicle for the various components. In one embodiment, the primary vehicle is water or a biocompatible solvent that is substantially neutral or that has been rendered substantially neutral. The liquid vehicle can include other materials, such as buffers, alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired pH, consistency and viscosity. It is possible that the compositions can be produced as solids, such as powders or granules. The solids can be applied directly or dissolved in water or a biocompatible solvent prior to use to form a solution that is substantially neutral or that has been rendered substantially neutral and that can then be applied to the target site. In embodiments of the disclosure, the vehicle for topical application to the skin can include water, buffered solutions, various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials.
[0111] Formulations suitable for oral administration can consist of (a) liquid solutions, such as a therapeutically effective amount of the inventive compound dissolved in diluents, such as water, saline, or orange juice, (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules, (c) powders, (d) suspensions in an appropriate liquid, and (e) suitable emulsions. Liquid
formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a
pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, micro crystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
[0112] The compound or salt of the present disclosure, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation.
The compounds are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of active compound are 0.01%-20% by weight, preferably
1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such surfactants are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25%-5%.
The balance of the composition is ordinarily propellant. A carrier can also be included as desired, e.g., lecithin for intranasal delivery. These aerosol formulations can be placed into acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations may be used to spray mucosa.
[0113] Additionally, the compound or salt of the present disclosure may be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration may be presented as pessaries,
tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
[0114] It will be appreciated by one of ordinary skill in the art that, in addition to the aforedescribed pharmaceutical compositions, the compound or salt of the present disclosure may be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes. Liposomes serve to target the compounds to a particular tissue, such as lymphoid tissue or cancerous hepatic cells. Liposomes can also be used to increase the half-life of the inventive compound. Liposomes useful in the present disclosure include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations, the active agent to be delivered is incorporated as part of a liposome, alone or in conjunction with a suitable chemotherapeutic agent. Thus, liposomes filled with a desired inventive compound or salt thereof, can be directed to the site of a specific tissue type, hepatic cells, for example, where the liposomes then deliver the selected compositions. Liposomes for use in the disclosure are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, for example, liposome size and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, for example, Szoka et al, Ann. Rev. Biophys. Bioeng., 9, 467 (1980), and U.S. Patents 4,235,871, 4,501,728, 4,837,028, and 5,019,369. For targeting to the cells of a particular tissue type, a ligand to be
incorporated into the liposome can include, for example, antibodies or fragments thereof specific for cell surface determinants of the targeted tissue type. A liposome suspension containing a compound or salt of the present disclosure may be administered intravenously, locally, topically, etc. in a dose that varies according to the mode of administration, the agent being delivered, and the stage of disease being treated.
[0115] The disclosure further provides a method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1 comprising
administering to a mammal in need thereof a therapeutically effective amount of a compound or salt thereof represented by Formula (I):
wherein A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH2CH2-, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, or 1,2-heterocyclyl are optionally substituted with one or more substituents independently selected from halo, CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy -SR7, -SOR7, -S02R7, -SCF3, and S02CF3,
Ri is -NHCOR3, R4, -NHR5, or -OR6,
R2 is alkyl, cycloalkyl, heteroarylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy aryl, , halo alky laryl, heterocyclylalkyl, -SR7, -SOR7, -S02R7, -SCF3, -N02, -CN, and -S02CF3,
R3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, which are optionally substituted with one or more substituents selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, -N02,-CN, and -S02CF3,
R4 is phenyl optionally substituted with alkyloxy, haloalkyloxy, arylalkyl, or arylalkyloxy,
R5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl,
Re is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
and R7 is C1-C10 alkyl, C1-C10 haloalkyl, Ci-Ciohaloalkyl, or Ci-Ciohaloalkoxy.
[0116] In accordance with certain embodiments, R2 is phenyl substituted
with -S02CF3, -SCF3, or -CF3.
[0117] In accordance with certain embodiments, A is 1 ,2-phenylene optionally substituted with one or more substituents independently selected from halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0118] In accordance with certain embodiments, Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3, C1-C10 alkyl, C1-C10 alkyloxy,
Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, alkyloxyalkyloxy, dimethylaminoalkyloxy, -
SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0119] In accordance with certain preferred embodiments, R3 is
2-(Ci-Cio)alkyloxyphenyl.
[0120] In accordance with certain preferred embodiments, R2 is phenyl substituted with a substituent selected from -CF3, Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Ciohaloalkyl,
Ci-Ciohaloalkoxy -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0121] In certain preferred embodiments, the compound is selected from the group consisting of:
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
[0123] In accordance with certain preferred embodiments, Ri is -NHR5, wherein R5 is aryl optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl.
[0124] In accordance with certain embodiments, Ri is -OR6, wherein R^ is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl.
[0125] In accordance with certain embodiments, A is 1 ,2-heteroarylenyl optionally substituted with one or more subsitutents independently selected from halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0127] In accordance with certain preferred embodiments, Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from independently -CF3, C1-C10 alkyl, C1-C10 alkyloxy, Ci-Ciohalo alkyl, Cl-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0128] In accordance with certain preferred embodiments, R3 is
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
[0129] In certain preferred embodiments, wherein the compound is selected from the group consisting of:
[0130] In accordance with certain embodiments, A is [CH 2CH2-.
[0131] In accordance with certain embodiments, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3, C1-C10 alkyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
[0132] In accordance with certain embodimenst, R3 is 2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
[0133] In accordance with a particular embodiment, the compound is:
[0134] The facet of mammalian health can be any disease, disorder, or aspect of mammalian health that is mediated by a mammalian relaxin receptor 1. Examples of facets of mammalian health, wherein the mammal is a human, that are mediated by a mammalian relaxin receptor 1, wherein the mammalian relaxin receptor 1 is a human relaxin receptor 1,
are disclosed in, e.g., E.T. Van Der Westhuizen et al, Current Drug Targets 2007, 8, 91-104; U.S. Patent 8,053,411; and U.S. Patent Application Publication 2011/0177998, the discloses of which are incorporated herein.
[0135] The mammal can be any suitable mammal. Examples of suitable mammals include, but are not limited to, the order Rodentia, such as mice, and the order Logomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is more preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). It is most preferred that the mammals are of the order Primates, Ceboids, or Simioids (monkeys) or of the order Anthropoids (humans and apes). An especially preferred mammal is the human. Furthermore, the subject can be the unborn offspring of any of the forgoing hosts, especially mammals (e.g., humans), in which case any screening of the subject or cells of the subject, or administration of compounds to the subject or cells of the subject, can be performed in utero.
[0136] The mammalian relaxin receptor 1 can be any suitable mammalian relaxin receptor 1. Typically, the mammalian relaxin receptor 1 is a relaxin receptor 1 that exists in the particular mammal being treated.
[0137] In some embodiments, the facet of mammalian health is a facet of human health. In these embodiments, the mammalian relaxin receptor 1 is a human relaxin receptor 1.
[0138] In an embodiment, the facet of mammalian health is cardiovascular disease. Non-limiting examples of cardiovascular disease include acute heart failure, myocardial ischemia-reperfusion injury, cardiac fibrosis, acute congestive heart failure, cerebrovascular disease and stroke, post-infarction heart, cardiac anaphylaxis, cerebral ischemia (stroke), intestinal ischemia-reperfusion injury, systemic and pulmonary hypertension, vascular inflammation, hypertension, high blood pressure; left ventricular hypertrophy (LVH);
vasodilation; renal hypertension; diuresis; nephritis; natriuresis; scleroderma renal crisis; angina pectoris (stable and unstable); myocardial infarction; heart attack; coronary artery disease; coronary heart disease; cardiac arrhythmias; atrial fibrillation; portal hypertension; raised intraocular pressure; vascular restenosis; chronic hypertension; valvular disease;
myocardial ischemia; acute pulmonary edema; acute coronary syndrome; hypertensive retinopathy; hypertensive pregnancy sickness; Raynaud's phenomenon; erectile dysfunction, glaucoma, and preeclampsia.
[0139] In an embodiment, the facet of mammalian health is dyspnea associated with acute heart failure in a human subject, wherein said subject has dyspnea associated with acute heart failure and is in a hypertensive or normotensive state at the onset of said administering.
[0140] In an embodiment, the facet of mammalian health is acute decompensated heart failure, wherein the method is effective to reduce in-hospital worsening of said acute decompensated heart failure in said subject. In a preferred embodiment, the in-hospital worsening of said acute decompensated heart failure comprises one or more of worsening dyspnea, need for additional therapy to treat said heart failure, need for mechanical support of breathing, and need for mechanical support of blood pressure. In another preferred embodiment, the method further comprises a reduction in the risk of death or
rehospitalization of said subject.
[0141] In an embodiment, the facet of mammalian health is fibrotic disease. In selected embodiments, the fibrotic disease is selected from the group of but not limited to pulmonary fibrosis, renal tubulo interstitial fibrosis, mesangial proliferative nephritis, hepatic fibrosis (cirrhosis) alcohol and non-alcohol related (including viral infection such as HAV, HBV and HCV); fibromatosis; granulomatous lung disease; glomerulonephritis, myocardial scarring following infarction; endometrial fibrosis and endometriosis, polycystic kidney disease, scleroderma and systemic sclerosis, keloids, arthritis, autoimmune disorder, inflammatory condition associated with infection, skeletal muscle injuries, conditions involving tissue remodeling following inflammation or ischemia-reperfusion injury and is selected from endomyocardial and cardiac fibrosis; mediastinal fibrosis; retroperitoneal fibrosis; fibrosis of the spleen; fibrosis of the pancreas; wound healing whether by injury or surgical procedures, diabetes related wound fibrosis.
[0142] In an embodiment, the facet of mammalian health is respiratory disease selected from asthma, bronchial disease, lung diseases, chronic obstructive pulmonary disease (COPD), Acute Respiratory Distress Syndrome (ARDS), severe acute respiratory syndrome (SARS), Fibrosis related Asthma, and cystic fibrosis.
[0143] In an embodiment, the facet of mammalian health is skin disease selected from dermal repair, wound healing; burns, erythemas, lesions, wound healing following surgical procedures; skin or tissue lesions including lesions induced by Psoriasis, Lupus and Kaposhi Sarcoma; Scleroderma, and collagenous diseases of the skin and skin tumors.
[0144] In an embodiment, the facet of mammalian health is female reproduction. In selected embodiments, the facet of female reproduction is selected from in vitro fertilization, abnormal implantation, pre-term birth and induction of labor, mammary functions and lactation disorders;, plasma osmolarity during pregnancy, uterine fibroids, abnormal endometrial angiogenesis; placental development defects; cervical ripening (softening); nipple development and disfunction; pregnancy related remodeling of the uterine tissue; endometriosis; preeclampsia; estrogenic and non-estrogenic related hormonal disorders; preterm labor; post term labor; and labor complications.
[0145] In an embodiment, the facet of mammalian health is male reproduction. In particular embodiments, the facet of male reproduction is selected from sperm functions and fertilization.
[0146] In an embodiment, the facet of mammalian health is surgical transplantation of a liver.
[0147] In an embodiment, the facet of mammalian health is a cancer selected from colon cancer, lung cancer, breast cancer, prostate cancer, brain cancer, pancreatic cancer, ovarian cancer, kidney cancer, testicular cancer, bone cancer, osteosarcoma, liver cancer, melanoma, glioma, sarcoma, leukemia, or lymphoma, and wherein the cancer is invasive or metastatic.
[0148] In an embodiment, the facet of mammalian health is enhancement of drug delivery in the treatment of a solid cancer, in combination with a chemotherapeutic treatment or radiation treatment of the cancer.
[0149] In an embodiment, the facet of mammalian health is orthodontic tooth movement.
[0150] In an embodiment, the facet of mammalian health is bone joint disease.
[0151] In an embodiment, the facet of mammalian health is selected from osteoporosis; osteoarthritis; osteopetrosis; bone inconsistency; osteosarcoma; and cancer metastasis to the bone.
[0152] In an embodiment, the facet of mammalian health is diabetes mellitus.
[0153] In an embodiment, the facet of mammalian health is ischemia-reperfusion injury associated with ischemic and post-ischemic events in organs and tissues and in a group of patients with thrombotic stroke; myocardial infarction; angina pectoris; embolic vascular occlusions; peripheral vascular insufficiency; splanchnic artery occlusion; arterial occlusion by thrombi or embolisms, arterial occlusion by non-occlusive processes such as following low mesenteric flow or sepsis; mesenteric arterial occlusion; mesenteric vein occlusion;
ischemia-reperfusion injury to the mesenteric microcirculation; ischemic acute renal failure; ischemia-reperfusion injury to the cerebral tissue; intestinal intussusception; hemodynamic shock; tissue dysfunction; organ failure; restenosis; atherosclerosis; thrombosis; platelet aggregation, ischemia-reperfusion injury following cardiac surgery; organ surgery; organ transplantation; angiography; cardiopulmonary and cerebral resuscitation.
[0154] In an embodiment, the facet of mammalian health is an inflammatory condition associated with an infection, wherein the infection is selected from a viral infection caused by human immunodeficiency virus I (HIV-1) or HIV-2, acquired immune deficiency (AIDS), West Nile encephalitis virus, coronavirus, rhinovirus, influenza virus, dengue virus, HCV, HBV, HAV, hemorrhagic fever; an otological infection; severe acute respiratory syndrome (SARS), sepsis and sinusitis.
[0155] In an embodiment, the facet of mammalian health is kidney diseases selected from diabetic nephropathy; glomerulosclerosis; nephropathies; renal impairment; scleroderma renal crisis and chronic renal failure.
[0156] In an embodiment, the facet of mammalian health is an angiogenesis related condition selected from retinal angiogenesis in a number of mammalian ocular diseases such as diabetes mellitus, retinopathy of prematury, and age-related macular degeneration, or cancer associated angiogenesis in primary or metastatic cancer, including but not limited to cancer of the prostate, brain, breast, colorectal, lung, ovarian, pancreatic, renal, cervical, melanoma, soft tissue sarcomas, lymphomas, head-and-neck, and glioblastomas.
[0157] In an embodiment, the facet of mammalian health is an inflammatory disorder selected from gastritis, gout, gouty arthritis, arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ulcers, chronic bronchitis, asthma, allergy, acute lung injury, pulmonary inflammation, airway hyper-responsiveness, vasculitis, septic shock and inflammatory skin disorders, including but not limited to psoriasis, atopic dermatitis, eczema.
[0158] In an embodiment, the facet of mammalian health is an autoimmune disorder is selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus
erythematosus, ulcerative colitis, Crohn's disease, transplant rejection, immune disorders associated with graft transplantation rejection, benign lymphocytic angiitis, lupus
erythematosus, Hashimoto's thyroiditis, primary myxedema, Graves' disease, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, insulin dependent diabetes mellitis,
Good pasture's syndrome, myasthenia gravis, pemphigus, sympathetic ophthalmia, autoimmune uveitis, autoimmune hemolytic anemia, idiopathic thrombocytopenia, primary biliary cirrhosis, chronic action hepatitis, ulceratis colitis, Sjogren's syndrome, rheumatic disease, polymyositis, scleroderma, mixed connective tissue disease, inflammatory rheumatism, degenerative rheumatism, extra-articular rheumatism, collagen diseases, chronic polyarthritis, psoriasis arthropathica, ankylosing spondylitis, juvenile rheumatoid arthritis, periarthritis humeroscapularis, panarteriitis nodosa, progressive systemic scleroderma, arthritis uratica, dermatomyositis, muscular rheumatism, myositis, myogelosis, and chondro calcino sis .
[0159] In an embodiment, the facet of mammalian health is an behavioral abnormality or disease.
[0160] [Therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1 Qefers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. As used herein, the term ameliorating, Qvith reference to a disease or pathological condition, refers to any observable beneficial effect of the treatment. The beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, an improvement in the overall health or well-being of the subject, or by other parameters well known in the art that are specific to the particular disease. Treatment of cardiovascular disease can be evidenced, for example, by reduction of blood pressure, an enhancement of vascular compliance, a reduction in clinical symptoms resulting from the cardiovascular disease, or other parameters well known in the art that are specific to the cardiovascular disease. The phrase [treating a disease ttefers to inhibiting the full
development of a disease or condition, for example, in a subject who is at risk for a disease such as cardiovascular disease.
[0161] In other embodiments, the therapeutic intervention provides an enhancement in a desirable facet of mammalian health.In certain embodiments the therapeutic intervention provides an enhancement in a desirable facet of human health. For example, the therapeutic intervention can lead to improved outcomes in organ transplantation, in improvements in female fertility such as increased success in in vitro fertilization, and the like.
[0162] One skilled in the art will appreciate that suitable methods of utilizing a compound and administering it to a mammal for the treatment or prevention of disease states which would be useful in the method of the present disclosure, are available. Although more than one route can be used to administer a particular compound, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described methods are merely exemplary and are in no way limiting.
[0163] The dose administered to a mammal, particularly, a human, in accordance with the present disclosure should be sufficient to effect the desired response. Such responses include reversal or prevention of the bad effects of the disease for which treatment is desired or to elicit the desired benefit. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the age, condition, and body weight of the mammal, as well as the source, particular type of the disease, and extent of the disease in the human. The size of the dose will also be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular compound and the desired physiological effect. It will be appreciated by one of skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
[0164] Suitable doses and dosage regimens can be determined by conventional range- finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound.
Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. The present inventive method typically will involve the administration of about 0.1 to about 300 mg of one or more of the compounds described above per kg body weight of the mammal.
[0165] The therapeutically effective amount of the compound or compounds
administered can vary depending upon the desired effects and the factors noted
above. Typically, dosages will be between 0.01 mg/kg and 250 mg/kg of the subjects body weight, and more typically between about 0.05 mg/kg and 100 mg/kg, such as from about 0.2 to about 80 mg/kg, from about 5 to about 40 mg/kg or from about 10 to about 30 mg/kg of the subjects body weight. Thus, unit dosage forms can be formulated based upon the suitable ranges recited above and the subjects body weight. The term Unit dosage formCas
used herein refers to a physically discrete unit of therapeutic agent appropriate for the subject to be treated.
[0166] Alternatively, dosages are calculated based on body surface area and from about 1 mg/m2 to about 200 mg/m2, such as from about 5 mg/m2 to about 100 mg/m2 will be administered to the subject per day. In particular embodiments, administration of the therapeutically effective amount of the compound or compounds involves administering to the subject from about 5 mg/m2 to about 50 mg/m2, such as from about 10 mg/m2 to about 40 mg/m2 per day. It is currently believed that a single dosage of the compound or compounds is suitable, however a therapeutically effective dosage can be supplied over an extended period of time or in multiple doses per day. Thus, unit dosage forms also can be calculated using a subjects body surface area based on the suitable ranges recited above and the desired dosing schedule.
[0167] The disclosure further provides a use of a compound or salt of the disclosure in the manufacture of a medicament for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1. The medicament typically is a pharmaceutical composition as described herein.
[0168] The following examples further illustrate the disclosure but, of course, should not be construed as in any way limiting its scope.
[0169] General Methods for Chemistry. All air or moisture sensitive reactions were performed under positive pressure of nitrogen with oven-dried glassware. Anhydrous solvents such as dichloromethane, N,N-dimethylformamide (DMF), acetonitrile, methanol and triethylamine were purchased from Sigma- Aldrich (St. Louis, MO). Preparative purification was performed on a Waters semi-preparative HPLC system (Waters Corp.,
Milford, MA). The column used was a Phenomenex Luna C18 (5 micron, 30 x 75 mm;
Phenomenex, Inc., Torrance, CA) at a flow rate of 45.0 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoro acetic acid). A gradient of 10% to
50% acetonitrile over 8 minutes was used during the purification. Fraction collection was triggered by UV detection at 220 nM. Analytical analysis was performed on an Agilent
LC/MS (Agilent Technologies, Santa Clara, CA). Method 1 ( ): A 7-minute gradient of 4% to 100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8-minute run time at a flow rate of 1.0 mL/min.
Method 2 (t2): A 3-minute gradient of 4% to 100% acetonitrile (containing 0.025%
trifluoro acetic acid) in water (containing 0.05% trifluoroacetic acid) was used with a 4.5- minute run time at a flow rate of 1.0 mL/min. A Phenomenex Luna C18 column (3 micron, 3 x 75 mm) was used at a temperature of 50 °C. Purity determination was performed using an Agilent diode array detector for both Method 1 and Method 2. Mass determination was performed using an Agilent 6130 mass spectrometer with electrospray ionization in the positive mode. 1H NMR spectra were recorded on Varian 400 MHz spectrometers (Agilent Technologies, Santa Clara, CA). Chemical shifts are reported in ppm with undeuterated solvent (DMSO-<i6 at 2.49 ppm) as internal standard for DMSO-<i6 solutions. All of the analogs tested in the biological assays have a purity of greater than 95% based on both analytical methods. High resolution mass spectrometry was recorded on Agilent 6210 Time- of-Flight (TOF) LC/MS system. Confirmation of molecular formula was accomplished using electrospray ionization in the positive mode with the Agilent Masshunter software (Version B.02).
[0170] General Protocol A. A solution of methyl or ethyl benzoate (0.191 mmol) and amine (0.383 mmol) in toluene (2.00 mL) was treated at room temperature with AlMe3 (0.192 mL, 2.0 M in toluene, 0.384 mmol). The reaction mixture was stirred overnight at 100 °C and then quenched with 100 of water. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product.
[0171] General Protocol B. A solution of carboxylic acid (0.178 mmol) in DMF (2.00 mL) was treated at room temperature with 2-amino-N-(3-(trifluoromethyl)phenyl)benzamide (25.0 mg, 0.089 mmol) followed by EDC (17.1 mg, 0.089 mmol) and DMAP (10.9 mg, 0.089 mmol). The reaction mixture was stirred overnight at room temperature. The mixture was purified via C18 reverse phase HPLC to give the final product.
[0172] General Protocol C. A solution of 2-amino-N-(3-
(trifluoromethyl)phenyl)benzamide (50.0 mg, 0.178 mmol) in dichloromethane (2.00 mL) and TEA (0.075 mL, 0.535 mmol) was treated at room temperature with carbonyl chloride (0.357 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product.
[0173] General Protocol D. A solution of carboxylic acid (0.357 mmol) in DMF (2.00 mL) was added DIPEA (0.093 mL, 0.535 mmol) and HATU (136 mg, 0.357 mmol). The
reaction mixture was stirred at room temperature for 5 min, followed by 2-amino-N-(3- (trifluoromethyl)phenyl)benzamide (50.0 mg, 0.178 mmol). The reaction mixture was stirred overnight at room temperature, filtered and purified via C18 reverse phase HPLC to give the final product.
[0174] General Protocol E. A mixture of 2-bromo-N-(3- (trifluoromethyl)phenyl)benzamide (50.0 mg, 0.145 mmol, 1.0 equiv.) or N-(3- bromophenyl)-2-(cyclohexanecarboxamido)benzamide (100 mg, 0.249 mmol, 1.0 equiv.), boronic acid or pinacol ester (2.0 equiv.) and Pd(PPh3)4 (0.05 equiv) in DMF (1.50 mL) and 2.0 N Na2C03 (0.50 mL) aqueous solution was heated in μW at 100 °C for 30 min - 1 h. The reaction was cooled to room temperature, added a small portion of Si-THIOL to get rid of Palladium. The reaction mixture was filtered and purified via C18 reverse phase HPLC to give the final product.
[0175] General Protocol F. 2-Iodo-N-(3-(trif uoromethyl)phenyl)benzamide (100 mg, 0.256 mmol), amine (0.767 mmol), and CuCl (7.59 mg, 0.077 mmol) in DMF (1.00 mL) was stirred at room temperature for 15-30 min. The reaction was treated with a small portion of Si-THIOL to get rid of Palladium, filtered and purified via C18 reverse phase HPLC to give the final product.
[0176] General Protocol G. A solution of thio-compound (0.255 mmol) in
dichloromethane (3.00 mL) was treated at room temperature with MCPBA (220 mg, 1.27 mmol). The reaction mixture was stirred overnight at room temperature. 10% aqueous NaHS03 solution was added to quench excess MCPBA and the mixture was stirred at room temperature for 15 min. The reaction mixture was worked up with dichloromethane and water. The organic layer was separated, dried, concentrated, and purified via C18 reverse phase HPLC to give the final product.
[0177] General Protocol H. A tube was charged with Cul (0.1 equiv.), 1,10- phenanthroline (0.2 equiv.), Cs2C03 (2.0 equiv.), iodo substrate (1.0 equiv.) and alcohol (2.0 equiv.) in toluene (2.00 mL) under N2. The tube was sealed and the reaction mixture was stirred at 110 °C for 24 h. The resulting mixture was cooled to room temperature and treated with a small portion of Si-THIOL to get rid of copper. The mixture was concentrated, re- dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product
EXAMPLE 1
[0179] This example illustrates a synthesis of Methyl 2-
(cyclohexanecarboxamido)benzoate (XJB05-077, NCGC00189490-01). A solution of methyl 2-aminobenzoate (3.00 g, 19.9 mmol) in dichloromethane (100 mL) and triethylamine (8.30 mL, 59.5 mmol) was treated at 0 °C with cyclohexanecarbonyl chloride (2.70 mL, 19.9 mmol). The reaction was stirred at 0 °C for 2 h and room temperature for additional 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-40% of EtOAc in hexanes to give 5.00 g (96%>) of the title product as a white solid. LC- MS Retention Time: ti (Method 1) = 6.453 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.65 (s, 1 H), 8.31 (dd, J=8.5, 1.1 Hz, 1 H), 7.90 (dd, J=7.9, 1.7 Hz, 1 H), 7.57 (ddd, J=8.6, 7.2, 1.7 Hz, 1 H), 6.87 - 7.29 (m, 1 H), 3.83 (s, 3 H), 2.31 (tt, J=11.3, 3.5 Hz, 1 H), 1.88 (dd, J=12.9, 2.5 Hz, 2 H), 1.73 (ddd, J=12.4, 3.3, 3.1 Hz, 2 H), 1.55 - 1.67 (m, 1 H), 1.08 - 1.47 (m, 5 H).
EXAMPLE 2
[0181] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)benzoic acid (XJB05-087, NCGC00189489-01). A solution of methyl 2-
(cyclohexanecarboxamido)benzoate (4.00 g, 15.3 mmol) in MeOH (100 mL) was treated at
room temperature with 4.0 N NaOH aqueous solution (40.0 mL, 153 mmol). The reaction mixture was stirred at room temperature for 1 h. MeOH was removed by rotavapor and the mixture was cooled in ice-bath and acidified with 5.0 N HC1 until white precipitation was appeared. The white precipitation was filtered and washed with water to give 3.60 g (95%) of the title product as a white solid. LC-MS Retention Time: ti (Method 1) = 5.345 min.
EXAMPLE 3
[0183] This example illustrates a synthesis of tert-Butyl 2-(3-
(trifiuoromethyl)phenylcarbamoyl)phenylcarbamate (XJB05-088, NCGC00189488-01). A solution of 2-(fert-butoxycarbonylamino)benzoic acid (3.00 g, 12.6 mmol) and 3- (trifluoromethyl)aniline (2.36 mL, 19.0 mmol) in dichloromethane (75.0 mL) was treated at room temperature with DMAP (1.55 g, 12.6 mmol) and EDC (4.85 g, 25.3 mmol) and stirred at room temperature for 24 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of dichloromethane in hexanes followed by 10% of EtOAc in dichloromethane to give 2.20 g (46%) of the title product as a white solid. LC-MS Retention Time: ti (Method 1) = 7.042 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.64 (s, 1 H), 9.75 (s, 1 H), 8.14 (s, 1 H), 7.98 (d, J=7.6 Hz, 1 H), 7.94 (d, J=9.2 Hz, 1 H), 7.77 (dd, J=7.9, 1.5 Hz, 1 H), 7.58 (t, J=8.0 Hz, 1 H), 7.51 (ddd, J=8.5, 7.2, 1.5 Hz, 1 H), 7.45 (d, J=7.8 Hz, 1 H), 7.16 (td, J=7.6, 1.1 Hz, 1 H), 1.41 (s, 9 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.20 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C19H20F3N2O3, 381.1421; found 381.1426.
EXAMPLE 4
[0185] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N- phenylbenzamide (XJB06-001, NCGC00189487-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.326 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.54 (s, 1 H), 10.37 (s, 1 H), 8.23 (dd, J=8.2, 1.0 Hz, 1 H), 7.77 (dd, J=7.9, 1.5 Hz, 1 H), 7.63 - 7.71 (m, 2 H), 7.49 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.28 - 7.41 (m, 2 H), 7.19 (td, J=7.6, 1.3 Hz, 1 H), 7.07 - 7.14 (m, 1 H), 2.17 - 2.34 (m, 1 H), 1.76 - 1.88 (m, 2 H), 1.69 (ddd, J=12.5, 3.4, 3.2 Hz, 2 H), 1.59 (d, J=12.1 Hz, 1 H), 1.03 - 1.43 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C20H23N2O0, 323.1754; found 323.1758.
EXAMPLE 5
[0187] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-002, NCGC00189486-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.910 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.61 (s, 1 H), 10.27 (s, 1 H), 8.12 (s, 1 H), 8.07 (dd, J=8.4, 1.0 Hz, 1 H), 7.94 (d, J=9.2 Hz, 1 H), 7.74 (dd, J=7.7, 1.5 Hz, 1 H), 7.58 (t, J=8.0 Hz, 1 H), 7.47 - 7.54 (m, 1 H), 7.44 (dt, J=7.7, 0.8 Hz, 1 H), 7.21 (td, J=7.5, 1.2 Hz, 1 H),
2.22 - 2.35 (m, 1 H), 1.79 (dd, J=13.3, 2.3 Hz, 2 H), 1.68 (ddd, J=12.3, 3.1, 2.9 Hz, 2 H), 1.58 (ddd, J=l 1.9, 3.2, 3.0 Hz, 1 H), 1.00 - 1.40 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.30 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H22F3N2O2, 391.1628; found 391.1632.
EXAMPLE 6
[0189] This example illustrates a synthesis of N-(3-Bromophenyl)-2- (cyclohexanecarboxamido)benzamide (XJB06-005, NCGC00189485-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.904 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.47 (s, 1 H), 10.31 (s, 1 H), 8.11 (dd, J=8.4, 1.0 Hz, 1 H), 7.94 - 8.04 (m, 1 H), 7.72 (dd, J=7.8, 1.6 Hz, 1 H), 7.64 (ddd, J=6.7, 2.3, 2.2 Hz, 1 H), 7.49 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.24 - 7.35 (m, 2 H), 7.19 (td, J=7.6, 1.2 Hz, 1 H), 2.21 - 2.37 (m, 1 H), 1.80 (d, J=11.5 Hz, 2 H), 1.69 (dt, J=12.2, 3.2 Hz, 2 H), 1.59 (d, J=12.5 Hz, 1 H), 1.07 - 1.42 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2oH22BrN202, 401.0859; found 401.0859.
EXAMPLE 7
[0191] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- fhiorophenyl)benzamide (XJB06-006, NCGC00189484-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.529 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.51 (s, 1 H), 10.33 (s, 1 H), 8.12 (dd, J=8.3, 1.1 Hz, 1 H), 7.73 (dd, J=7.7, 1.5 Hz, 1 H), 7.64 (dt, J=11.7, 2.3 Hz, 1 H), 7.43 - 7.55 (m, 2 H), 7.37 (td, J=8.2, 6.7 Hz, 1 H), 7.20 (td, J=7.5, 1.2 Hz, 1 H), 6.82 - 6.98 (m, 1 H), 2.21 - 2.35 (m, 1 H), 1.81 (d, J=11.5 Hz, 2 H), 1.69 (dt, J=12.4, 3.3 Hz, 2 H), 1.59 (d, J=11.7 Hz, 1 H), 1.02 - 1.43 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -112.20 - -112.29 (m, 1 F); HRMS (ESI) m/z (M+H)+ calcd. for C20H22FN2O2, 341.1660; found 341.1660.
EXAMPLE 8
[0193] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- methoxyphenyl)benzamide (XJB06-007, NCGC00189483-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.344 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.47 (s, 1 H), 10.33 (s, 1 H), 8.20 (dd, J=8.4, 1.0 Hz, 1 H), 7.74 (dd, J=7.8, 1.4 Hz, 1 H), 7.49 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.33 (t, J=2.2 Hz, 1 H), 7.13 - 7.30 (m, 3 H), 6.69 (ddd, J=7.8, 2.5, 1.4 Hz, 1 H), 3.73 (s, 3 H), 2.26 (tt, J=11.3, 3.6 Hz, 1 H), 1.82 (dd, J=12.5, 2.7 Hz, 2 H), 1.69 (ddd, J=12.4, 3.1, 2.8 Hz, 2 H), 1.51 - 1.64 (m, 1 H), 1.02 - 1.41 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N203, 353.1860; found 353.1856.
EXAMPLE 9
[0195] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-m- tolylbenzamide (XJB06-008, NCGC00189482-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.632 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.54 (s, 1 H), 10.30 (s, 1 H), 8.24 (dd, J=8.3, 1.1 Hz, 1 H), 7.76 (dd, J=7.8, 1.4 Hz, 1 H), 7.38 - 7.54 (m, 3 H), 7.10 - 7.31 (m, 2 H), 6.93 (dddd, J=7.5, 1.5, 1.1, 0.8 Hz, 1 H), 2.29 (s, 3 H), 2.19 - 2.35 (m, 1 H), 1.82 (dd, J=12.8, 2.6 Hz, 2 H), 1.69 (dt, J=12.4, 3.4 Hz, 2 H), 1.59 (d, J=12.3 Hz, 1 H), 1.04 - 1.42 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N202, 337.1911; found 337.1908.
EXAMPLE 10
[0197] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- nitrophenyl)benzamide (XJB06-009, NCGC00189481-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.392 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.76 (s, 1 H), 10.26 (s, 1 H), 8.69 (t, J=2.2 Hz, 1 H), 8.01 - 8.15 (m, 2 H), 7.95 (ddd, J=8.3, 2.3, 1.0 Hz, 1 H), 7.75 (dd, J=7.8, 1.6 Hz, 1 H), 7.64 (t, J=8.2 Hz, 1 H), 7.46 - 7.56 (m, 1 H), 7.22 (td, J=7.6, 1.2 Hz, 1 H), 2.19 - 2.35 (m, 1 H), 1.79 (dd, J=12.5, 2.5 Hz, 2 H), 1.68 (dt, J=12.3, 3.1 Hz, 2 H), 1.58 (d, J=12.5 Hz, 1 H), 1.03 - 1.43 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C20H22N3O4, 368.1605; found 368.1616.
EXAMPLE 11
[0199] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4- (trifiuoromethyl)phenyl)benzamide (XJB06-012, NCGC00189480-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.943 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.65 (s, 1 H), 10.29 (s, 1 H), 8.09 (dd, J=8.4, 1.0 Hz, 1 H), 7.91 (d, J=8.6 Hz, 2 H), 7.74 (dd, J=7.8, 1.4 Hz, 1 H), 7.71 (d, J=8.4 Hz, 2 H), 7.51 (ddd, J=8.4, 7.3, 1.6 Hz, 1 H), 7.21 (td, J=7.6, 1.2 Hz, 1 H), 2.18 - 2.35 (m, 1 H), 1.80 (dd, J=12.7, 2.9 Hz, 2 H), 1.68 (dt, J= 12.2, 3.4 Hz, 2 H), 1.59 (d, J=11.9 Hz, 1 H), 1.01 - 1.43 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -60.26 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H22F3N2O2, 391.1628; found 391.1628.
EXAMPLE 12
[0201] This example illustrates a synthesis of N-(4-Bromophenyl)-2- (cyclohexanecarboxamido)benzamide (XJB06-013, NCGC00189479-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.893 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.46 (s, 1 H), 10.41 (s, 1 H), 8.16 (dd, J=8.2, 1.0 Hz, 1 H), 7.74 (dd, J=7.8, 1.6 Hz, 1 H), 7.60 - 7.69 (m, 2 H), 7.50 - 7.56 (m, 2 H), 7.46 - 7.50 (m, 1 H), 7.19 (td, J=7.5, 1.2 Hz, 1 H), 2.18 - 2.34 (m, 1 H), 1.81
(dd, J=12.1, 3.3 Hz, 2 H), 1.69 (dt, J=12.3, 3.1 Hz, 2 H), 1.59 (d, J=11.9 Hz, 1 H), 1.06 - 1.42 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2oH22BrN202, 401.0859; found 401.0858.
EXAMPLE 13
[0203] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4- fluorophenyl)benzamide (XJB06-014, NCGC00189478-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.413 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.52 (s, 1 H), 10.41 (s, 1 H), 8.22 (dd, J=8.3, 0.9 Hz, 1 H), 7.76 (dd, J=7.8, 1.4 Hz, 1 H), 7.62 - 7.73 (m, 2 H), 7.49 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.10 - 7.28 (m, 3 H), 2.17 - 2.35 (m, 1 H), 1.82 (dd, J=12.9, 2.5 Hz, 2 H), 1.69 (dt, J=12.3, 3.3 Hz, 2 H), 1.53 - 1.63 (m, 1 H), 0.97 - 1.43 (m, 5 H); 19F NMR (376 MHz, DMSO- d6) δ ppm -118.31 - -118.38 (m, 1 F); HRMS (ESI) m/z (M+H)+ calcd. for C20H22FN2O2, 341.1660; found 341.1659.
EXAMPLE 14
[0205] This example illustrates a synthesis of 2-(cyclohexanecarboxamido)-N-p- tolylbenzamide (XJB06-015, NCGC00189477-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.636 min; 1H
NMR (400 MHz, DMSO- 6) δ ppm 10.61 (s, 1 H), 10.30 (s, 1 H), 8.26 (dd, J=8.2, 0.8 Hz, 1 H), 7.77 (dd, J=7.8, 1.4 Hz, 1 H), 7.52 - 7.59 (m, 2 H), 7.48 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.18 (dd, J=7.8, 1.2 Hz, 1 H), 7.11 - 7.17 (m, 2 H), 2.26 (s, 3 H), 2.16 - 2.36 (m, 1 H), 1.82 (dd, J=13.0, 2.1 Hz, 2 H), 1.69 (ddd, J=12.2, 3.3, 3.1 Hz, 2 H), 1.51 - 1.64 (m, 1 H), 1.02 - 1.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N202, 337.1911; found 337.1916.
EXAMPLE 15
[0207] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4- methoxyphenyl)benzamide (XJB06-016, NCGC00189476-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.243 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.71 (s, 1 H), 10.27 (s, 1 H), 8.29 (dd, J=8.3, 0.9 Hz, 1 H), 7.78 (dd, J=7.8, 1.4 Hz, 1 H), 7.52 - 7.63 (m, 2 H), 7.48 (ddd, J=8.4, 7.3, 1.5 Hz, 1 H), 7.17 (td, J=7.5, 1.2 Hz, 1 H), 6.83 - 7.02 (m, 2 H), 3.73 (s, 3 H), 2.25 (tt, J=l 1.2, 3.4 Hz, 1 H), 1.77 - 1.93 (m, 2 H), 1.70 (ddd, J=12.3, 3.2, 2.9 Hz, 2 H), 1.52 - 1.64 (m, 1 H), 1.00 - 1.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N203, 353.1860; found 353.1857.
EXAMPLE 16
[0209] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4- nitrophenyl)benzamide (XJB06-017, NCGC00189475-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.408 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.85 (s, 1 H), 10.17 (s, 1 H), 8.16 - 8.32 (m, 2 H), 7.85 - 8.06 (m, 3 H), 7.72 (dd, J=7.8, 1.4 Hz, 1 H), 7.43 - 7.58 (m, 1 H), 7.22 (td, J=7.5, 1.2 Hz, 1 H), 2.27 (tt, J=11.2, 3.5 Hz, 1 H), 1.72 - 1.88 (m, 2 H), 1.68 (ddd, J=9.0, 6.1 , 2.7 Hz, 2 H), 1.52 - 1.63 (m, 1 H), 0.99 - 1.45 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C20H22N3O4, 368.1605; found 368.1605.
EXAMPLE 17
[0211] This example illustrates a synthesis of N-(2-Bromophenyl)-2- (cyclohexanecarboxamido)benzamide (XJB06-027, NCGC00189474-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti
(Method 1) = 6.689 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.91 (s, 1 H), 10.26 (s, 1 H), 8.36 (dd, J=8.4, 1.0 Hz, 1 H), 7.93 (dd, J=7.8, 1.4 Hz, 1 H), 7.71 (dd, J=8.0, 1.4 Hz, 1 H), 7.49 - 7.59 (m, 2 H), 7.44 (td, J=7.6, 1.4 Hz, 1 H), 7.22 - 7.27 (m, 1 H), 7.20 (td, J=7.6, 1.2 Hz, 1 H), 2.24 (tt, J=11.3, 3.5 Hz, 1 H), 1.82 (dd, J=12.6, 2.4 Hz, 2 H), 1.69 (ddd, J=12.5, 3.2, 2.9 Hz, 2 H), 1.51 - 1.64 (m, 1 H), 1.05 - 1.45 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2oH22BrN202, 401.0859; found 401.0863.
EXAMPLE 18
[0213] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2- fhiorophenyl)benzamide (XJB06-028, NCGC00189473-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.305 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.85 (br. s., 1 H), 10.28 (s, 1 H), 8.34 (dd, J=8.4, 1.0 Hz, 1 H), 7.88 (dd, J=7.8, 1.4 Hz, 1 H), 7.42 - 7.64 (m, 2 H), 7.24 - 7.34 (m, 2 H), 7.13 - 7.24 (m, 2 H), 2.24 (tt, J=11.2, 3.5 Hz, 1 H), 1.76 - 1.86 (m, 2 H), 1.64 - 1.75 (m, 2 H), 1.52 - 1.64 (m, 1 H), 0.99 - 1.43 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -120.74 - - 120.85 (m, 1 F); HRMS (ESI) m/z (M+H)+ calcd. for C20H22FN2O2, 341.1660; found
341.1656.
EXAMPLE 19
[0215] This example illustrates a synthesis of 2-(cyclohexanecarboxamido)-N-o- tolylbenzamide (XJB06-029, NCGC00189472-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.401 min; 1H
NMR (400 MHz, DMSC /6) δ ppm 11.00 (s, 1 H), 10.09 (s, 1 H), 8.38 (dd, J=8.4, 1.2 Hz, 1 H), 7.91 (d, J=7.8 Hz, 1 H), 7.51 (ddd, J=8.6, 7.2, 1.7 Hz, 1 H), 7.25 - 7.35 (m, 2 H), 7.10 - 7.25 (m, 3 H), 2.21 (s, 3 H), 2.16 - 2.28 (m, 1 H), 1.77 - 1.91 (m, 2 H), 1.69 (dt, J=12.4, 3.5
Hz, 2 H), 1.53 - 1.65 (m, 1 H), 0.99 - 1.44 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N202, 337.1911; found 337.1912.
EXAMPLE 20
[0217] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2- nitrophenyl)benzamide (XJB06-031, NCGC00189471-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.550 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.85 (s, 1 H), 10.44 (s, 1 H), 8.25 (dd, J=8.4, 1.2 Hz, 1 H), 8.01 (dd, J=8.2, 1.6 Hz, 1 H), 7.84 (dd, J=7.8, 1.6 Hz, 1 H), 7.67 - 7.80 (m, 2 H), 7.54 (ddd, J=8.6, 7.3, 1.6 Hz, 1 H), 7.44 (ddd, J=8.4, 6.7, 2.0 Hz, 1 H), 7.23 (td, J=7.6, 1.3 Hz, 1 H), 2.22 (tt, J=11.4, 3.5 Hz, 1 H), 1.80 (d, J=14.7 Hz, 2 H), 1.68 (ddd, J=12.3, 3.4, 3.3 Hz, 2 H), 1.59 (d, J=11.9 Hz, 1 H), 1.05 - 1.41 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2oH22N304, 368.1605; found 368.1605.
EXAMPLE 21
[0219] This example illustrates a synthesis of 2-Amino-N-(3-
(trifiuoromethyl)phenyl)benzamide (XJB06-036, NCGC00189470-01). A solution of tert- butyl 2-(3-(trifluoromethyl)phenylcarbamoyl)phenylcarbamate (2.11 g, 5.55 mmol) in dichloro methane (15.0 mL) was treated at 0 °C with TFA (5.34 mL, 69.3 mmol). The reaction mixture was stirred at 0 °C for 1 h and room temperature for additional 2 h. The
reaction mixture was concentrated and re-dissolved in dichloromethane and washed with saturated Na2C03 aqueous solution. The organic layer was separated, dried and concentrated to give 1.45 g (99%) of the title compound as a white solid. LC-MS Retention Time:
(Method 1) = 5.590 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.24 (s, 1 H), 8.18 (t, J=2.2 Hz, 1 H), 7.95 (ddd, J=8.4, 1.2, 1.0 Hz, 1 H), 7.63 (dd, J=8.0, 1.6 Hz, 1 H), 7.54 (t, J=8.3 Hz, 1 H), 7.34 - 7.43 (m, 1 H), 7.19 (ddd, J=8.4, 7.0, 1.6 Hz, 1 H), 6.74 (dd, J=8.3, 1.3 Hz, 1 H), 6.57 (ddd, J=8.1, 7.0, 1.2 Hz, 1 H), 6.34 (br. s., 2 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.18 (s, 3 F).
EXAMPLE 22
[0221] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2-
(trifiuoromethyl)benzyl)benzamide (XJB06-038, NCGC00189469-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.797 min; !H NMR (400 MHz, DMSO- 6) δ ppm 11.12 (s, 1 H), 9.29 (t, J=5.9 Hz, 1 H), 8.40 (dd, J=8.4, 1.4 Hz, 1 H), 7.82 (dd, J=7.9, 1.7 Hz, 1 H), 7.73 (dt, J=7.8, 0.8 Hz, 1 H), 7.64 (t, J=7.3 Hz, 1 H), 7.42 - 7.56 (m, 3 H), 7.09 - 7.19 (m, 1 H), 4.65 (d, J=6.1 Hz, 2 H), 2.21 (tt, J=11.2, 3.5 Hz, 1 H), 1.76 - 1.88 (m, 2 H), 1.63 - 1.73 (m, 2 H), 1.51 - 1.63 (m, 1 H), 1.03 - 1.44 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -58.97 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22H24F3N202, 405.1784; found 405.1790.
EXAMPLE 23
[0223] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(furan-2- ylmethyl)benzamide (XJB06-039, NCGC00189468-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 5.946 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.24 (s, 1 H), 9.19 (t, J=5.7 Hz, 1 H), 8.40 (dd, J=8.4, 1.4 Hz, 1 H), 7.72 (dd, J=7.8, 1.6 Hz, 1 H), 7.56 (dd, J=1.9, 0.9 Hz, 1 H), 7.45 (ddd, J=8.5, 7.1, 1.6 Hz, 1 H), 6.99 - 7.15 (m, 1 H), 6.38 (dd, J=3.2, 1.9 Hz, 1 H), 6.22 - 6.33 (m, 1 H), 4.45 (dd, J=5.6, 0.5 Hz, 2 H), 2.23 (tt, J=11.2, 3.5 Hz, 1 H), 1.79 - 1.93 (m, 2 H), 1.71 (dt, J=12.6, 3.6 Hz, 2 H), 1.54 - 1.67 (m, 1 H), 1.03 - 1.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C19H23N2O3, 327.1703; found 327.1708.
EXAMPLE 24
[0225] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2-fluoro- 5-(trifiuoromethyl)phenyl)benzamide (XJB06-040, NCGC00189467-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.825 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.51 (s, 1 H), 10.44 (s, 1 H), 8.14 (dd, J=8.3, 1.3 Hz, 1 H), 8.07 (dd, J=6.8, 2.3 Hz, 1 H), 7.81 (dd, J=7.8, 1.6 Hz, 1 H), 7.61 - 7.73 (m, 1 H), 7.46 - 7.59 (m, 2 H), 7.21 (td, J=7.6, 1.3 Hz, 1 H), 2.20 - 2.34 (m, 1 H), 1.75 - 1.88 (m, 2
H), 1.68 (ddd, J=12.8, 3.1, 2.9 Hz, 2 H), 1.52 - 1.64 (m, 1 H), 1.07 - 1.42 (m, 5 H); F NMR (376 MHz, DMSO-dg) δ ppm -60.47 (s, 3 F), -119.15 - -111.85 (m, 1 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H21F4N2O2, 409.1534; found 409.1534.
EXAMPLE 25
[0227] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3-
(trifiuoromethyl)benzyl)benzamide (XJB06-041, NCGC00189466-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.781 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.13 (s, 1 H), 9.34 (t, J=6.1 Hz, 1 H), 8.37 (dd, J=8.4, 1.4 Hz, 1 H), 7.76 (dd, J=7.9, 1.7 Hz, 1 H), 7.66 - 7.70 (m, 1 H), 7.58 - 7.66 (m, 2 H), 7.53 - 7.58 (m, 1 H), 7.47 (ddd, J=8.5, 7.2, 1.7 Hz, 1 H), 7.13 (td, J=7.6, 1.3 Hz, 1 H), 4.54 (d, J=5.9 Hz, 2 H), 2.20 (tt, J=11.2, 3.5 Hz, 1 H), 1.75 - 1.87 (m, 2 H), 1.68 (dt, J=12.3, 3.2 Hz, 2 H), 1.53 - 1.64 (m, 1 H), 1.02 - 1.42 (m, 5 H); 19F NMR (376 MHz, DMSO- d6) δ ppm - 61.02 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22H24F3N2O2, 405.1784; found 405.1790.
EXAMPLE 26
[0229] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(thiophen- 2-ylmethyl)benzamide (XJB06-042, NCGC00189465-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.211 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.21 (s, 1 H), 9.22 - 9.73 (m, 1 H), 8.40 (dd, J=8.4, 1.4 Hz, 1 H), 7.70 (dd, J=8.0, 1.6 Hz, 1 H), 7.45 (ddd, J=8.5, 7.1 , 1.6 Hz, 1 H), 7.38 (dd, J=5.1, 1.2 Hz, 1 H), 7.10 (td, J=7.6, 1.3 Hz, 1 H), 6.99 - 7.05 (m, 1 H), 6.94 (dd, J=5.1 , 3.5 Hz, 1 H), 4.61 (dd, J=5.9, 1.0 Hz, 2 H), 2.23 (tt, J=l 1.3, 3.4 Hz, 1 H), 1.80 - 1.93 (m, 2 H), 1.68 - 1.79 (m, 2 H), 1.56 - 1.68 (m, J=12.3, 3.4, 1.8, 1.8 Hz, 1 H), 1.03 - 1.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C19H23N2O2S, 343.1475; found 343.1485.
EXAMPLE 27
[0231] This example illustrates a synthesis of 2-(cyclohexanecarboxamido)-N-(4-
(trifiuoromethyl)benzyl)benzamide (XJB06-043, NCGC00189464-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.763 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.15 (s, 1 H), 9.36 (t, J=6.0 Hz, 1 H), 8.38 (dd, J=8.4, 1.4 Hz, 1 H), 7.78 (dd, J=7.8, 1.6 Hz, 1 H), 7.68 (d, J=8.0 Hz, 2 H), 7.50 - 7.58 (m, 2 H), 7.47 (ddd, J=8.6, 7.3, 1.6 Hz, 1 H), 7.08 - 7.20 (m, 1 H), 4.54 (d, J=5.9 Hz, 2 H), 2.20 (tt, J=11.2, 3.4 Hz, 1 H), 1.73 - 1.89 (m, 2 H), 1.68 (ddd, J=12.5, 3.4, 3.1 Hz, 2 H), 1.53 - 1.63 (m, 1 H), 1.02 - 1.43 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -60.75 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22H24F3N2O2, 405.1784; found 405.1789.
EXAMPLE 28
[0233] This example illustrates a synthesis of 2-(Cyclopentanecarboxamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-046, NCGC00189463-01). The title compound was prepared according to general protocol B. LC-MS Retention Time: ti (Method 1) = 6.780 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.60 (s, 1 H), 10.29 (s, 1 H), 8.15 (t, J=2.2 Hz, 1 H), 8.04 (d, J=7.8 Hz, 1 H), 7.93 (d, J=8.4 Hz, 1 H), 7.73 (dd, J=7.8, 1.6 Hz, 1 H), 7.57 (t, J=7.9 Hz, 1 H), 7.50 (ddd, J=8.5, 7.2, 1.6 Hz, 1 H), 7.44 (d, J=7.6 Hz, 1 H), 7.21 (td, J=7.6, 1.3 Hz, 1 H), 2.75 (quin, J=8.0 Hz, 1 H), 1.74 - 1.86 (m, 2 H), 1.63 - 1.74 (m, 2 H), 1.41 - 1.63 (m, 4 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.21 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C20H20F3N2O2, 377.1471; found 377.1481.
EXAMPLE 29
[0235] This example illustrates a synthesis of 2-(2-Ethylbutanamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-047, NCGC00189462-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.751 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.60 (s, 1 H), 10.25 (s, 1 H), 8.15 (t, J=2.2 Hz, 1 H), 7.98 (dd, J=8.2, 1.4 Hz, 1 H), 7.93 (ddd, J=8.2, 1.2, 1.0 Hz, 1 H), 7.72 (dd, J=7.7, 1.7 Hz, 1 H), 7.57 (t, J=7.9 Hz, 1 H), 7.50 (ddd, J=8.4, 7.1, 1.7 Hz, 1 H), 7.38 - 7.47 (m, 1 H),
7.23 (td, J=7.6, 1.3 Hz, 1 H), 2.15 (tt, J=8.8, 5.4 Hz, 1 H), 1.30 - 1.62 (m, 4 H), 0.74 - 0.86 (m, 6 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.23 (s, 3 F); HRMS (ESI) m/z (M+H)4 calcd. for C20H22F3N2O2, 379.1628; found 379.1634.
EXAMPLE 30
[0237] This example illustrates a synthesis of 2-Pentanamido-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-048, NCGC00189461-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.546 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.61 (s, 1 H), 10.19 (s, 1 H), 8.17 (t, J=2.2 Hz, 1 H), 7.98 (dd, J=8.1, 1.1 Hz, 1 H), 7.92 (ddd, J=8.2, 2.0, 0.8 Hz, 1 H), 7.71 (dd, J=7.7, 1.7 Hz, 1 H), 7.57 (t, J=8.1 Hz, 1 H), 7.47 - 7.54 (m, 1 H), 7.39 - 7.47 (m, 1 H), 7.21 (td, J=7.6, 1.3 Hz, 1 H), 2.28 (t, J=7.4 Hz, 2 H), 1.43 - 1.60 (m, 2 H), 1.18 - 1.34 (m, 2 H), 0.80 (t, J=7.6 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.21 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C19H20F3N2O2, 365.1471; found 365.1476.
EXAMPLE 31
[0239] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)adamantane- 1 -carboxamide (XJB06-049,
NCGC00189460-01). The title compound was prepared according to general protocol C. LC- MS Retention Time: ti (Method 1) = 7.461 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.68 (s, 1 H), 10.64 (s, 1 H), 8.34 (dd, J=8.3, 1.3 Hz, 1 H), 8.07 (t, J=2.2 Hz, 1 H), 7.95 - 8.04 (m, 1 H), 7.85 (dd, J=7.8, 1.6 Hz, 1 H), 7.61 (t, J=8.0 Hz, 1 H), 7.53 (ddd, J=8.6, 7.2, 1.7 Hz, 1 H), 7.41 - 7.50 (m, 1 H), 7.17 - 7.26 (m, 1 H), 1.90 - 2.10 (m, 3 H), 1.79 - 1.89 (m, 6 H), 1.57 - 1.75 (m, 6 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.22 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C25H26F3N2O2, 443.1941; found 443.1939.
EXAMPLE 32
[0241] This example illustrates a synthesis of 2-Amino-N-(furan-2-ylmethyl)benzamide (XJB06-052, NCGC00165247-02). A solution of methyl 2-aminobenzoate (0.857 mL, 6.62 mmol) and furan-2-ylmethanamine (1.84 mL, 19.9 mmol) in toluene (20.0 mL) was treated at room temperature with AlMe3 (6.62 mL, 2.0 M in toluene, 13.2 mmol). The reaction mixture was stirred at 100 °C for 5 h and then quenched with water after cooling to room temperature. The reaction mixture was concentrated in vacuo and the crude residue was purified via silica gel chromatography using a gradient of 0-80% of EtOAc in hexanes to give 1.35 g (94%) of the title compound as a white solid. LC-MS Retention Time: (Method 1) = 3.644 min.
EXAMPLE 33
[0243] This example illustrates a synthesis of 2-(Cyclobutanecarboxamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-053, NCGC00189459-01). The title compound was prepared according to general protocol B. LC-MS Retention Time: ti (Method 1) = 6.412
min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.61 (s, 1 H), 10.22 (s, 1 H), 8.15 (t, J=2.2 Hz, 1 H), 8.09 (dt, J=8.1, 0.6 Hz, 1 H), 7.93 (ddd, J=8.2, 1.2, 1.0 Hz, 1 H), 7.75 (dd, J=7.8, 1.6 Hz, 1 H), 7.58 (t, J=7.8 Hz, 1 H), 7.51 (ddd, J=8.5, 7.2, 1.6 Hz, 1 H), 7.40 - 7.48 (m, 1 H), 7.21 (td, J=7.6, 1.3 Hz, 1 H), 3.15 - 3.26 (m, 1 H), 2.01 - 2.24 (m, 4 H), 1.80 - 1.97 (m, 1 H), 1.64 - 1.80 (m, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.18 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for Ci9Hi8F3N202, 363.1315; found 363.1317.
EXAMPLE 34
[0245] This example illustrates a synthesis of 2-(4-Methylcyclohexanecarboxamido)-N- (3-(trifluoromethyl)phenyl)benzamide (XJB06-054, NCGC00189458-01, mixture of cis- and trans-isomers). The title compound was prepared according to general protocol B. LC-MS Retention Time: ti (Method 1) = 7.150 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.60 (s, 1 H), 10.32 (s, 0.5 H), 10.27 (s, 0.5 H), 8.09 - 8.18 (m, 1 H), 8.02 - 8.09 (m, 1 H), 7.88 - 7.97 (m, 1 H), 7.68 - 7.80 (m, 1 H), 7.54 - 7.61 (m, 1 H), 7.47 - 7.54 (m, 1 H), 7.40 - 7.47 (m, 1 H), 7.14 - 7.26 (m, 1 H), 2.13 - 2.26 (m, 1 H), 1.73 - 1.89 (m, 2 H), 1.66 (dd, J=13.4, 3.4 Hz, 1 H), 1.13 - 1.60 (m, 5 H), 0.85 - 1.01 (m, 1 H), 0.83 (d, J=6.7 Hz, 1.5 H), 0.80 (d, J=6.8 Hz, 1.5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.21 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22H24F3N202, 405.1784; found 405.1788.
EXAMPLE 35
[0247] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)benzo [d] [ 1 ,3 ] dioxo le-5 -carboxamide (XJB06- 055, NCGC00189457-01). The title compound was prepared according to general protocol B. LC-MS Retention Time: ti (Method 1) = 6.524 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.19 (s, 1 H), 10.72 (s, 1 H), 8.28 (dd, J=8.3, 1.3 Hz, 1 H), 8.08 (t, J=2.2 Hz, 1 H), 7.92 - 8.01 (m, 1 H), 7.87 (dd, J=7.8, 1.6 Hz, 1 H), 7.53 - 7.64 (m, 2 H), 7.41 - 7.49 (m, 2 H), 7.37 (d, J=1.8 Hz, 1 H), 7.27 (td, J=7.6, 1.3 Hz, 1 H), 7.05 (d, J=8.2 Hz, 1 H), 6.11 (s, 2 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.18 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi6F3N204, 429.1057; found 429.1055.
EXAMPLE 36
[0249] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)cyclo-heptanecarboxamide (XJB06-056, NCGC00189456-01, CID-56593317). The title compound was prepared according to general protocol B. LC-MS Retention Time: ti (Method 1) = 7.093 min; 1H NMR (400 MHz, DMSO- ά6) δ ppm 10.58 (s, 1 H), 10.18 (s, 1 H), 8.13 (s, 1 H), 7.98 (dd, J=8.1 , 0.9 Hz, 1 H), 7.93 (d,
J=8.0 Hz, 1 H), 7.71 (dd, J=7.8, 1.6 Hz, 1 H), 7.57 (t, J=7.8 Hz, 1 H), 7.49 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.39 - 7.46 (m, 1 H), 7.21 (td, J=7.6, 1.2 Hz, 1 H), 2.40 - 2.51 (m, 1 H), 1.75 - 1.88 (m, 2 H), 1.31 - 1.71 (m, 10 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.20 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22H24F3N2O2, 405.1784; found 405.1794.
EXAMPLE 37
[0251] This example illustrates a synthesis of 2-Benzamido-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-058, NCGC00189455-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.644 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi6F3N202, 385.1158; found 385.1163.
[0253] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)isonicotinamide (XJB06-059, NCGC00189454- 01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 5.174 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.35 (s, 1 H), 10.74 (d, J=0.4 Hz, 1 H), 8.67 - 8.99 (m, 2 H), 8.13 - 8.22 (m, 1 H), 8.04 - 8.1 1 (m, 1 H), 7.94 - 8.02 (m, 1 H), 7.87 (dd, J=7.8, 1.6 Hz, 1 H), 7.74 - 7.81 (m, 2 H), 7.52 - 7.67 (m, 2 H), 7.44 (dt, J=7.7, 1.0 Hz, 1 H), 7.34 (td, J=7.6, 1.3 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm
-61.18 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for
386.1111; found
386.1123.
EXAMPLE 39
[0255] This example illustrates a synthesis of N-(2-((3-
(trifluoromethyl)phenyl)carbamoyl)phenyl)thiophene-2-carboxamide (XJB06-060,
NCGC00189453-01). The title compound was prepared according to general protocol C. LC- MS Retention Time: ti (Method 1) = 6.571 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.31 (s, 1 H), 10.73 (s, 1 H), 8.21 (dd, J=8.2, 1.2 Hz, 1 H), 8.10 (td, J=1.8, 0.9 Hz, 1 H), 7.99 (d, J=8.8 Hz, 1 H), 7.81 - 7.92 (m, 2 H), 7.75 (dd, J=3.8, 1.3 Hz, 1 H), 7.55 - 7.63 (m, 2 H), 7.43 - 7.49 (m, 1 H), 7.29 (td, J=7.6, 1.2 Hz, 1 H), 7.22 (dd, J=5.0, 3.8 Hz, 1 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.16 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C19H14F3N2O2S, 391.0723; found 391.0731.
[0257] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)furan-2-carboxamide (XJB06-061 ,
NCGC00189452-01). The title compound was prepared according to general protocol C. LC-
MS Retention Time: ti (Method 1) = 6.221 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.42
(s, 1 H), 10.77 (s, 1 H), 8.41 (dd, J=8.4, 1.4 Hz, 1 H), 8.04 - 8.15 (m, 1 H), 7.98 - 8.04 (m, 1 H), 7.96 (dd, J=1.9, 0.9 Hz, 1 H), 7.91 (dd, J=8.0, 1.6 Hz, 1 H), 7.52 - 7.65 (m, 2 H), 7.44 - 7.50 (m, 1 H), 7.28 (td, J=7.6, 1.2 Hz, 1 H), 7.24 (dd, J=3.5, 0.8 Hz, 1 H), 6.69 (dd, J=3.5, 1.8 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.15 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C19H14F3N2O3, 375.0951; found 375.0957.
EXAMPLE 41
[0259] This example illustrates a synthesis of N-(2-((3-
(Trifiuoromethyl)phenyl)carbamoyl)phenyl)nicotinamide (XJB06-062, NCGC00189451-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 5.342 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 1 1.27 (s, 1 H), 10.74 (s, 1 H), 8.95 - 9.12 (m, 1 H), 8.67 - 8.91 (m, 1 H), 8.19 - 8.29 (m, 1 H), 8.17 (dd, J=8.3, 1.3 Hz, 1 H), 8.10 (t, J=2.1 Hz, 1 H), 7.92 - 8.02 (m, 1 H), 7.86 (dd, J=7.8, 1.6 Hz, 1 H), 7.52 - 7.69 (m, 3 H), 7.38 - 7.48 (m, 1 H), 7.33 (td, J=7.6, 1.4 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.20 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for CzoH^^Oz, 386.1111; found 386.1116.
EXAMPLE 42
(Trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide (XJB06-063,
NCGC00189450-01). The title compound was prepared according to general protocol C. LC- MS Retention Time: ti (Method 1) = 6.043 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.63 (s, 1 H), 10.79 (s, 1 H), 8.80 (d, J=2.0 Hz, 1 H), 8.23 (dd, J=8.4, 1.2 Hz, 1 H), 8.08 - 8.15 (m, 1 H), 7.99 (dd, J=8.3, 1.5 Hz, 1 H), 7.91 (dd, J=7.8, 1.6 Hz, 1 H), 7.56 - 7.68 (m, 2 H), 7.44 - 7.51 (m, 1 H), 7.36 (td, J=7.6, 1.4 Hz, 1 H), 7.19 (d, J=2.0 Hz, 1 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.18 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C18H13F3N3O3, 376.0904; found 376.0910.
EXAMPLE 43
[0263] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2-((furan- 2-ylmethyl)carbamoyl)phenyl)benzamide (XJB06-065, NCGC00189449-01). A solution of methyl 2-(cyclohexanecarboxamido)benzoate (50.0 mg, 0.191 mmol) and 2-amino-N-(furan- 2-ylmethyl)benzamide (41.4 mg, 0.191 mmol) in toluene (2.00 mL) was treated at room temperature with AlMe3 (0.192 mL, 2.0 M in toluene, 0.384 mmol). The reaction mixture was stirred at 100 °C for overnight and then quenched with 100 of water. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the title compound as a white solid. LC-MS Retention Time: ti (Method 1) = 6.799 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 12.07 (s, 1 H), 10.69 (s, 1 H), 9.29 (t, J=5.8 Hz, 1 H), 8.41 (dd, J=8.3, 1.3 Hz, 1 H), 8.22 (dd, J=8.3, 1.3 Hz, 1 H), 7.80 (dd, J=8.0, 1.6 Hz, 1 H), 7.73 (dd, J=7.8, 1.6 Hz, 1 H), 7.45 - 7.64 (m, 3 H), 7.13 - 7.29 (m, J=7.9, 7.7, 7.7, 1.3 Hz, 2 H), 6.36 (dd, J=3.2, 1.9 Hz, 1 H), 6.22 - 6.33 (m, 1 H), 4.45 (d, J=5.5 Hz, 2 H),
2.18 - 2.36 (m, 1 H), 1.76 - 1.91 (m, 2 H), 1.64 - 1.76 (m, 2 H), 1.50 - 1.64 (m, 1 H), 1.05 - 1.44 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C26H28N3O4, 446.2074; found 446.2080.
EXAMPLE 44
[0265] This example illustrates a synthesis of Methyl 2-(furan-2-carboxamido)benzoate (XJB06-066, NCGC00026064-02). A solution of methyl 2-aminobenzoate (1.71 mL, 13.2 mmol) in dichloro methane (50.0 mL) and TEA (5.53 mL, 39.7 mmol) was treated at room temperature with furan-2-carbonyl chloride (2.62 mL, 26.5 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with methanol, concentrated, and purified via silica gel chromatography using a gradient of 0-40% of EtOAc in hexanes to give 3.00 g (92%) of the title compound as a white solid. LC-MS Retention Time: ti (Method 1) = 6.516 min.
[0267] This example illustrates a synthesis of N-(2-((2-((Furan-2- ylmethyl)carbamoyl)phenyl)carbamoyl)phenyl)furan-2-carboxamide (XJB06-067,
NCGC00052938-02). A solution of 2-(furan-2-carboxamido)benzoate (50.0 mg, 0.204 mmol) and 2-amino-N-(furan-2-ylmethyl)benzamide (44.1 mg, 0.204 mmol) in toluene (2.00 mL)
was treated at room temperature with AlMe3 (0.204 mL, 2.0 M in toluene, 0.408 mmol). The reaction mixture was stirred at 100 °C for overnight and then quenched with 100 of water. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via Ci8 reverse phase HPLC to give the title compound as a white solid. LC-MS Retention Time: ti (Method 1) = 6.103 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 12.33 (s, 1 H), 11.87 (s, 1 H), 9.32 (t, J=5.3 Hz, 1 H), 8.53 (dd, J=8.4, 1.4 Hz, 1 H), 8.45 (dd, J=8.3, 1.3 Hz, 1 H), 7.97 (dd, J=1.8, 1.0 Hz, 1 H), 7.86 (dd, J=8.0, 1.6 Hz, 1 H), 7.83 (dd, J=8.0, 1.6 Hz, 1 H), 7.55 - 7.67 (m, 2 H), 7.53 (dd, J=2.0, 1.0 Hz, 1 H), 7.27 - 7.35 (m, 1 H), 7.18 - 7.27 (m, 2 H), 6.70 (dd, J=3.5, 1.8 Hz, 1 H), 6.35 (dd, J=3.2, 1.9 Hz, 1 H), 6.28 (dd, J=3.1, 1.0 Hz, 1 H), 4.44 (d, J=5.5 Hz, 2 H); HRMS (ESI) m/z (M+H)+ calcd. for C24H2oN305, 430.1397; found 430.1406.
EXAMPLE 46
[0269] This example illustrates a synthesis of 2-(3-(Trifluoromethyl)benzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-070, NCGC00189448-01). The title compound was prepared according to general protocol D. LC-MS Retention Time: ti (Method 1) = 7.060 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.28 (s, 1 H), 10.72 (s, 1 H), 8.13 - 8.32 (m, 3 H), 8.11 (dd, J=8.2, 1.2 Hz, 1 H), 7.88 - 8.00 (m, 2 H), 7.84 (dd, J=7.8, 1.6 Hz, 1 H), 7.78 (t, J=7.7 Hz, 1 H), 7.49 - 7.66 (m, 2 H), 7.39 - 7.45 (m, 1 H), 7.33 (td, J=7.6, 1.4 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.32 (s, 6 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi5F6N202, 453.1032; found 453.1033.
EXAMPLE 47
[0271] This example illustrates a synthesis of 2-Acetamido-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-071, NCGCOO 189447-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 5.593 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.64 (s, 1 H), 10.18 (br. s., 1 H), 8.18 (t, J=2.2 Hz, 1 H), 7.97 - 8.04 (m, 1 H), 7.92 (dt, J=8.0, 1.2 Hz, 1 H), 7.71 (dd, J=7.7, 1.7 Hz, 1 H), 7.57 (t, J=8.0 Hz, 1 H), 7.50 (ddd, J=8.4, 7.1, 1.7 Hz, 1 H), 7.41 - 7.47 (m, 1 H), 7.21 (td, J=7.6, 1.3 Hz, 1 H), 2.02 (s, 3 H); 19F NMR (376 MHz, DMSO- d6) δ ppm -61.18 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C16H14F3N2O2, 323.1002; found 323.1010.
EXAMPLE 48
[0273] This example illustrates a synthesis of 2-Acetamido-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-072, NCGCOO 189446-01). The title compound was prepared according to general protocol D. LC-MS Retention Time: ti (Method 1) = 7.415 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.25 (s, 1 H), 10.71 (s, 1 H), 8.39 - 8.57 (m, 2 H), 8.35 (s, 1 H), 8.19 (s, 1 H), 7.92 - 8.00 (m, 1 H), 7.84 - 7.92 (m, 1 H), 7.81 (dd, J=7.7, 1.7 Hz, 1 H), 7.58 - 7.68 (m, 1 H), 7.53 (t, J=7.9 Hz, 1 H), 7.22 - 7.47 (m, 2 H); 19F NMR (376
MHz, DMSO- g) δ ppm -61.42 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C23H14F9N2O2, 521.0906; found 521.0905.
EXAMPLE 49
[0275] This example illustrates a synthesis of 2-(2-Phenylacetamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-074, NCGC00189445-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.443 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.61 (s, 1 H), 10.30 (s, 1 H), 8.17 (t, J=2.1 Hz, 1 H), 8.00 - 8.07 (m, 1 H), 7.83 - 7.91 (m, 1 H), 7.71 (dd, J=7.8, 1.6 Hz, 1 H), 7.57 (t, J=7.9 Hz, 1 H), 7.50 (ddd, J=8.5, 7.2, 1.6 Hz, 1 H), 7.41 - 7.47 (m, 1 H), 7.1 1 - 7.34 (m, 6 H), 3.66 (s, 2 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.15 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N202, 399.1315; found 399.1312.
EXAMPLE 50
[0277] This example illustrates a synthesis of 2-(Cyclopropanecarboxamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB06-081, NCGCOO 189444-01). The title compound was prepared according to general protocol B. LC-MS Retention Time: ti (Method 1) = 6.131 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.61 (s, 1 H), 10.46 (s, 1 H), 8.17 (s, 1 H), 7.95 - 8.08 (m, 1 H), 7.91 (dd, J=7.9, 1.3 Hz, 1 H), 7.71 (dd, J=7.9, 1.5 Hz, 1 H), 7.57 (t, J=7.9
Hz, 1 H), 7.46 - 7.53 (m, 1 H), 7.40 - 7.46 (m, 1 H), 7.20 (tt, J=7.6, 0.8 Hz, 1 H), 1.61 - 1.81 (m, 1 H), 0.65 - 0.79 (m, 4 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for Ci8Hi6F3N202, 349.1158; found 349.1160.
EXAMPLE 51
[0279] This example illustrates a synthesis of N-(3-(fert-Butyl)phenyl)-2- (cyclohexanecarboxamido)benzamide (XJB07-026, NCGC00238733-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.324 min; HRMS (ESI) m/z (M+H)+ calcd. for C24H31N2O2, 379.2380; found 379.2387.
EXAMPLE 52
[0281] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2,3- dihydro-lH-inden-5-yl)benzamide (XJB07-028, NCGC00238732-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.053 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.62 (s, 1 H), 10.27 (s, 1 H), 8.26 (d, J=8.2 Hz, 1 H), 7.75 (d, J=7.8 Hz, 1 H), 7.55 (s, 1 H), 7.42 - 7.51 (m, 1 H), 7.31 - 7.41 (m, 1 H), 7.08 - 7.23 (m, 2 H), 2.74 - 2.90 (m, 4 H), 2.17 - 2.32 (m, 1 H), 1.92 - 2.08 (m, J=7.8, 7.5, 7.4, 7.4
Hz, 2 H), 1.76 - 1.89 (m, 2 H), 1.63 - 1.76 (m, 2 H), 1.52 - 1.63 (m, 1 H), 1.05 - 1.46 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C23H27N2O2, 363.2067; found 363.2075.
EXAMPLE 53
[0283] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(lH-indol- 5-yl)benzamide (XJB07-031, NCGC00238734-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 5.982 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.04 (br. s., 1 H), 10.87 (s, 1 H), 10.26 (s, 1 H), 8.34 (d, J=8.4 Hz, 1 H), 7.65 - 8.00 (m, 2 H), 7.44 - 7.53 (m, 1 H), 7.24 - 7.41 (m, 3 H), 7.16 (t, J=7.6 Hz, 1 H), 6.31 - 6.45 (m, 1 H), 2.17 - 2.31 (m, 1 H), 1.77 - 1.92 (m, 2 H), 1.68 (ddd, J=12.5, 3.4, 3.2 Hz, 2 H), 1.51 - 1.62 (m, 1 H), 1.01 - 1.44 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C22H24N3O2, 362.1863; found 362.1867.
EXAMPLE 54
[0285] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- iodophenyl)benzamide (XJB07-032, NCGC00238735-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.076 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.39 (s, 1 H), 10.32 (s, 1 H), 8.05 - 8.20 (m, 2 H), 7.68 -
7.76 (m, 1 H), 7.66 (ddd, J=8.2, 1.1, 0.9 Hz, 1 H), 7.39 - 7.55 (m, 2 H), 7.06 - 7.27 (m, 2 H), 2.11 - 2.33 (m, 1 H), 1.79 (dd, J=12.7, 2.2 Hz, 2 H), 1.63 - 1.73 (m, 2 H), 1.49 - 1.63 (m, 1 H), 1.05 - 1.44 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C20H22IN2O2, 449.0720; found 449.0720.
EXAMPLE 55
[0287] This example illustrates a synthesis of N-(3-Chlorophenyl)-2- (cyclohexanecarboxamido)benzamide (XJB07-033, NCGC00238736-01, CID-56593336). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.898 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.48 (s, 1 H), 10.31 (s, 1 H), 8.11 (d, J=7.8 Hz, 1 H), 7.85 (t, J=2.0 Hz, 1 H), 7.71 (dd, J=7.7, 1.3 Hz, 1 H), 7.59 (dd, J=8.0, 1.8 Hz, 1 H), 7.43 - 7.54 (m, 1 H), 7.35 (t, J=8.1 Hz, 1 H), 7.06 - 7.24 (m, 2 H), 2.26 (tt J=11.3, 3.6 Hz, 1 H), 1.79 (d, J=14.1 Hz, 2 H), 1.68 (ddd, J=12.7, 3.0, 2.7 Hz, 2 H), 1.52 - 1.62 (m, 1 H), 1.03 - 1.41 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C20H22CI 2O2, 357.1364; found 357.1366.
EXAMPLE 56
[0289] This example illustrates a synthesis of N-([ 1 , 1 '-Biphenyl]-3-yl)-2- (cyclohexanecarboxamido)benzamide (XJB07-034, NCGC00238737-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti
(Method 1) = 7.181 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.49 (s, 1 H), 10.44 (s, 1 H), 8.19 (ddd, J=8.2, 0.8, 0.6 Hz, 1 H), 7.96 (t, J=2.0 Hz, 1 H), 7.78 (dd, J=7.8, 1.6 Hz, 1 H), 7.70 (dt, J=7.6, 1.9 Hz, 1 H), 7.56 - 7.66 (m, 2 H), 7.31 - 7.55 (m, 6 H), 7.15 - 7.23 (m, 1 H), 2.19 - 2.32 (m, 1 H), 1.76 - 1.87 (m, 2 H), 1.62 - 1.74 (m, 2 H), 1.52 - 1.62 (m, 1 H), 1.04 - 1.45 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C26H27N2O2, 399.2067; found 399.2071.
EXAMPLE 57
[0291] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- ethynylphenyl)benzamide (XJB07-035, NCGC00238738-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.586 min; !H NMR (400 MHz, DMSO- 6) δ ppm 10.42 (s, 1 H), 10.38 (s, 1 H), 8.15 (d, J=8.2 Hz, 1 H), 7.84 (s, 1 H), 7.71 - 7.78 (m, 1 H), 7.62 - 7.71 (m, 1 H), 7.44 - 7.53 (m, 1 H), 7.34 (t, J=8.0 Hz, 1 H), 7.14 - 7.24 (m, 2 H), 4.17 (s, 1 H), 2.08 - 2.35 (m, 1 H), 1.74 - 1.89 (m, 2 H), 1.62 - 1.74 (m, 2 H), 1.53 - 1.62 (m, 1 H), 1.00 - 1.43 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C22H23N2O2, 347.1754; found 347.1757.
EXAMPLE 58
[0293] This example illustrates a synthesis of N-(4-(tert-Butyl)phenyl)-2- (cyclohexanecarboxamido)benzamide (XJB07-037, NCGC00238739-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.389 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.63 (s, 1 H), 10.33 (s, 1 H), 8.26 (d, J=8.2 Hz, 1 H), 7.76 (dt, J=7.9, 1.0 Hz, 1 H), 7.52 - 7.61 (m, 2 H), 7.43 - 7.52 (m, 1 H), 7.29 - 7.42 (m, 2 H), 7.17 (tt, J=7.6, 1.0 Hz, 1 H), 2.16 - 2.29 (m, 1 H), 1.77 - 1.89 (m, 2 H), 1.64 - 1.77 (m, 2 H), 1.49 - 1.64 (m, 1 H), 1.25 (s, 9 H), 1.01 - 1.44 (m, 5 H);
HRMS (ESI) m/z (M+H)+ calcd. for C24H31N2O2, 379.2380; found 379.2391.
EXAMPLE 59
[0295] This example illustrates a synthesis of N-(Benzo[d][l,3]dioxol-5-yl)-2- (cyclohexanecarboxamido)benzamide (XJB07-039, NCGC00238740-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.279 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.57 (s, 1 H), 10.28 (s, 1 H), 8.23 (d, J=8.6 Hz, 1 H), 7.73 (dd, J=7.9, 1.7 Hz, 1 H), 7.44 - 7.62 (m, 1 H), 7.26 - 7.35 (m, 1 H), 7.13 - 7.21 (m, 1 H), 7.08 (dd, J=8.4, 2.0 Hz, 1 H), 6.88 (d, J=8.4 Hz, 1 H), 5.98 (s, 2 H), 2.25 (tt, J=11.3, 3.6 Hz, 1 H), 1.75 - 1.90 (m, 2 H), 1.64 - 1.75 (m, 2 H), 1.50 - 1.64 (m, 1 H), 1.01 - 1.43 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C21H23N2O4, 367.1652; found 367.1657.
EXAMPLE 60
[0297] This example illustrates a synthesis of 2-(3-Nitrobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-047, NCGC00238741-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.687 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.32 (s, 1 H), 10.73 (s, 1 H), 8.68 (t, J=2.1 Hz, 1 H), 8.36 - 8.48 (m, 1 H), 8.29 (dt, J=7.8, 1.5 Hz, 1 H), 8.12 (s, 1 H), 7.99 - 8.10 (m, 1 H), 7.95 (d, J=8.2 Hz, 1 H), 7.76 - 7.88 (m, 2 H), 7.58 - 7.66 (m, J=7.6, 7.6, 1.2, 0.8 Hz, 1 H), 7.50 - 7.58 (m, 1 H), 7.38 - 7.45 (m, 1 H), 7.29 - 7.38 (m, 1 H); 19F NMR (376 MHz, DMSO- d6) δ ppm -61.34 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H15F3N3O4, 430.1009; found 430.1012.
EXAMPLE 61
[0299] This example illustrates a synthesis of 2-(3-Cyanobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-048, NCGC00238743-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.508 min; 1H NMR (400 MHz, DMSO-< 6) δ ppm 11.16 (s, 1 H), 10.71 (s, 1 H), 8.27 (t, J=1.8 Hz, 1 H), 8.15 (dt, J=7.9, 1.6 Hz, 1 H), 8.01 - 8.12 (m, 3 H), 7.88 - 7.96 (m, 1 H), 7.79 - 7.87 (m,
1 H), 7.73 (t, J=7.8 Hz, 1 H), 7.51 - 7.65 (m, 2 H), 7.42 (d, J=7.6 Hz, 1 H), 7.32 (td, J=7.7, 0.8 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.33 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi5F3N302, 410.1111; found 410.1120.
EXAMPLE 62
[0301] This example illustrates a synthesis of 2-Bromo-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB07-050, NCGC00238742-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.641 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5BrF3N202, 463.0264; found 463.0264.
EXAMPLE 63
[0303] This example illustrates a synthesis of 2-(4-Chlorobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-051, NCGC00238744-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 7.132 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.26 (s, 1 H), 10.72 (s, 1 H), 8.21 (d, J=8.2 Hz, 1 H), 8.06 (s, 1 H), 7.96 (d, J=8.4 Hz, 1 H), 7.82 - 7.93 (m, 3 H), 7.52 - 7.66 (m, 4 H), 7.44 (d, J=7.8 Hz, 1 H), 7.30 (t, J=7.4 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5ClF3N202, 419.0769; found 419.0775.
EXAMPLE 64
[0305] This example illustrates a synthesis of 2-(4-Methylbenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-052, NCGC00238745-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.967 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.31 (s, 1 H), 10.73 (s, 1 H), 8.33 (d, J=8.4 Hz,
1 H), 8.08 (s, 1 H), 7.98 (d, J=8.4 Hz, 1 H), 7.88 (dd, J=7.6, 1.6 Hz, 1 H), 7.78 (d, J=8.2 Hz,
2 H), 7.53 - 7.64 (m, 2 H), 7.45 (ddd, J=7.7, 1.8, 0.9 Hz, 1 H), 7.33 (d, J=8.6 Hz, 2 H), 7.27 (td, J=7.6, 1.2 Hz, 1 H), 2.34 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N202, 399.1315; found 399.1321.
EXAMPLE 65
[0307] This example illustrates a synthesis of 2-(4-(Trifluoromethyl)benzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-054, NCGC00238746-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 7.128 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.33 (d, J=0.4 Hz, 1 H), 10.73 (s, 1 H), 8.19 (d, J=8.2 Hz, 1 H), 8.01 - 8.11 (m, 3 H), 7.97 (d, J=8.4 Hz, 1 H), 7.90 (d, J=8.6 Hz, 2 H), 7.82 - 7.88 (m, 1 H), 7.51 - 7.64 (m, 2 H), 7.40 - 7.45 (m, 1 H), 7.32 (t, J=7.4 Hz, 1 H); 19F NMR
(376 MHz, DMSO- g) δ ppm -61.30 (s, 3 F), -61.45 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi5F6N202, 453.1032; found 453.1034.
EXAMPLE 66
[0309] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)-[l, -biphenyl]-3-carboxamide (XJB07-055, NCGC00238747-01). The title compound was prepared according to general protocol C. LC- MS Retention Time: ti (Method 1) = 7.398 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.40 (s, 1 H), 10.76 (s, 1 H), 8.25 - 8.35 (m, 1 H), 8.10 - 8.22 (m, 2 H), 7.99 (d, J=8.2 Hz, 1 H), 7.81 - 7.94 (m, 3 H), 7.67 - 7.75 (m, 2 H), 7.54 - 7.66 (m, 3 H), 7.43 - 7.51 (m, 3 H), 7.37 - 7.43 (m, 1 H), 7.32 (td, J=7.6, 1.3 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C27H20F3N2O2, 461.1471; found 461.1478.
EXAMPLE 67
[0311] This example illustrates a synthesis of 2-(3-Methylbenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-056, NCGC00238759-02). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.975
min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.27 (s, 1 H), 10.75 (s, 1 H), 8.30 (dd, J=8.3, 1.3 Hz, 1 H), 8.14 (s, 1 H), 7.98 (d, J=8.4 Hz, 1 H), 7.88 (dd, J=7.8, 1.6 Hz, 1 H), 7.71 (t, J=1.7 Hz, 1 H), 7.64 - 7.69 (m, 1 H), 7.54 - 7.64 (m, 2 H), 7.43 - 7.48 (m, 1 H), 7.37 - 7.43 (m, 2 H), 7.30 (td, J=7.6, 1.3 Hz, 1 H), 2.36 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.31 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N202, 399.1315; found
399.1323.
[0313] This example illustrates a synthesis of 2-(4-Methoxybenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-057, NCGC00238760-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.679 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.31 (s, 1 H), 10.75 (s, 1 H), 8.36 (dd, J=8.3, 1.3 Hz, 1 H), 8.08 (t, J=2.2 Hz, 1 H), 8.01 (ddd, J=8.2, 1.2, 1.0 Hz, 1 H), 7.78 - 7.92 (m, 3 H), 7.54 - 7.64 (m, 2 H), 7.42 - 7.49 (m, 1 H), 7.27 (td, J=7.6, 1.2 Hz, 1 H), 7.00 - 7.12 (m, 2 H), 3.81 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.25 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N203, 415.1264; found 415.1272.
EXAMPLE 69
[0315] This example illustrates a synthesis of 2-Methyl-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB07-058, NCGC00238761-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.769 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.74 (s, 1 H), 10.70 (s, 1 H), 8.08 - 8.19 (m, 2 H), 7.95 (dt, J=8.2, 1.2 Hz, 1 H), 7.79 (dd, J=7.8, 1.8 Hz, 1 H), 7.48 - 7.65 (m, 3 H), 7.33 - 7.47 (m, 2 H), 7.22 - 7.33 (m, 3 H), 2.37 (s, 3 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.30 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N202, 399.1315; found 399.1324.
EXAMPLE 70
[0317] This example illustrates a synthesis of 2-(Trifluoromethyl)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB07-059, NCGC00238762-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.708 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.83 (s, 1 H), 10.71 (s, 1 H), 8.13 (s, 1 H), 8.00 (d, J=8.2 Hz, 1 H), 7.94 (d, J=8.2 Hz, 1 H), 7.64 - 7.87 (m, 5 H), 7.49 - 7.63 (m, 2 H), 7.42 (dt, J=7.8, 1.0 Hz, 1 H), 7.33 (td, J=7.6, 1.4 Hz, 1 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -57.86 (s, 3 F), -61.31 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi5F6N202, 453.1032; found 453.1027.
EXAMPLE 71
[0319] This example illustrates a synthesis of 2-(3-Methoxybenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-060, NCGC00238763-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.778 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.33 (s, 1 H), 10.75 (s, 1 H), 8.32 (dd, J=8.3, 1.3 Hz, 1 H), 8.14 (t, J=2.1 Hz, 1 H), 7.98 (dt, J=8.1, 1.2 Hz, 1 H), 7.89 (dd, J=7.9, 1.7 Hz, 1 H), 7.52 - 7.66 (m, 2 H), 7.39 - 7.52 (m, 4 H), 7.30 (td, J=7.6, 1.4 Hz, 1 H), 7.13 - 7.25 (m, 1 H), 3.80 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.31 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N203, 415.1264; found 415.1270.
EXAMPLE 72
[0321] This example illustrates a synthesis of 2-(3-Chlorobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-062, NCGC00238764-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 7.105 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.20 (s, 1 H), 10.73 (s, 1 H), 8.15 (dd, J=8.2, 1.4 Hz, 1 H), 8.13 (t, J=2.1 Hz, 1 H), 7.92 - 7.99 (m, 1 H), 7.90 (t, J=2.0 Hz, 1 H), 7.76 - 7.89 (m, 2 H), 7.64 - 7.69 (m, 1 H), 7.53 - 7.64 (m, 3 H), 7.40 - 7.47 (m, 1 H), 7.33 (td, J=7.6, 1.2
Hz, 1 H); iyF NMR (376 MHz, DMSO- 6) δ ppm -61.30 (s, 3 F); HRMS (ESI) m/z (M+H) calcd. for C2iHi5ClF3N202, 419.0769; found 419.0772.
EXAMPLE 73
[0323] This example illustrates a synthesis of 2-Methoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB07-063 , NCGC00238748-01 ). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.734 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.54 (s, 1 H), 10.84 (s, 1 H), 8.52 - 8.63 (m, 1 H), 8.32 (t, J=2.2 Hz, 1 H), 7.94 - 8.06 (m, 2 H), 7.79 (dd, J=7.7, 1.7 Hz, 1 H), 7.51 - 7.68 (m, 3 H), 7.43 - 7.51 (m, 1 H), 7.24 - 7.30 (m, 1 H), 7.17 - 7.23 (m, 1 H), 6.99 - 7.13 (m, 1 H), 3.97 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.40 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N203, 415.1264; found 415.1266.
EXAMPLE 74
[0325] This example illustrates a synthesis of N-(2-((3-
(Trifiuoromethyl)phenyl)carbamoyl)phenyl)- 1 -naphthamide (XJB07-064, NCGC00238749- 01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.952 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.94 (s, 1 H),
10.74 (s, 1 H), 8.26 - 8.32 (m, 1 H), 8.16 (t, J=2.2 Hz, 1 H), 8.02 - 8.1 1 (m, 2 H), 7.91 - 8.01 (m, 2 H), 7.81 (dd, J=3.2, 1.5 Hz, 1 H), 7.79 (dd, J=3.9, 1.6 Hz, 1 H), 7.44 - 7.67 (m, 5 H), 7.38 - 7.43 (m, 1 H), 7.34 (td, J=7.6, 1.3 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm - 61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C25Hi8F3N202, 435.1315; found 435.1318
EXAMPLE 75
[0327] This example illustrates a synthesis of 2-(3-Bromobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-065, NCGC00238750-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 7.174 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.19 (s, 1 H), 10.73 (s, 1 H), 8.09 - 8.24 (m, 2 H), 8.04 (t, J=1.8 Hz, 1 H), 7.96 (dt, J=8.2, 1.2 Hz, 1 H), 7.82 - 7.91 (m, 2 H), 7.79 (ddd, J=8.0, 2.1, 1.1 Hz, 1 H), 7.54 - 7.65 (m, 2 H), 7.50 (t, J=7.8 Hz, 1 H), 7.44 (dt, J=7.8, 0.9 Hz, 1 H), 7.32 (td, J=7.6, 1.3 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.29 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5BrF3N202, 463.0264; found 463.0271.
EXAMPLE 76
[0329] This example illustrates a synthesis of 2-(4-Cyanobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-066, NCGC00238751-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.522 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.32 (s, 1 H), 10.74 (s, 1 H), 8.18 (dd, J=8.2, 1.2 Hz, 1 H), 8.08 (t, J=2.2 Hz, 1 H), 8.00 - 8.06 (m, 4 H), 7.94 - 7.99 (m, 1 H), 7.87 (dd, J=7.8, 1.6 Hz, 1 H), 7.54 - 7.66 (m, 2 H), 7.40 - 7.50 (m, 1 H), 7.34 (td, J=7.6, 1.4 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.27 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi5F3N302, 410.1111; found 410.1119.
EXAMPLE 77
[0331] This example illustrates a synthesis of 2-(4-Nitrobenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-067, NCGC00238752-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.711 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.36 (s, 1 H), 10.75 (s, 1 H), 8.33 - 8.41 (m, 2 H), 8.16 (dd, J=8.2, 1.2 Hz, 1 H), 8.05 - 8.14 (m, 3 H), 7.93 - 8.01 (m, 1 H), 7.83 - 7.92 (m, 1 H), 7.63 (ddd, J=8.4, 7.3, 1.6 Hz, 1 H), 7.58 (t, J=8.0 Hz, 1 H), 7.45 (dt, J=7.8, 0.9 Hz, 1 H), 7.35 (td, J=7.6, 1.2 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.27 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5F3N304, 430.1009; found 430.1008.
EXAMPLE 78
[0333] This example illustrates a synthesis of N-(2-((3-
(Trifiuoromethyl)phenyl)carbamoyl)phenyl)-2-naphthamide (XJB07-069, NCGC00238753- 01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 7.197 min; HRMS (ESI) m/z (M+H)+ calcd. for CzsHigFsNzOz, 435.1315; found 435.1314.
EXAMPLE 79
[0335] This example illustrates a synthesis of 2-(4-Bromobenzamido)-N-(3-
(trifiuoromethyl)phenyl)benzamide (XJB07-073, NCGC00238754-01). A solution of 2- amino-N-(3-(trifluoromethyl)phenyl)benzamide (50.0 mg, 0.178 mmol) in dichloromethane
(2.00 mL) and TEA (0.075 mL, 0.535 mmol) was treated at room temperature with 4- bromobenzoyl bromide (70.6 mg, 0.268 mmol). The reaction mixture was stirred at room temperature for overnight. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention
Time: ti (Method 1) = 7.158 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.28 (s, 1 H),
10.74 (s, 1 H), 8.23 (dd, J=8.2, 1.2 Hz, 1 H), 8.08 (t, J=2.2 Hz, 1 H), 7.92 - 8.02 (m, 1 H),
7.87 (dd, J=7.8, 1.8 Hz, 1 H), 7.79 - 7.85 (m, 2 H), 7.72 - 7.78 (m, 2 H), 7.55 - 7.64 (m, 2 H),
7.42 - 7.50 (m, 1 H), 7.27 - 7.36 (m, 1 H); iyF NMR (376 MHz, DMSO-dg) δ ppm -61.26 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5BrF3N202, 463.0264; found 463.0268.
PLE 80
[0337] This example illustrates a synthesis of 2-(3-(Methylsulfonyl)benzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-075, NCGC00238755-01). The title compound was prepared according to general protocol D. LC-MS Retention Time: ti (Method 1) = 6.025 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.30 (s, 1 H), 10.74 (s, 1 H), 8.42 (t, J=1.9 Hz, 1 H), 8.20 (ddd, J=7.9, 1.5, 1.4 Hz, 1 H), 8.08 - 8.17 (m, 3 H), 7.97 (d, J=8.2 Hz, 1 H), 7.77 - 7.89 (m, 2 H), 7.62 (ddd, J=8.4, 7.2, 1.6 Hz, 1 H), 7.57 (t, J=8.0 Hz, 1 H), 7.44 (dd, J=6.8, 1.2 Hz, 1 H), 7.35 (td, J=7.6, 1.2 Hz, 1 H), 3.25 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N204S, 463.0934; found 463.0939.
EXAMPLE 81
[0339] This example illustrates a synthesis of 2-(4-Acetylbenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-076, NCGC00238756-01). The title compound was prepared according to general protocol D. LC-MS Retention Time: ti (Method 1) = 6.474
min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.38 (s, 1 H), 10.76 (s, 1 H), 8.21 - 8.30 (m, 1 H), 8.04 - 8.12 (m, 3 H), 7.94 - 8.03 (m, 3 H), 7.89 (dd, J=7.8, 1.6 Hz, 1 H), 7.54 - 7.68 (m, 2 H), 7.41 - 7.52 (m, 1 H), 7.33 (td, J=7.6, 1.2 Hz, 1 H), 2.62 (s, 3 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.26 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for CzsHigFsNzOs, 427.1264; found 427.1267.
EXAMPLE 82
[0341] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- isopropylphenyl)benzamide (XJB07-080, NCGC00238757-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.166 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.52 (s, 1 H), 10.30 (s, 1 H), 8.21 (dd, J=8.4, 1.4 Hz, 1 H), 7.77 (dd, J=7.8, 1.6 Hz, 1 H), 7.44 07.58 (m, 3 H), 7.26 (t, J=7.8 Hz, 1 H), 7.19 (td, J=7.6, 1.2 Hz, 1 H), 7.00 (dt, J=7.7, 1.5 Hz, 1 H), 2.86 (quin, J=6.8 Hz, 1 H), 2.20 02.36 (m, 1 H), 1.76 01.90 (m, 2 H), 1.65 01.76 (m, 2 H), 1.55 01.65 (m, 1 H), 1.20 (d, J=4.0 Hz, 6 H), 1.08 01.44 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C23H29N2O2, 365.2239; found 365.2239.
EXAMPLE 83
[0343] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-((5- methylfuran-2-yl)methyl)benzamide (XJB07-081, NCGC00238758-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.284 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.26 (s, 1 H), 9.16 (t, J=5.5 Hz, 1 H), 8.40 (dd, J=8.4, 1.2 Hz, 1 H), 7.72 (dd, J=7.8, 1.6 Hz, 1 H), 7.42 07.48 (m, 1 H), 7.10 (ddd, J=8.0, 7.2, 1.2 Hz, 1 H), 6.15 (d, J=2.9 Hz, 1 H), 5.96 Q5.00 (m, 1 H), 4.39 (d, J=5.7 Hz, 2 H), 2.21 (d, J=0.8 Hz, 3 H), 2.18 02.28 (m, 1 H), 1.78 01.94 (m, 2 H), 1.66 01.78 (m, 2 H), 1.55 01.66 (m, 1 H), 1.07 01.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2oH25N203, 341.1860; found 341.1869. XAMPLE 84
[0345] This example illustrates a synthesis of 2-(3-Methylbenzamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB07-093, NCGC00238759-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.938 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.26 (s, 1 H), 10.74 (s, 1 H), 8.29 (dd, J=8.3, 0.9 Hz, 1 H), 8.13 (s, 1 H), 7.94 - 7.99 (m, 1 H), 7.87 (ddd, J=7.8, 1.1 , 0.9 Hz, 1 H), 7.70 (s, 1 H), 7.63 - 7.69 (m, 1 H), 7.54 - 7.63 (m, 2 H), 7.36 - 7.49 (m, 3 H), 7.20 - 7.32 (m, 1 H), 2.35 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.31 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N202, 399.1315; found 399.1319.
[0347] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)-[ 1 , 1 Bbiphenyl]-3-carboxamide (XJB07-094, NCGC00238747-02). The title compound was prepared according to general protocol C. LC- MS Retention Time: ti (Method 1) = 7.389 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.39 (s, 1 H), 10.75 (s, 1 H), 8.28 (dt, J=8.3, 0.7 Hz, 1 H), 8.13 C8.19 (m, 2 H), 7.97 ES.01 (m, 1 H), 7.82 07.92 (m, 3 H), 7.67 07.79 (m, 2 H), 7.53 07.66 (m, 3 H), 7.36 07.53 (m, 4 H), 7.31 (tt, J=7.7, 0.7 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.29 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C27H20F3N2O2, 461.1471; found 461.1476.
[0349] This example illustrates a synthesis of 2-Bromo-N-(3-
(trifluoromethyl)phenyl)benzamide (XJB09-014). A solution of 3-(trifluoromethyl)aniline (0.850 mL, 6.83 mmol) in dichloromethane (15.0 mL) and triethylamine (2.86 mL, 20.5 mmol) was treated at 0 °C with 2-bromobenzoyl chloride (0.893 mL, 6.83 mmol) and stirred at room temperature for 3 h. The reaction mixture was diluted with dichloromethane and washed with Na2C03 solution. The organic layer was separated, dried, and concentrated to give 2.30 g (98%) of the title compound as a white foam which was used directly for the next reaction without further purification.
[0351] This example illustrates a synthesis of N-(3-(Trifluoromethyl)phenyl)-[l,l 0 biphenyl]-2-carboxamide (XJB09-016, NCGC00244471-01). The title compound was prepared according to general protocol E. LC-MS Retention Time: ti (Method 1) = 6.365 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.54 (s, 1 H), 7.97 (t, J=2.1 Hz, 1 H), 7.64□ 7.73 (m, 1 H), 7.55 07.64 (m, 2 H), 7.44 07.54 (m, 3 H), 7.32 07.44 (m, 5 H), 7.25 07.32 (m, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.34 (s, 3 F); HRMS (ESI) m/z (M+H) calcd. for C2oHi5F3NO, 342.1100; found 342.1110. LE 88
[0353] This example illustrates a synthesis of 2 B(Benzyloxy)-N-(3- (trifiuoromethyl)phenyl)-[l,l 0biphenyl]-2-carboxamide (XJB09-019, NCGC00244472-01). The title compound was prepared according to general protocol E. LC-MS Retention Time: ti (Method 1) = 6.997 min; HRMS (ESI) m/z (M+H)+ calcd. for C27H2iF3N02, 448.1519; found 448.1524.
[0355] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(30 (trifiuoromethyl)-[l,l Bbiphenyl]-3-yl)benzamide (XJB09-023, NCGC00244469-01). A mixture ofN-(3-bromophenyl)-2-(cyclohexanecarboxamido)benzamide (50.0 mg, 0.125 mmol), 3-(trifluoromethyl)phenylboronic acid (35.5 mg, 0.187 mmol) and Pd(PPh3)4 (7.2 mg, 6.23 μιηοΐ) in DMF (1.50 mL) and 2.0 N Na2C03 (0.50 mL) aqueous solution was heated in μW at 100 °C for 30 min. The reaction was cooled to room temperature, added a small portion of Si-THIOL to get rid of Palladium. The mixture was filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 7.438 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.50 (br. s., 1 H), 10.49 (s, 1 H), 8.14 C8.24 (m, 1 H), 8.01 C8.08 (m, 1 H), 7.94 [3.01 (m, 1 H), 7.91 (s, 1 H), 7.78 07.84 (m, 2 H), 7.70 □7.77 (m, 2 H), 7.41 07.56 (m, 3 H), 7.22 (td, J=7.6, 1.3 Hz, 1 H), 2.21 02.35 (m, 1 H), 1.83 (d, J=15.8 Hz, 2 H), 1.64 [1.74 (m, 2 H), 1.52 01.63 (m, 1 H), 1.08 01.46 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.11 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C27H26F3N202, 467.1941; found 467.1943.
[0357] This example illustrates a synthesis of 2-Iodo-N-(3-
(trifluoromethyl)phenyl)benzamide (XJB09-026). A solution of 3-(trifluoromethyl)aniline (0.467 mL, 3.75 mmol) in dichloromethane (15.0 mL) and triethylamine (1.57 mL, 11.3 mmol) was treated at 0 °C with 2-iodobenzoyl chloride (1.00 g, 3.75 mmol) and stirred at
room temperature for 3 h. The reaction mixture was diluted with dichloromethane and washed with Na2C03 solution. The organic layer was separated, dried, and concentrated to give 1.40 g (95%) of the title compound as a white foam which was used directly for the next reaction without further purification.
EXAMPLE 91
[0359] This example illustrates a synthesis of 2-(Benzylamino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-027, NCGC00244464-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 7.001 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi8F3N02, 371.1366; found 371.1374. MPLE 92
[0361] This example illustrates a synthesis of 2-((2-Methoxybenzyl)amino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-028, NCGC00244511-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 6.914 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.36 (s, 1 H), 8.18 (t, J=2.1 Hz, 1 H), 7.87□ 8.01 (m, 1 H), 7.65 07.80 (m, 2 H), 7.49 07.61 (m, 1 H), 7.38 07.45 (m, 1 H), 7.16 07.31 (m, 3 H), 6.95 07.03 (m, 1 H), 6.83 05.90 (m, 1 H), 6.57 05.67 (m, 2 H), 4.35 (d, J=5.9 Hz, 2 H), 3.81 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.25 (s, 3 F).
XAMPLE 93
[0363] This example illustrates a synthesis of 2-(Phenylamino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-029, NCGC00244510-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 6.999 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.59 (s, 1 H), 8.99 (s, 1 H), 8.18 (t, J=2.2 Hz, 1 H), 7.89 07.99 (m, 1 H), 7.76 (dd, J=7.8, 1.6 Hz, 1 H), 7.57 (t, J=7.9 Hz, 1 H), 7.34□ 7.47 (m, 2 H), 7.20 07.33 (m, 3 H), 7.11 07.20 (m, 2 H), 6.82 D7.02 (m, 2 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.26 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for
C2oHi6F3N20, 357.1209; found 357.1216. XAMPLE 94
[0365] This example illustrates a synthesis of 2-((2-Methoxyphenyl)amino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-030, NCGC00244488-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 6.918 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.59 (s, 1 H), 9.02 (s, 1 H), 8.13 (t, J=2.2 Hz, 1 H), 7.94 C8.03 (m, 1 H), 7.78 (dd, J=7.8, 1.6 Hz, 1 H), 7.53 07.65 (m, 1 H), 7.42 07.49 (m, 1 H), 7.35 07.42 (m, 1 H), 7.24 07.34 (m, 2 H), 7.01 D7.08 (m, 1 H), 6.82 07.01 (m, 3 H), 3.82 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.23 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C2iHi8F3N202, 387.1315; found 387.1322.
AMPLE 95
[0367] This example illustrates a synthesis of 2-(Phenethylamino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-031, NCGC00244489-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 7.119 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.32 (s, 1 H), 8.16 (t, J=2.2 Hz, 1 H), 7.85 - 7.98 (m, 1 H), 7.70 (dd, J=7.9, 1.7 Hz, 1 H), 7.56 (t, J=8.0 Hz, 1 H), 7.47 (t, J=5.5 Hz, 1 H), 7.39 - 7.44 (m, 1 H), 7.35 (ddd, J=8.5, 7.0, 1.6 Hz, 1 H), 7.23 - 7.31 (m, 4 H), 7.12 - 7.22 (m, 1 H), 6.76 - 6.87 (m, 1 H), 6.64 (ddd, J=7.9, 7.0, 1.1 Hz, 1 H), 3.33 - 3.46 (m, 2 H), 2.87 (t, J=7.3 Hz, 2 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.25 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22H20F3N2O, 385.1522; found 385.1533. AMPLE 96
[0369] This example illustrates a synthesis of 2-((2-Methoxyethyl)amino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-032, NCGC00244512-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 6.254 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.33 (s, 1 H), 8.14 (t, J=2.2 Hz, 1 H), 7.88□ 8.05 (m, 1 H), 7.70 (dd, J=7.8, 1.6 Hz, 1 H), 7.54 07.63 (m, 1 H), 7.44 07.52 (m, 1 H), 7.37 □7.44 (m, 1 H), 7.34 (ddd, J=8.6, 7.0, 1.7 Hz, 1 H), 6.72 05.84 (m, 1 H), 6.65 (ddd, J=8.0, 7.1, 1.2 Hz, 1 H), 3.53 (t, J=5.5 Hz, 2 H), 3.28 (s, 3 H), 3.24 03.33 (m, 2 H); 19F NMR (376
MHz, DMSO- g) δ ppm -61.23 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for Ci7Hi8F3N202, 339.1315; found 339.1326.
EXAMPLE 97
[0371] This example illustrates a synthesis of 2-((Cyclohexylmethyl)amino)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-033, NCGC00244473-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 7.597 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.31 (s, 1 H), 8.11 (t, J=2.2 Hz, 1 H), 7.92□ 8.00 (m, 1 H), 7.70 (dd, J=8.0, 1.6 Hz, 1 H), 7.49 07.61 (m, 2 H), 7.39 07.45 (m, 1 H), 7.32 (ddd, J=8.6, 7.0, 1.6 Hz, 1 H), 6.69 05.76 (m, 1 H), 6.61 (ddd, J=8.0, 7.1, 1.2 Hz, 1 H), 2.92 D3.06 (m, 2 H), 1.72 01.83 (m, 2 H), 1.65 01.72 (m, 2 H), 1.49 01.65 (m, 2 H), 1.04 Dl.30 (m, 3 H), 0.88 01.05 (m, 2 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.21 (s, 3 F);
HRMS (ESI) m/z (M+H)+ calcd. for C2iH24F3N20, 377.1835; found 377.1843. XAMPLE 98
[0373] This example illustrates a synthesis of N-(3-(Trifluoromethyl)phenyl)-2-((3- (trifiuoromethyl)phenyl)amino)benzamide (XJB09-034, NCGC00244513-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method
1) = 7.252 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5F6N20, 425.1083; found
425.1092.
EXAMPLE 99
[0375] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- (methylthio)phenyl)benzamide (XJB09-035, NCGC00244465-02). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.687 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.44 (s, 1 H), 10.37 (s, 1 H), 8.18 (d, J=8.2 Hz, 1 H), 7.75 (dd, J=7.8, 1.6 Hz, 1 H), 7.63 (t, J=2.1 Hz, 1 H), 7.44 - 7.55 (m, 2 H), 7.29 (t, J=7.9 Hz, 1 H), 7.20 (td, J=7.6, 1.3 Hz, 1 H), 7.01 (ddd, J=7.8, 2.0, 1.0 Hz, 1 H), 2.46 (s, 3 H), 2.19 - 2.35 (m, 1 H), 1.76 - 1.90 (m, 2 H), 1.65 - 1.76 (m, 2 H), 1.52 - 1.65 (m, 1 H), 1.03 - 1.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N202S, 369.1631; found
369.1625. E 100
[0377] This example illustrates a synthesis of 2-((3-(Trifluoromethyl)benzyl)amino)-N- (3-(trifluoromethyl)phenyl)benzamide (XJB09-037, NCGC00244514-01). The title compound was prepared according to general protocol F. LC-MS Retention Time: ti (Method 1) = 7.370 min; HRMS (ESI) m/z (M+H)+ calcd. for C22Hi7F6N20, 439.1240; found
439.1247.
AMPLE 101
[0379] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- (piperidin-l-yl)phenyl)benzamide (XJB09-040, NCGC00244515-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 4.605 min; HRMS (ESI) m/z (M+H)+ calcd. for C25H32N3O2, 406.2489; found 406.2501. MPLE 102
[0381] This example illustrates a synthesis of 2-Chloro-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-047, NCGC00244490-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.765 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.83 (s, 1 H), 10.70 (s, 1 H), 8.01 C8.22 (m, 2 H), 7.89 C8.00 (m, 1 H), 7.69 07.85 (m, 1 H), 7.38 07.67 (m, 7 H), 7.33 (td, J=7.6, 1.4 Hz, 1 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for
419.0769; found 419.0769.
XAMPLE 103
[0383] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- ((trifiuoromethyl)thio)phenyl)benzamide (XJB09-048, NCGC00244491-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.349 min; HRMS (ESI) m/z (M+H)+ calcd. for C21H22F3N2O2S, 423.1349; found 423.1360. AMPLE 104
[0385] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- (thiophen-2-yl)phenyl)benzamide (XJB09-050, NCGC00244466-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.234 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.46 (br. s., 1 H), 10.45 (br. s., 1 H), 8.1 1□ 8.25 (m, 1 H), 7.92 C8.02 (m, 1 H), 7.75 07.83 (m, 1 H), 7.62 07.71 (m, 1 H), 7.55 (dd, J=5.1, 1.2 Hz, 1 H), 7.48 07.54 (m, 1 H), 7.34 07.48 (m, 3 H), 7.17 07.26 (m, 1 H), 7.14 (dd, J=5.0, 3.6 Hz, 1 H), 2.19 02.31 (m, 1 H), 1.78 01.89 (m, 2 H), 1.65 01.76 (m, 2 H), 1.53 01.64 (m, 1 H), 1.08 01.47 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for
C24H25N202S, 405.1631; found 405.1637.
PLE 105
[0387] This example illustrates a synthesis of 2-(Trifluoromethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-052, NCGC00244470-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.983 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.97 (s, 1 H), 10.74 (s, 1 H), 8.09 - 8.26 (m, 2 H), 7.91 - 8.03 (m, 1 H), 7.83 (dd, J=7.8, 1.6 Hz, 1 H), 7.77 (dd, J=7.6, 2.0 Hz, 1 H), 7.39 - 7.70 (m, 6 H), 7.33 (td, J=7.6, 1.3 Hz, 1 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -56.63 (s, 3 F), -61.33 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi5F6N203, 468.0981; found 468.0982. MPLE 106
[0389] This example illustrates a synthesis of 2-Ethoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-053, NCGC00244467-01, compound 99). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.998 min; 1H NMR (400 MHz, DMSO-d6) δ 1 1.33 (s, 1 H), 10.82 (s, 1 H), 8.51 (dd, J=8.4, 1.2 Hz, 1 H), 8.28 (t, J=2.1 Hz, 1 H), 7.89 - 8.07 (m, 2 H), 7.80 (dd, J=7.8, 1.6 Hz, 1 H), 7.55 - 7.65 (m, 2 H), 7.38 - 7.55 (m, 2 H), 7.27 (td, J=7.6, 1.3 Hz, 1 H), 7.19 (dd, J=8.4, 1.0 Hz, 1 H), 7.01 - 7.12 (m, 1 H), 4.30 (q, J=6.9 Hz, 2 H), 1.30 (t,
J=6.9 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.40 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C23H20F3N2O3, 429.1421; found 429.1425. MPLE 107
[0391] This example illustrates a synthesis of 2-Nitro-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-055, NCGC00244468-01). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.695 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5F3N304, 430.1009; found 430.1009. MPLE 108
[0393] This example illustrates a synthesis of 2,6-Dimethoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-056, NCGC00244474-01 , CID-56593296). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.400 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.68 (s, 1 H), 10.62 (s, 1 H), 8.43 (d, J=8.2 Hz, 1 H), 8.08 (s, 1 H), 7.93 (d, J=8.4 Hz, 1 H), 7.85 (dd, J=7.7, 1.1 Hz, 1 H), 7.52 - 7.64 (m, 2 H), 7.45 (d, J=7.6 Hz, 1 H), 7.34 (t, J=8.4 Hz, 1 H), 7.27 (td, J=7.6, 1.1 Hz, 1 H), 6.71 (d, J=8.4 Hz, 2 H), 3.69 (s, 6 H); 19F NMR (376 MHz,
DMSO- g) δ ppm -61.29 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C23H20F3N2O4, 445.1370; found 445.1380.
EXAMPLE 109
[0395] This example illustrates a synthesis of Methyl 2-(2-methoxybenzamido)benzoate (XJB09-051). A solution of 2-aminobenzoate (2.57 mL, 19.9 mmol) in dichloro methane (50.0 mL) and TEA (8.30 mL, 59.5 mmol) was treated at 0 °C with 2-methoxybenzoyl chloride (2.67 mL, 19.9 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-50% of EtOAc in hexanes to give 5.50 g (97%) of the title product as a white solid. LC-MS Retention Time: t2 (Method 2) = 3.761 min; m/z (M+H)+ 286.0. PLE 110
[0397] This example illustrates a synthesis of 2-Methoxy-N-(2-((3- ((trifiuoromethyl)thio)phenyl)carbamoyl)phenyl)benzamide (XJB09-058, NCGC00244475- 01, compound 158). The title compound was prepared according to general protocol A. LC- MS Retention Time: ti (Method 1) = 7.128 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.53 (s, 1 H), 10.79 (s, 1 H), 8.56 (dd, J=8.4, 1.2 Hz, 1 H), 8.22 - 8.39 (m, 1 H), 8.02 (dd, J=7.8,
1.8 Hz, 1 H), 7.91 (ddd, J=8.2, 2.2, 1.2 Hz, 1 H), 7.78 (dd, J=7.8, 1.6 Hz, 1 H), 7.50 - 7.64 (m, 3 H), 7.43 - 7.49 (m, 1 H), 7.26 (td, J=7.5, 1.2 Hz, 1 H), 7.20 (dd, J=8.5, 1.1 Hz, 1 H),
7.09 (ddd, J=7.9, 7.2, 1.2 Hz, 1 H), 3.97 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm - 41.91 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N203S, 447.0985; found
447.0984. PLE 111
[0399] This example illustrates a synthesis of 2-Methoxy-N-(2-((3- (methylthio)phenyl)carbamoyl)phenyl)benzamide (XJB09-059, NCGC00244476-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.575 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.55 (s, 1 H), 10.54 (s, 1 H), 8.56 (dd, J=8.4, 1.2 Hz, 1 H), 8.02 (dd, J=7.8, 1.8 Hz, 1 H), 7.67 - 7.86 (m, 2 H), 7.46 - 7.65 (m, 3 H), 7.30 (t, J=7.9 Hz, 1 H), 7.24 (td, J=7.6, 1.3 Hz, 1 H), 7.19 (dd, J=8.5, 1.1 Hz, 1 H), 7.05 - 7.12 (m, 1 H), 7.01 (ddd, J=7.8, 2.0, 1.0 Hz, 1 H), 3.98 (s, 3 H), 2.46 (s, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C22H2iN203S, 393.1267; found 393.1268. LE 112
[0401] This example illustrates a synthesis of 2-Methoxy-N-(2-((3-(piperidin-l- yl)phenyl)carbamoyl)phenyl)benzamide (XJB09-061, NCGC00244492-01). The title
compound was prepared according to general protocol A. LC-MS Retention Time: ti
(Method 1) = 4.511 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.56 (br. s., 1 H), 10.43 (br. s., 1 H), 8.56 (dd, J=8.4, 1.2 Hz, 1 H), 8.01 (dd, J=7.8, 1.8 Hz, 1 H), 7.62 - 7.80 (m, 1 H), 7.50 - 7.61 (m, 4 H), 7.15 - 7.31 (m, 4 H), 7.09 (ddd, J=7.9, 7.2, 1.2 Hz, 1 H), 3.98 (s, 3 H), 3.10 - 3.33 (m, 4 H), 1.60 - 1.78 (m, 4 H), 1.50 - 1.61 (m, 2 H); HRMS (ESI) m/z (M+H)+ calcd. for C26H28N3O3, 430.2125; found 430.2135. PLE 113
[0403] This example illustrates a synthesis of 2-(2-Methoxybenzamido)-N-methyl-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-062, NCGC00244493-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.442 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.65 (d, J=0.8 Hz, 1 H), 8.21 (dt, J=8.4, 0.6 Hz,
1 H), 8.03 (dd, J=7.8, 1.8 Hz, 1 H), 7.54 - 7.66 (m, 2 H), 7.37 - 7.54 (m, 3 H), 7.20 - 7.33 (m,
2 H), 7.13 (ddd, J=7.9, 7.2, 1.0 Hz, 1 H), 7.04 - 7.11 (m, 1 H), 6.86 - 6.96 (m, 1 H), 4.02 (s, 3 H), 3.44 (s, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C23H20F3N2O3, 429.1241; found 429.1418. MPLE 114
[0405] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)benzamide (XJB09-067, NCGC00244477-01). The title compound was prepared according to general protocol G. LC-MS Retention Time: ti
(Method 1) = 6.964 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.83 (s, 1 H), 10.16 (s, 1 H), 8.57 (t, J=1.6 Hz, 1 H), 8.26 (ddd, J=5.7, 3.7, 2.2 Hz, 1 H), 7.93 (dd, J=8.3, 1.3 Hz, 1 H), 7.76 - 7.86 (m, 2 H), 7.72 (dd, J=7.8, 1.6 Hz, 1 H), 7.52 (ddd, J=8.5, 7.2, 1.6 Hz, 1 H), 7.23 (td, J=7.6, 1.2 Hz, 1 H), 2.16 - 2.36 (m, 1 H), 1.73 - 1.87 (m, 2 H), 1.62 - 1.73 (m, 2 H), 1.50 - 1.62 (m, 1 H), 0.82 - 1.46 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -78.42 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H22F3N2O4S, 455.1247; found 455.1253. AMPLE 115
[0407] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(3- (methylsulfonyl)phenyl)benzamide (XJB09-068, NCGC00244478-01). The title compound was prepared according to general protocol G. LC-MS Retention Time: ti (Method 1) = 5.745 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.69 (s, 1 H), 10.34 (s, 1 H), 8.30 - 8.40 (m, 1 H), 8.11 (dd, J=8.3, 1.3 Hz, 1 H), 8.00 (dt, J=7.2, 2.1 Hz, 1 H), 7.76 (dd, J=7.8, 1.6 Hz, 1 H), 7.59 - 7.71 (m, 2 H), 7.52 (ddd, J=8.5, 7.1, 1.6 Hz, 1 H), 7.22 (td, J=7.6, 1.3 Hz, 1 H), 3.20 (s, 3 H), 2.20 - 2.37 (m, 1 H), 1.75 - 1.91 (m, 2 H), 1.65 - 1.75 (m, 2 H), 1.52 - 1.64 (m, 1 H), 0.95 - 1.45 (m, 5 H); HRMS (ESI) m/z (M+H)+ calcd. for C2iH25N204S, 401.1530; found 401.1524. E 116
[0409] This example illustrates a synthesis of 2-Methoxy-N-(2-((3- ((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-069,
NCGC00244479-01, compound 159). The title compound was prepared according to general protocol G. LC-MS Retention Time: ti (Method 1) = 6.810 min; 1H NMR (400 MHz, DMSO- d6) δ ppm 11.58 (s, 1 H), 1 1.09 (s, 1 H), 8.82 (t, J=2.1 Hz, 1 H), 8.58 (dd, J=8.5, 1.3 Hz, 1 H), 8.23 (dt, J=7.0, 2.2 Hz, 1 H), 8.02 (dd, J=7.7, 1.9 Hz, 1 H), 7.76 - 7.99 (m, 3 H), 7.51 - 7.63 (m, 2 H), 7.27 (td, J=7.5, 1.2 Hz, 1 H), 7.22 (dd, J=8.4, 1.2 Hz, 1 H), 7.09 (ddd, J=7.9, 7.2, 1.2 Hz, 1 H), 3.99 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -78.39 (s, 3 F);
HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N205S, 479.0883; found 479.0886. LE 117
[0411] This example illustrates a synthesis of 2-Methoxy-N-(2-((3- (methylsulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-070, NCGC00244501-01). The title compound was prepared according to general protocol G. LC-MS Retention Time: ti (Method 1) = 5.590 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 1 1.60 (s, 1 H), 10.90 (s, 1 H), 8.47 - 8.71 (m, 2 H), 7.93 - 8.16 (m, 2 H), 7.81 (dd, J=7.8, 1.6 Hz, 1 H), 7.62 - 7.72 (m, 2 H), 7.47 - 7.62 (m, 2 H), 7.26 (td, J=7.6, 1.3 Hz, 1 H), 7.21 (dd, J=8.5, 1.1 Hz, 1 H), 7.09 (ddd, J=7.9, 7.2, 1.0 Hz, 1 H), 4.00 (s, 3 H), 3.20 (s, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C22H2iN205S, 425.1166; found 425.1169.
EXAMPLE 118
[0413] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(4'- (trifiuoromethyl)-[l,r-biphenyl]-3-yl)benzamide (XJB09-073, NCGC00244494-01). The title compound was prepared according to general protocol E. LC-MS Retention Time: ti (Method 1) = 7.588 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.51 (d, J=0.4 Hz, 1 H), 10.48 (d, J=0.4 Hz, 1 H), 8.20 (dd, J=8.4, 1.2 Hz, 1 H), 7.99 - 8.09 (m, 1 H), 7.85 (s, 4 H), 7.75 - 7.82 (m, 2 H), 7.46 - 7.59 (m, 3 H), 7.22 (td, J=7.6, 1.3 Hz, 1 H), 2.18 - 2.35 (m, 1 H), 1.77 - 1.89 (m, 2 H), 1.64 - 1.75 (m, 2 H), 1.51 - 1.64 (m, 1 H), 1.08 - 1.45 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -60.89 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C27H26F3N2O2, 467.1941; found 467.1942.
EXAMPLE 119
[0415] This example illustrates a synthesis of Methyl 3-
(cyclohexanecarboxamido)benzoate (XJB09-080). A solution of methyl 3-aminobenzoate (0.903 mL, 6.62 mmol) in dichloromethane (10.0 mL) and triethylamine (2.77 mL, 19.9 mmol) was treated at 0 °C with cyclohexanecarbonyl chloride (0.970 g, 6.62 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0- 50% of EtOAc in hexanes to give 1.61 g (94%>) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.676 min; m/z (M+H)+ 276.1.
EXAMPLE 120
[0417] This example illustrates a synthesis of 3-(Cyclohexanecarboxamido)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB09-097, NCGC00244495-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.516 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.53 (s, 1 H), 10.00 (s, 1 H), 8.21 (t, J=2.1 Hz, 1 H), 8.14 (t, J=2.0 Hz, 1 H), 8.03 (ddd, J=8.2, 1.2, 1.0 Hz, 1 H), 7.81 (ddd, J=8.1 , 2.2, 1.1 Hz, 1 H), 7.55 - 7.64 (m, 2 H), 7.37 - 7.49 (m, 2 H), 2.24 - 2.41 (m, 1 H), 1.69 - 1.92 (m, 4 H), 1.57 - 1.69 (m, 1 H), 1.08 - 1.50 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.29 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H22F3N2O2, 391.1628; found 391.1637.
EXAMPLE 121
[0419] This example illustrates a synthesis of Ethyl 3-
(cyclohexanecarboxamido)benzoate (XJB09-079). A solution of ethyl 3-aminobenzoate (1.00 g, 6.05 mmol) in dichloromethane (10.0 mL) and triethylamine (2.53 mL, 18.2 mmol) was treated at 0 °C with 2-methoxybenzoyl chloride (0.814 mL, 6.05 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-50% of EtOAc
in hexanes to give 1.11 g (61%) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.664 min; m/z (M+H)+ 300.1.
EXAMPLE 122
[0421] 2-Methoxy-N-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB09-098, NCGC00244496-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.471 min; 1H NMR (400 MHz, DMSO- d6) δ ppm 10.58 (s, 1 H), 10.30 (s, 1 H), 8.27 - 8.35 (m, 1 H), 8.23 (t, J=2.1 Hz, 1 H), 8.04 (dt, J=8.2, 1.1 Hz, 1 H), 7.88 - 7.99 (m, 1 H), 7.67 (ddd, J=8.0, 1.4, 1.2 Hz, 1 H), 7.63 (dd, J=7.6, 1.8 Hz, 1 H), 7.56 - 7.62 (m, 1 H), 7.47 - 7.56 (m, 2 H), 7.41 - 7.47 (m, 1 H), 7.14 - 7.23 (m, 1 H), 7.06 (td, J=7.4, 1.0 Hz, 1 H), 3.90 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N203, 415.1264; found
415.1275.
EXAMPLE 123
[0423] This example illustrates a synthesis of Ethyl 4-(2-methoxybenzamido)benzoate (XJB09-077). A solution of ethyl 3-aminobenzoate (1.00 g, 6.05 mmol) in dichloromethane (10.0 mL) and triethylamine (2.53 mL, 18.2 mmol) was treated at 0 °C with 2- methoxybenzoyl chloride (0.814 mL, 6.05 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-50% of EtOAc in hexanes to give 1.77 g (98%>) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.683 min; m/z (M+H) 300.1.
EXAMPLE 124
[0425] This example illustrates a synthesis of 2-Methoxy-N-(4-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-001 , NCGC00244497-01 ). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.452 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.43 (s, 1 H), 10.39 (s, 1 H), 8.24 (t, J=2.2 Hz, 1 H), 8.02 - 8.10 (m, 1 H), 7.95 - 8.02 (m, 2 H), 7.80 - 7.94 (m, 2 H), 7.63 (dd, J=7.6, 1.8 Hz, 1 H), 7.55 - 7.62 (m, 1 H), 7.47 - 7.55 (m, 1 H), 7.43 (ddd, J=7.8, 1.9, 0.9 Hz, 1 H), 7.19 (dd, J=8.5, 1.1 Hz, 1 H), 7.07 (td, J=7.5, 1.1 Hz, 1 H), 3.90 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.27 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi8F3N203, 415.1264; found 415.1269.
EXAMPLE 125
[0427] This example illustrates a synthesis of Ethyl 4-
(cyclohexanecarboxamido)benzoate (XJB09-078). A solution of ethyl 4-aminobenzoate (1.00 g, 6.05 mmol) in dichloromethane (10.0 mL) and triethylamine (2.53 mL, 18.2 mmol) was treated at 0 °C with cyclohexanecarbonyl chloride (0.888 g, 6.05 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-50% of EtOAc in hexanes to give 1.58 g (95%>) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.687 min; m/z (M+H)+ 276.1.
EXAMPLE 126
[0429] This example illustrates a synthesis of 4-(Cyclohexanecarboxamido)-N-(3-
(trifiuoromethyl)phenyl)benzamide (XJB10-015, NCGC00244480-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.473 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.37 (s, 1 H), 10.09 (s, 1 H), 8.23 (t, J=2.1 Hz,
1 H), 8.03 (dd, J=8.4, 1.0 Hz, 1 H), 7.85 - 7.97 (m, 2 H), 7.68 - 7.79 (m, 2 H), 7.52 - 7.64 (m,
1 H), 7.36 - 7.47 (m, 1 H), 2.27 - 2.43 (m, 1 H), 1.69 - 1.94 (m, 4 H), 1.58 - 1.69 (m, 1 H),
1.10 - 1.51 (m, 5 H); 19F NMR (376 MHz, DMSO- 6) δ ppm -61.28 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C21H22F3N2O2, 391.1628; found 391.1631. MPLE 127
[0431] This example illustrates a synthesis of 2-(2-(Dimethylamino)ethoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJBlO-024, NCGC00244498-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.204 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.49 (s, 1 H), 8.11 - 8.39 (m, 1 H), 7.76 - 7.99 (m, 1 H), 7.48 - 7.68 (m, 3 H), 7.39 - 7.47 (m, 1 H), 7.23 (dd, J=8.4, 0.8 Hz, 1 H), 7.13 (td, J=7.5, 1.0 Hz, 1 H), 4.41 (dd, J=5.5, 4.5 Hz, 2 H), 3.41 - 3.57 (m, 2 H), 2.80 (s, 6 H); HRMS (ESI) m/z (M+H)+ calcd. for C18H20F3N2O2, 353.1471; found 353.1474.
EXAMPLE 128
[0433] This example illustrates a synthesis of Methyl 2-(2-methoxy-N- methylbenzamido)benzoate (XJB 10-022). A solution of methyl 2-(2- methoxybenzamido)benzoate (1.16 g, 4.07 mmol) in DMF (10.0 mL) and was treated at 0 °C with NaH (0.813 g, 60%, 20.3 mmol). The reaction mixture was warmed to room temperature and stirred at room temperature for 1 h. Then a solution of Mel (1.27 mL, 20.3 mmol) in DMF (4.00 mL) was added drop wise. The reaction mixture was stirred at room temperature for 1.5 h. The mixture was carefully quenched with water and extracted with EtOAc. The organic layer was separated, dried, concentrated to give the final product which was used
directly in the next reaction. LC-MS Retention Time: t2 (Method 2) = 3.293 min; m/z (M+H) 300.1. PLE 129
[0435] This example illustrates a synthesis of 2-Methoxy-N-methyl-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-025 , NCGC00244499-01 ). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.046 min; HRMS (ESI) m/z (M+H)+ calcd. for C23H20F3N2O3, 429.1421;
found 429.1438. PLE 130
[0437] This example illustrates a synthesis of 2-Methoxy-N-methyl-N-(2-(methyl(3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-026, NCGC00244500-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 5.994 min; HRMS (ESI) m/z (M+H)+ calcd. for C24H22F3N2O3, 443.1577;
found 443.1579.
AMPLE 131
[0439] This example illustrates a synthesis of 2-Iodo-N-(2-((3-
(trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-027, NCGC00244482-01 ). The title compound was prepared according to general protocol C. LC-MS Retention Time: ti (Method 1) = 6.879 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi5F3IN202, 511.0125; found 511.0122. 132
[0441] This example illustrates a synthesis of 2-(2-(Dimethylamino)ethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-028, NCGC00244483-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.705 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.1 1 (s, 1 H), 10.84 (s, 1 H), 8.41 (dd, J=8.5, 1.3 Hz, 1 H), 8.07 - 8.20 (m, 1 H), 7.96 (dd, J=8.0, 1.2 Hz, 1 H), 7.87 (dd, J=7.7, 1.9 Hz, 1 H), 7.84 (dd, J=7.8, 1.8 Hz, 1 H), 7.57 - 7.65 (m, 2 H), 7.52 - 7.57 (m, 1 H), 7.45 - 7.52 (m, 1 H), 7.24 - 7.33 (m, 2 H), 7.13 (td, J=7.5, 1.0 Hz, 1 H), 4.55 (t, J=5.1 Hz, 2 H), 3.49 - 3.74 (m, 2 H), 2.78 (s, 6 H); HRMS (ESI) m/z (M+H)+ calcd. for C25H25F3N303, 472.1843; found 472.1851.
133
[0443] This example illustrates a synthesis of 2-(2-Methoxyethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-029, NCGC00244484-01 ). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 6.625 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1H NMR (400 MHz, DMSO-de) δ ppm 11.22 (s, 1 H), 10.80 (s, 1 H), 8.44 (dd, J=8.3, 1.3 Hz, 1 H), 8.21 (t, J=2.2 Hz, 1 H), 7.93 - 7.99 (m, 1 H), 7.91 (dd, J=7.8, 1.8 Hz, 1 H), 7.80 (dd, J=7.7, 1.7 Hz, 1 H), 7.55 - 7.64 (m, 2 H), 7.48 - 7.55 (m, 1 H), 7.42 - 7.48 (m, 1 H), 7.27 (td, J=7.6, 1.3 Hz, 1 H), 7.23 (dd, J=8.5, 1.1 Hz, 1 H), 7.03 - 7.13 (m, 1 H), 4.26 - 4.37 (m, 2 H), 3.61 - 3.72 (m, 2 H), 3.11 (s, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.36 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C24H22F3N2O4, 459.1526; found 459.1527. MPLE 134
[0445] This example illustrates a synthesis of 2-(2-Methoxyethoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB10-030, NCGC00244485-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 6.644 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.45 (s, 1 H), 8.08 - 8.29 (m, 1 H), 7.93 (d, J=8.2 Hz, 1 H), 7.83 (dt, J=7.7, 1.8 Hz, 1 H), 7.57 - 7.66 (m, 1 H), 7.49 - 7.57 (m, 1 H), 7.40 - 7.49 (m, 1 H), 7.20 - 7.28 (m, 1 H), 7.05 - 7.18 (m, 1 H), 4.31 (td, J=4.5, 1.9 Hz, 2 H), 3.70
- 3.83 (m, 2 H), 3.29 (s, 3 H); 19F NMR (376 MHz, DMSO- 6) δ ppm -61.26 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C17H17F3NO3, 340.1155; found 340.1162. 135
[0447] This example illustrates a synthesis of tert-Butyl 4-(2-(2-((3- (trifluoromethyl)phenyl)carbamoyl)phenoxy)ethyl)piperazine- 1 -carboxylate (XJB 10-031 , NCGC00244486-01). The title compound was prepared according to general protocol H. LC- MS Retention Time: ti (Method 1) = 4.945 min; HRMS (ESI) m/z (M+H)+ calcd. for
C25H31F3N3O4, 494.2261; found 494.2270. PLE 136
[0449] This example illustrates a synthesis of 2-Isopropoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB10-036, NCGC00244516-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 7.126 min; HRMS (ESI) m/z (M+H)+ calcd. For C24H22F3N2O3, 443.1577; found 443.1599.
E 137
[0451] This example illustrates a synthesis of 2-Phenoxy-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB10-037, NCGC00244517-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 7.314 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.45 (s, 1 H), 10.73 (s, 1 H), 8.41 - 8.58 (m, 1 H), 8.11 (t, J=2.1 Hz, 1 H), 7.97 (dd, J=7.8, 2.0 Hz, 1 H), 7.85 (ddd, J=8.3, 2.2, 1.3 Hz, 1 H), 7.80 (dd, J=7.8, 1.6 Hz, 1 H), 7.42 - 7.65 (m, 4 H), 7.21 - 7.37 (m, 4 H), 7.15 (tt, J=7.4, 1.2 Hz, 1 H), 7.01 - 7.12 (m, 2 H), 6.84 (dd, J=8.2, 1.2 Hz, 1 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -61.27 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for
C27H20F3N2O3, 477.1421; found 477.1425. 8
[0453] This example illustrates a synthesis of 2-(2-(Piperidin-l-yl)ethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-038, NCGC00244518-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.945 min; HRMS (ESI) m/z (M+H)+ calcd. for C28H29F3N3O3, 512.2156;
[0455] This example illustrates a synthesis of 2-(2-Morpholinoethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB10-039, NCGC00244519-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.752 min; HRMS (ESI) m/z (M+H)+ calcd. for C27H27F3N3O4, 514.1948;
found 514.1972. PLE 140
[0457] This example illustrates a synthesis of 2-(2-(Piperidin-l-yl)ethoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJB 10-040, NCGC00244519-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.527 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.57 (s, 1 H), 8.23 (br. s., 1 H), 7.89 (d, J=8.8 Hz, 1 H), 7.49 - 7.66 (m, 3 H), 7.45 (d, J=8.0 Hz, 1 H), 7.23 (d, J=8.4 Hz, 1 H), 7.13 (t, J=7.4 Hz, 1 H), 4.24 - 4.54 (m, 2 H), 3.40 - 3.61 (m, 4 H), 2.84 - 3.05 (m, 2 H), 1.44 - 1.80 (m, 5 H), 1.21 - 1.35 (m, 1 H); HRMS (ESI) m/z (M+H)+ calcd. for C27H27F3N3O4, 514.1948; found 514.1972.
LE 141
[0459] This example illustrates a synthesis of 2-(2-Morpholinoethoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJBlO-041, NCGC00244502-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.280 min; HRMS (ESI) m/z (M+H)+ calcd. for C20H22F3N2O3, 395.1577; found 395.1585. AMPLE 142
[0461] This example illustrates a synthesis of 2-(Cyclohexanecarboxamido)-N-(2'- (trifiuoromethyl)-[l,r-biphenyl]-3-yl)benzamide (XJB10-042, NCGC00244503-01). The title compound was prepared according to general protocol E. LC-MS Retention Time: ti (Method 1) = 7.417 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.46 (s, 1 H), 10.40 (s, 1 H), 8.15 (dd, J=8.3, 1.3 Hz, 1 H), 7.83 (dt, J=7.7, 0.8 Hz, 1 H), 7.66 - 7.79 (m, 4 H), 7.57 - 7.65 (m, 1 H), 7.45 - 7.57 (m, 1 H), 7.33 - 7.45 (m, 2 H), 7.20 (td, J=7.6, 1.3 Hz, 1 H), 7.05 (dd, J=7.6, 1.0 Hz, 1 H), 2.18 - 2.36 (m, 1 H), 1.73 - 1.88 (m, 2 H), 1.63 - 1.74 (m, 2 H), 1.50 - 1.63 (m, 1 H), 0.99 - 1.42 (m, 5 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -55.34 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C27H26F3N2O2, 467.1941; found 467.1931.
EXAMPLE 143
[0463] This example illustrates a synthesis of 2-(2-(Piperazin-l-yl)ethoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJBlO-043, NCGC00244504-01). A solution of tert- butyl 4-(2-(2-(3-(trifluoromethyl)phenylcarbamoyl)phenoxy)ethyl)piperazine-l-carboxylate (0.099 g, 0.200 mmol) in dichloromethane (2.00 mL) was treated at 0 °C with TFA (1.00 mL). The reaction mixture was stirred at 0 °C for 1 h. The mixture was concentrated, re- dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 3.872 min; HRMS (ESI) m/z (M+H)+ calcd. for C20H23F3N3O2, 394.1737; found 394.1745.
EXAMPLE 144
[0465] This example illustrates a synthesis of 2-Methoxy-N-(2-((3-(thiophen-2- yl)phenyl)carbamoyl)phenyl)benzamide (XJB10-044, NCGC00244505-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.455 min; HRMS (ESI) m/z (M+H)+ calcd. for C25H21N2O3S, 429.1267; found 429.1285.
EXAMPLE 145
[0467] This example illustrates a synthesis of 2-(3-(Dimethylamino)propoxy)-N-(3- (trifiuoromethyl)phenyl)benzamide (XJBlO-045, NCGC00244506-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.371 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.27 - 10.74 (m, 1 H), 8.25 (s, 1 H), 7.92 (d, J=7.4 Hz, 1 H), 7.55 - 7.65 (m, 2 H), 7.48 - 7.54 (m, 1 H), 7.44 (d, J=7.8 Hz, 1 H), 7.17 (d, J=8.4 Hz, 1 H), 7.09 (t, J=7.5 Hz, 1 H), 4.16 (t, J=5.5 Hz, 2 H), 3.04 - 3.21 (m, 2 H), 2.68 (s, 6 H), 1.97 - 2.18 (m, 2 H); HRMS (ESI) m/z (M+H)+ calcd. for C19H22F3N2O2, 367.1628; found 367.1628. 6
[0469] This example illustrates a synthesis of 2-(3-(Dimethylamino)propoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB 10-046, NCGC00244507-01 ). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.868 min; HRMS (ESI) m/z (M+H)+ calcd. for C26H27F3N3O3, 486.1999;
[0471] This example illustrates a synthesis of tert-Butyl 4-(2-(2-((2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)carbamoyl)phenoxy)ethyl)piperazine-l- carboxylate (XJB 10-047, NCGC00244481-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 5.211 min; HRMS (ESI) m/z (M+H)+ calcd. for C32H36F3N405, 613.2632; found 613.2642. MPLE 148
[0473] This example illustrates a synthesis of N-(2-((3-
(Trifluoromethyl)phenyl)carbamoyl)phenyl)- 1 H-benzo [d] imidazo le-7-carboxamide (XJB 10- 049, NCGC00244508-01). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 4.777 min; HRMS (ESI) m/z (M+H)+ calcd. for C22Hi6F3N402, 425.1220; found 425.1227.
[0475] This example illustrates a synthesis of 2-(2-(Piperazin-l-yl)ethoxy)-N-(2-((3- (trifiuoromethyl)phenyl)carbamoyl)phenyl)benzamide (XJB10-050, NCGC00244509-01). A solution of tert-butyl 4-(2-(2-(2-(3-
(trifluoromethyl)phenylcarbamoyl)phenylcarbamoyl)phenoxy)ethyl)piperazine-l-carboxylate (50.0 mg, 0.082 mmol) in dichloromethane (2.00 mL) was treated at 0 °C with TFA (1.00 mL). The reaction mixture was stirred at 0 °C for 1 h. The mixture was concentrated, re- dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 4.303 min; HRMS (ESI) m/z (M+H)+ calcd. for C27H28F3N4O3, 513.2108; found 513.2128.
EXAMPLE 150
[0477] This example illustrates a synthesis of Methyl 2-(2-ethoxybenzamido)benzoate (XJB11-036). A solution of ethyl methyl 2-aminobenzoate (1.29 mL, 9.92 mmol) in dichloromethane (25.0 mL) and triethylamine (4.15 mL, 29.8 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (1.83 g, 9.92 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-50% of EtOAc in hexanes to give 2.70 g (9 /o) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.908 min; m/z (M+H)+ 300.1.
EXAMPLE 151
[0479] This example illustrates a synthesis of 2-Ethoxy-N-(2-(pyridin-2- ylcarbamoyl)phenyl)benzamide (XJBl 1-037, NCGC00250128-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 5.072 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.30 (s, 1 H), 11.01 (s, 1 H), 8.46 (d, J=8.2 Hz, 1 H), 8.37 (dd, J=5.1, 2.3 Hz, 1 H), 8.13 (d, J=8.2 Hz, 1 H), 7.92 (dd, J=7.6, 2.2 Hz, 1 H), 7.82 - 7.89 (m, 1 H), 7.79 (dd, J=7.8, 2.0 Hz, 1 H), 7.44 - 7.61 (m, 2 H), 7.13 - 7.25 (m, 3 H), 7.02 - 7.10 (m, 1 H), 4.28 (q, J=6.9 Hz, 2 H), 1.29 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C21H20N3O3, 362.1499; found 362.1505.
EXAMPLE 152
[0481] This example illustrates a synthesis of 2-Ethoxy-N-(2-(pyridin-4- ylcarbamoyl)phenyl)benzamide (XJBl 1-039, NCGC00250119-02). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 4.341 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.01 (s, 1 H), 10.65 (s, 1 H), 8.17 - 8.36 (m, 3 H), 7.72 (dd, J=7.8, 2.0 Hz, 1 H), 7.57 (dd, J=7.6, 1.8 Hz, 1 H), 7.51 (dd, J=4.9, 1.8 Hz, 2 H), 7.38 (td, J=7.9, 1.8 Hz, 1 H), 7.31 (ddd, J=8.5, 7.1, 2.0 Hz, 1 H), 7.03 - 7.10 (m, 1 H), 6.99 (d, J=8.6 Hz, 1 H), 6.68 - 6.91 (m, 1 H), 4.09 (q, J=6.8 Hz, 2 H), 1.1 1 (t, J=6.8 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C21H20N3O3, 362.1499; found 362.1499.
MPLE 153
[0483] This example illustrates a synthesis of N-(3-(fert-Butyl)phenyl)-2-(2- ethoxybenzamido)benzamide (XJBl 1-040, NCGC00250129-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.379 min; HRMS (ESI) m/z (M+H)+ calcd. for C26H29N2O3, 417.2173; found 417.2175. PLE 154
[0485] This example illustrates a synthesis of 2-Ethoxy-N-(2-(pyridin-4- ylcarbamoyl)phenyl)benzamide (XJBl 1-041, NCGC00250107-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.305 min; HRMS (ESI) m/z (M+H)+ calcd. for C23H20F3N2O3S, 461.1141; found 461.1146. LE 155
[0487] This example illustrates a synthesis of 2-Ethoxy-N-(2-((3- ((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJB 11 -043 ,
NCGC00250130-01, compound 174). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.963 min; HRMS (ESI) m/z (M+H)+ calcd. for
493.1040; found 493.1044.
EXAMPLE 156
[0489] This example illustrates a synthesis of 2-Ethoxy-N-(2-(pyridin-3- ylcarbamoyl)phenyl)benzamide (XJBl 1-047, NCGC00250104-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 4.330 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.32 (s, 1 H), 10.71 (s, 1 H), 8.89 (d, J=2.3 Hz, 1 H), 8.51 (d, J=8.2 Hz, 1 H), 8.31 (dd, J=4.7, 1.6 Hz, 1 H), 8.13 (ddd, J=8.7, 2.4, 1.4 Hz, 1 H), 7.92 (dd, J=7.8, 2.0 Hz, 1 H), 7.80 (dd, J=7.8, 2.0 Hz, 1 H), 7.54 - 7.63 (m, 1 H), 7.51 (td, J=7.8, 2.0 Hz, 1 H), 7.39 (dd, J=8.2, 4.7 Hz, 1 H), 7.22 - 7.32 (m, 1 H), 7.18 (d, J=8.2 Hz, 1 H), 7.06 (t, J=7.4 Hz, 1 H), 4.27 (q, J=7.0 Hz, 2 H), 1.29 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C21H20N3O3, 362.1499; found 362.1507. XAMPLE 157
[0491] This example illustrates a synthesis of 2-Ethoxy-N-(2-((5-iodopyridin-3- yl)carbamoyl)phenyl)benzamide (XJBl 1-048, NCGC00250103-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.305 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.31 (s, 1 H), 10.78 (s, 1 H), 8.85 (d, J=2.3 Hz, 1 H), 8.63 (t, J=2.3 Hz, 1 H), 8.54 (d, J=2.3 Hz, 1 H), 8.49 (d, J=8.2 Hz, 1 H), 7.93 (dd, J=7.8, 2.0 Hz, 1 H), 7.80 (dd, J=7.8, 2.0 Hz, 1 H), 7.59 (td, J=7.9, 1.8 Hz, 1 H), 7.52 (ddd, J=8.6, 7.0, 2.0 Hz, 1 H), 7.23 - 7.31 (m, 1 H), 7.20 (d, J=8.2 Hz, 1 H), 7.07 (t, J=7.4 Hz, 1 H), 4.31 (q, J=6.8 Hz, 2 H), 1.33 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C21H19IN3O3, 488.0466; found 488.0475.
EXAMPLE 158
[0493] This example illustrates a synthesis of Methyl 4-(2-ethoxybenzamido)nicotinate (XJBl 1-044). A solution of 4-aminonicotinate (500 mg, 3.29 mmol) in dichloromethane (25.0 mL) and triethylamine (1.37 mL, 9.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (607 mg, 3.29 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of EtOAc in hexanes to give 924 mg (94%) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.045 min; m/z (M+H)+ 301.1.
EXAMPLE 159
[0495] This example illustrates a synthesis of 4-(2-Ethoxybenzamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)nicotinamide (XJB11-049, NCGC00250117-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 5.507 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.71 (s, 1 H), 1 1.25 (s, 1 H), 9.00 (s, 1 H), 8.77 (t, J=2.2 Hz, 1 H), 8.65 - 8.71 (m, 1 H), 8.54 - 8.64 (m, 1 H), 8.15 - 8.26 (m, 1 H), 7.96 (dd, J=7.8, 2.3 Hz, 1 H), 7.78 - 7.93 (m, 2 H), 7.56 (ddd, J=8.6, 7.0, 2.0 Hz, 1 H), 7.24 (d, J=8.6 Hz, 1 H), 7.09 (t, J=7.4 Hz, 1 H), 4.35 (q, J=6.9 Hz, 2 H), 1.29 (t, J=6.8 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -78.37 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi9F3N305S, 494.0992; found 494.1004.
EXAMPLE 160
[0497] This example illustrates a synthesis of Methyl 2-(2-ethoxybenzamido)nicotinate (XJB11-045). A solution of 4-aminonicotinate (500 mg, 3.29 mmol) in dichloromethane (25.0 mL) and triethylamine (1.37 mL, 9.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (607 mg, 3.29 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of EtO Ac in hexanes to give 840 mg (85%) of
the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 2.975 min; m/z (M+H)+ 301.1. LE 161
[0499] This example illustrates a synthesis of 2-(2-Ethoxybenzamido)-N-(3- ((trifluoromethyl)sulfonyl)phenyl)nicotinamide (XJB11-050, NCGC00250118-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti
(Method 1) = 5.472 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.98 (s, 1 H), 10.81 (s, 1 H), 8.47 - 8.66 (m, 2 H), 8.05 - 8.24 (m, 2 H), 7.75 - 7.87 (m, 2 H), 7.72 (dd, J=7.8, 2.0 Hz, 1 H), 7.51 (ddd, J=8.5, 7.1, 2.0 Hz, 1 H), 7.39 (dd, J=7.6, 4.9 Hz, 1 H), 7.20 (d, J=8.2 Hz, 1 H), 7.00 (t, J=7.4 Hz, 1 H), 4.27 (q, J=7.0 Hz, 2 H), 1.42 (t, J=7.0 Hz, 3 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -78.44 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C22Hi9F3N305S, 494.0992; found 494.1004. XAMPLE 162
[0501] This example illustrates a synthesis of 2-Ethoxy-N-(2-((3- iodophenyl)carbamoyl)phenyl)benzamide (XJB11-053, NCGC00250105-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti
(Method 1) = 7.114 min; 1H NMR (400 MHz, DMSC /6) δ ppm 1 1.31 (s, 1 H), 10.59 (s, 1
H), 8.50 (d, J=8.2 Hz, 1 H), 8.27 (t, J=2.0 Hz, 1 H), 7.94 (dd, J=7.8, 2.0 Hz, 1 H), 7.75 (dd,
J=7.6, 1.8 Hz, 1 H), 7.69 (dd, J=8.2, 2.3 Hz, 1 H), 7.41 - 7.60 (m, 3 H), 7.10 - 7.29 (m, 3 H),
7.00 - 7.11 (m, 1 H), 4.31 (q, J=7.0 Hz, 2 H), 1.33 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C22H20IN2O3, 487.0513; found 487.0514.
EXAMPLE 163
[0503] This example illustrates a synthesis of Methyl 2-(2-iodobenzamido)benzoate (XJB11-035). A solution of methyl 2-aminobenzoate (1.29 mL, 9.92 mmol) in
dichloromethane (25.0 mL) and triethylamine (4.15 mL, 29.8 mmol) was treated at 0 °C with 2-iodobenzoyl chloride (2.64 g, 9.92 mmol).22 The reaction mixture was stirred at 0 °C for 2 hours and at room temperature for another 2 hours. The reaction mixture was concentrated in vacuo and the crude residue was purified via silica gel chromatography using a gradient of 0- 50% of EtOAc in hexanes to give 3.40 g (90%>) of the title compound as a white solid. LC- MS Retention Time: ti (Method 1) = 6.308 min; t2 (Method 2) = 3.744 min; 1H NMR (400
MHz, DMSO-dg) δ ppm 10.97 (s, 1 H), 8.33 (d, J=8.2 Hz, 1 H), 7.87 - 8.01 (m, 2 H), 7.63 - 7.73 (m, 1 H), 7.46 - 7.62 (m, 2 H), 7.13 - 7.33 (m, 2 H), 3.82 (s, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for Ci5Hi3IN03, 381.9935; found 381.9943. PLE 164
[0505] This example illustrates a synthesis of 2-Iodo-N-(2-(3-
(trifiuoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (XJB11-054, NCGC00250120- 01). A solution of methyl 2-(2-iodobenzamido)benzoate (500 mg, 1.31 mmol) in toluene
(15.0 mL) was treated at room temperature with 3-(trifluoromethylsulfonyl)aniline (443 mg, 1.97 mmol) followed by trimethylaluminum (1.31 mL, 2.0 M in toluene, 2.62 mmol). The reaction mixture was stirred at 100 °C overnight. After cooling, the reaction mixture was concentrated in vacuo; and the crude residue was purified via silica gel chromatography using a gradient of 0-50% of EtOAc in hexanes to give 677 mg (90%) of the title compound as a white solid. LC-MS Retention Time: ti (Method 1) = 6.816 min; t2 (Method 2) = 3.857 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.96 (s, 1 H), 10.69 (s, 1 H), 8.57 (s, 1 H), 8.17 - 8.36 (m, 1 H), 8.02 (d, J=7.8 Hz, 1 H), 7.91 (d, J=7.8 Hz, 1 H), 7.70 - 7.86 (m, 3 H), 7.61 (t, J=7.4 Hz, 1 H), 7.41 - 7.56 (m, 2 H), 7.34 (t, J=7.6 Hz, 1 H), 7.11 - 7.27 (m, 1 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -78.38 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for
C2iHi5F3lN204S, 574.9744; found 574.9752.
EXAMPLE 165
[0507] This example illustrates a synthesis of Methyl 3-(2- ethoxybenzamido)isonicotinate (XJB11-046). A solution of methyl 3-aminoisonicotinate (200 mg, 1.31 mmol) in dichloromethane (25.0 mL) and triethylamine (0.550 mL, 3.94 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (243 mg, 1.31 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of EtOAc in hexanes to give 45 mg (11%>) of the title product as a white solid which was used directly in the next reaction without further purification.
LE 166
[0509] This example illustrates a synthesis of 3-(2-Ethoxybenzamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)isonicotinamide (XJB11-055, NCGC00250121-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 5.766 min; HRMS (ESI) m/z (M+H)+ calcd. for C22Hi9F3N305S, 494.0992; found 494.1000.
EXAMPLE 167
[0511] This example illustrates a synthesis of Methyl 3-(2-ethoxybenzamido)picolinate (XJB11-056). A solution of methyl 3-aminopicolinate (500 mg, 3.29 mmol) in
dichloro methane (25.0 mL) and triethylamine (1.37 mL, 9.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (607 mg, 3.29 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of EtO Ac in hexanes to give 741 mg (75%>) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.519 min; m/z (M+H)
LE 168
[0513] This example illustrates a synthesis of 2-(2-Ethoxybenzamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)nicotinamide (XJB11-058, NCGC00250122-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.402 min; HRMS (ESI) m/z (M+Na)+ calcd. for C22Hi8F3N3Na05S, 516.0811; found 516.0837.
EXAMPLE 169
[0515] This example illustrates a synthesis of Methyl 2-(2-ethoxybenzamido)thiophene- 3-carboxylate (XJB 11-057). A solution of 2-aminothiophene-3-carboxylate (500 mg, 3.18 mmol) in dichloromethane (25.0 mL) and triethylamine (1.33 mL, 9.54 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (587 mg, 3.18 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of EtOAc in hexanes to give 798 mg (82%) of the title product as a white solid which was used directly in the next reaction without further purification.
LE 170
[0517] This example illustrates a synthesis of 2-(2-Ethoxybenzamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)thiophene-3-carboxamide (XJBl 1-059, NCGC00250123- 01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 7.341 min; HRMS (ESI) m/z (M+H)+ calcd. for C2iHi8F3N205S2, 499.0604; found 499.0608.
EXAMPLE 171
[0519] This example illustrates a synthesis of Methyl 2-(2- ethoxyphenylsulfonamido)benzoate (XJBl 1-060). A solution of methyl 2-aminobenzoate (206 mg, 1.359 mmol) in dichloromethane (5.00 mL) and triethylamine (0.568 mL, 4.08 mmol) was treated at 0 °C with 2-ethoxybenzene-l-sulfonyl chloride (300 mg, 1.359 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0- 100% of EtOAc in hexanes to give 274 mg (60%) of the title product as a white solid which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.698 min; m/z (M+H)+ 336.1.
LE 172
[0521] This example illustrates a synthesis of 2-(2-Ethoxyphenylsulfonamido)-N-(3- ((trifiuoromethyl)sulfonyl)phenyl)benzamide (XJB11-062, NCGC00250124-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.631 min; HRMS (ESI) m/z (M+H)+ calcd. for C22H20F3N2O6S2, 529.0709; found 529.0716. MPLE 173
[0523] This example illustrates a synthesis of N-(2-amino-5-(trifluoromethyl)phenyl)-2- (2-ethoxybenzamido)benzamide (XJB11-063, NCGC00250125-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.408 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.43 (s, 1 H), 9.89 (s, 1 H), 8.48 (d, J=7.8 Hz, 1 H), 7.88 (dd, J=7.8, 2.0 Hz, 2 H), 7.53 - 7.61 (m, 1 H), 7.49 (td, J=7.8, 2.0 Hz, 1 H), 7.42 (d, J=7.8 Hz, 1 H), 7.24 (t, J=7.6 Hz, 1 H), 7.14 (d, J=8.2 Hz, 1 H), 6.98 - 7.08 (m, 2 H), 6.85 (dd, J=8.6, 2.3 Hz, 1 H), 5.46 (s, 2 H), 4.20 (q, J=6.9 Hz, 2 H), 1.26 (t, J=6.8 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -60.99 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C23H21F3N3O3, 444.1530; found 444.1536.
EXAMPLE 174
[0525] This example illustrates a synthesis of Ethyl 3-(2-ethoxybenzamido)propanoate (XJB11-061). A solution of ethyl 3-aminopropanoate, HC1 salt (300 mg, 1.95 mmol) in dichloromethane (25.0 mL) and triethylamine (0.817 mL, 5.86 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (361 mg, 1.95 mmol). The reaction mixture was stirred at 0 °C for 2 h and at room temperature for 2 h. The reaction mixture was concentrated and purified via silica gel chromatography using a gradient of 0-100% of EtO Ac in hexanes to give 478 mg (92%) of the title product as a colorless oil which was used directly in the next reaction without further purification. LC-MS Retention Time: t2 (Method 2) = 3.346 min; m/z (M+H)+ 266.1.
EXAMPLE 175
[0527] This example illustrates a synthesis of 2-Ethoxy-N-(3-oxo-3-((3- ((trifiuoromethyl)sulfonyl)phenyl)amino)propyl)benzamide (XJB11-064, NCGC00250126- 01, CID-56593338). The title compound was prepared according to general protocol A. LC- MS Retention Time: ti (Method 1) = 5.985 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.62 (s, 1 H), 8.62 (s, 1 H), 8.39 (t, J=5.9 Hz, 1 H), 7.93 - 8.07 (m, 1 H), 7.82 (dd, J=7.8, 2.0 Hz, 1 H), 7.78 (d, J=5.5 Hz, 2 H), 7.38 - 7.48 (m, 1 H), 7.08 (d, J=8.6 Hz, 1 H), 6.96 - 7.04 (m, 1 H), 4.09 (q, J=6.8 Hz, 2 H), 3.61 (q, J=6.0 Hz, 2 H), 2.68 (t, J=6.3 Hz, 2 H), 1.29 (t, J=7.0
Hz, 3 H); iyF NMR (376 MHz, DMSO- 6) δ ppm -78.46 (s, 3 F); HRMS (ESI) m/z (M+H) calcd. for C19H20F3N2O5S, 445.1040; found 445.1042.
[0529] This example illustrates a synthesis of Mixture of 6-(2-ethoxyphenyl)-10- (trifluoromethyl)benzo[4,5]imidazo[ 1 ,2-c]quinazoline and 6-(2-ethoxyphenyl)-9- (trifiuoromethyl)benzo[4,5]imidazo[l,2-c]quinazoline (XJBl 1-067-2, NCGC00250127-01). A solution of N-(2-amino-5-(trifluoromethyl)phenyl)-2-(2-ethoxybenzamido)benzamide (30.0 mg, 0.068 mmol) in glacial acetic acid (1.00 mL) was heated at 70 °C for 16 h. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final products as a mixture. 77
[0531] This example illustrates a synthesis of 2-Propoxy-N-(2-((3- ((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJBl 1-068,
NCGC00250109-01, compound 179). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 7.147 min; HRMS (ESI) m/z (M+H)+ calcd. for C24H22F3N205S, 507.1196; found 507.1219.
MPLE 178
[0533] This example illustrates a synthesis of 2-Ethoxy-N-(2-(6-(trifluoromethyl)-lH- benzo[d]imidazol-2-yl)phenyl)benzamide (XJB11-069, NCGC00250108-01). A solution of N-(2-amino-5-(trifluoromethyl)phenyl)-2-(2-ethoxybenzamido)benzamide (30.0 mg, 0.068 mmol) in glacial acetic acid (1.00 mL) was stirred at room temperature for 24 h. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final products. LC-MS Retention Time: ti (Method 1) = 6.588 min; HRMS (ESI) m/z (M+H)+ calcd. for C23H19F3N3O2, 426.1424; found 426.1437.
[0535] This example illustrates a synthesis of 2-Butoxy-N-(2-((3- ((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJB 11 -070,
NCGC00250110-01, compound 180). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 7.325 min; t2 (Method 2) = 3.971 min; 1H NMR (400 MHz, DMSO- d6) δ ppm 11.25 (s, 1 H), 11.09 (s, 1 H), 8.69 (s, 1 H), 8.53 (d, J=8.6 Hz, 1 H), 8.24 (ddd, J=7.2, 2.2, 2.0 Hz, 1 H), 7.91 (dd, J=7.8, 2.0 Hz, 1 H), 7.77 - 7.89 (m, 3 H), 7.60 (td, J=7.8, 1.6 Hz, 1 H), 7.43 - 7.56 (m, 1 H), 7.28 (td, J=7.5, 1.0 Hz, 1 H),
7.20 (d, J=8.6 Hz, 1 H), 7.00 - 7.11 (m, 1 H), 4.18 (t, J=6.8 Hz, 2 H), 1.54 - 1.75 (m, 2 H),
1.21 (sxt, J=7.4 Hz, 2 H), 0.69 (t, J=7.4 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -
78.42 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C25H24F3N205S, 521.1353; found
521.1359. 80
[0537] This example illustrates a synthesis of 2-(2,2,2-Trifluoroethoxy)-N-(2-((3- ((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJB 11-071,
NCGC00250111-01, compound 177). The title compound was prepared according to general protocol H. LC-MS Retention Time: ti (Method 1) = 6.804 min; 1H NMR (400 MHz, DMSO- d6) δ ppm 11.07 (s, 1 H), 1 1.03 (s, 1 H), 8.61 (t, J=2.2 Hz, 1 H), 8.41 (d, J=8.2 Hz, 1 H), 8.19 - 8.33 (m, 1 H), 7.70 - 7.94 (m, 4 H), 7.58 - 7.67 (m, 1 H), 7.47 - 7.58 (m, 1 H), 7.35 (d, J=8.6 Hz, 1 H), 7.26 - 7.33 (m, 1 H), 7.17 (t, J=7.4 Hz, 1 H), 4.92 (q, J=9.0 Hz, 2 H); 19F NMR (376 MHz, DMSO-dg) δ ppm -72.45 (s, 3 F), -78.46 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C23Hi7F6N205S, 547.0757; found 547.0762. 181
[0539] This example illustrates a synthesis of 2-(Ethylthio)-N-(2-((3- ((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl)benzamide (XJB 11 -072,
NCGC00250106-01, CID-56593341). A tube was charged with Cul (3.3 mg, 0.017 mmol), 1,10-phenanthroline (6.3 mg, 0.035 mmol), (56.7 mg, 0.174 mmol), 2-iodo-N-(2-(3-
(trifiuoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (50.0 mg, 0.087 mmol) and ethanethiol (10.8 mg, 0.174 mmol) in toluene (1.50 mL) under N2. The tube was sealed and the reaction mixture was stirred at 110 °C for 24 h. The resulting mixture was cooled to room temperature and treated with a small portion of Si-THIOL to get rid of copper. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: (Method 1) = 6.910 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 10.95 (s, 1 H), 10.73 (s, 1 H), 8.55 (s, 1 H), 8.28 (dt, J=6.7, 2.0 Hz, 1 H), 8.10 (d, J=7.8 Hz, 1 H), 7.74 - 7.91 (m, 3 H), 7.57 - 7.66 (m, 1 H), 7.51 - 7.57 (m, 1 H), 7.39 - 7.48 (m, 2 H), 7.31 (td, J=7.6, 1.2 Hz, 1 H), 7.24 (ddd, J=7.4, 4.9, 3.7 Hz, 1 H), 2.90 (q, J=7.3 Hz, 2 H), 1.13 (t, J=7.2 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -78.40 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C23H20F3N2O4S2, 509.0811; found 509.0814.
EXAMPLE 182
[0541] This example illustrates a synthesis of Methyl 2-(2- isopropoxybenzamido)benzoate (XJB12-040). A solution of methyl 2-aminobenzoate (0.245 mL, 1.89 mmol) in dichloromethane (8.00 mL) and triethylamine (0.53 mL, 3.78 mmol) was treated at 0 °C with 2-isopropoxybenzoyl chloride (250 mg, 1.26 mmol). The reaction mixture was stirred at 0 °C for 2 hours and then at room temperature for another 2 hours. The reaction mixture was concentrated in vacuo and the crude residue was purified via silica gel chromatography using a gradient of 0-50% of EtOAc in hexanes to give 320 mg (81%) of the title compound as a colorless oil. LC-MS Retention Time: ti (Method 1) = 6.576 min; t2
(Method 2) = 3.825 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 1 1.59 (s, 1 H), 8.63 (d, J=8.6 Hz, 1 H), 7.98 (dd, J=7.8, 1.6 Hz, 1 H), 7.83 (dd, J=7.8, 2.0 Hz, 1 H), 7.64 (ddd, J=8.5, 7.1, 1.6 Hz, 1 H), 7.45 - 7.56 (m, 1 H), 7.13 - 7.27 (m, 2 H), 6.94 - 7.09 (m, 1 H), 4.82 (dq,
J=6.3, 6.0 Hz, 1 H), 3.85 (s, 3 H), 1.35 (d, J=5.9 Hz, 6 H); HRMS (ESI) m/z (M+H)+ calcd. for C18H20NO4, 314.1387; found 314.1399. 183
[0543] This exam le illustrates a synthesis of 2-Isopropoxy-N-(2-(3- (trifluoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (XJB11-073, NCGC00250135- 01, compound 178). A μW tube was charged with copper (I) iodide (3.3 mg, 0.017 mmol), 1,10-phenanthroline (6.3 mg, 0.035 mmol), cesium carbonate (56.7 mg, 0.174 mmol), 2-iodo- N-(2-(3-(trifluoromethylsulfonyl)phenylcarbamoyl)phenyl)benzamide (50.0 mg, 0.087 mmol), propan-2-ol (10.5 mg, 0.174 mmol), and dry toluene (1.50 mL). The tube was sealed, and the reaction mixture was stirred at 110 °C for overnight. The resulting suspension was cooled to room temperature and treated with Si-Thio. The reaction mixture was filtered and concentrated in vacuo to give an orange oil that was taken up in 1.5 mL of DMSO and purified via C18 reverse phase HPLC to give 1.7 mg (4%) of the title compound as a white solid. LC-MS Retention Time: ti (Method 1) = 6.974 min; t2 (Method 2) = 3.881 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 11.08 (br. s., 1 H), 1 1.07 (s, 1 H), 8.73 (s, 1 H), 8.46 (d, J=8.2 Hz, 1 H), 8.18 (dt, J=7.4, 2.0 Hz, 1 H), 7.89 (dd, J=7.8, 1.6 Hz, 1 H), 7.77 - 7.87 (m, 3 H), 7.57 - 7.63 (m, 1 H), 7.49 (ddd, J=8.7, 7.1, 1.8 Hz, 1 H), 7.28 (td, J=7.5, 1.0 Hz, 1 H), 7.19 (d, J=8.2 Hz, 1 H), 7.03 (t, J=7.6 Hz, 1 H), 4.79 (m, 1 H), 1.31 (d, 6 H); 19F NMR (376 MHz, DMSO-dg) d ppm -78.36 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C24H22F3N205S, 507.1196; found 507.1221.
[0544] Or a solution of methyl 2-(2-isopropoxybenzamido)benzoate (110 mg, 0.351 mmol) in toluene (4.00 mL) was treated with 3-(trifluoromethylsulfonyl)aniline (119 mg, 0.527 mmol) at room temperature, followed by trimethylaluminum (0.503 mL, 2.0 M in toluene, 1.06 mmol). The reaction mixture was stirred at 100 °C for overnight. After cooling,
the reaction mixture was concentrated in vacuo; and the crude residue was purified via silica gel chromatography using a gradient of 0-80% of EtOAc in hexanes to give 130 mg (73%) of the title compound as a white solid. E 184
[0546] This example illustrates a synthesis of (E)-2-Ethoxy-N-(2-((3-(prop-l-en-l- yl)phenyl)carbamoyl)phenyl)benzamide (XJB11-074, NCGC00250131-01). A mixture of 2- ethoxy-N-(2-(3-iodophenylcarbamoyl)phenyl)benzamide (50.0 mg, 0.103 mmol), (E)-prop- 1-enylboronic acid (13.3 mg, 0.154 mmol) and Pd(PPh3)4 (5.9 mg, 5.14 μιηοΐ) in DMF (1.50 mL) and 2.0 N Na2C03 (0.500 mL) aqueous solution was heated in μW at 100 °C for 30 min. The reaction was cooled to room temperature, added a small portion of Si-THIOL to get rid of Palladium. The mixture was filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 7.093 min; 1H NMR (400 MHz, DMSO- e) δ ppm 11.35 (s, 1 H), 10.48 (s, 1 H), 8.51 (d, J=8.2 Hz, 1 H), 7.93 (dd, J=7.8, 2.0 Hz, 1 H), 7.70 - 7.82 (m, 2 H), 7.42 - 7.63 (m, 3 H), 7.21 - 7.33 (m, 2 H), 7.18 (d, J=8.6 Hz, 1 H), 7.12 (d, J=7.8 Hz, 1 H), 7.06 (t, J=7.4 Hz, 1 H), 6.33 - 6.46 (m, 1 H), 6.16 - 6.32 (m, 1 H), 4.28 (q, J=7.0 Hz, 2 H), 1.84 (dd, J=6.7, 1.6 Hz, 3 H), 1.30 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C25H25N203, 401.1860; found 401.1859. PLE 185
[0548] This example illustrates a synthesis of (Z)-2-Ethoxy-N-(2-((3-(prop-l-en-l- yl)phenyl)carbamoyl)phenyl)benzamide (XJBl 1-075, NCGC00250132-01). A mixture of 2- ethoxy-N-(2-(3-iodophenylcarbamoyl)phenyl)benzamide (50.0 mg, 0.103 mmol), (Z)-prop- 1-enylboronic acid (13.3 mg, 0.154 mmol) and Pd(PPh3)4 (5.9 mg, 5.14 μιηοΐ) in DMF (1.50 mL) and 2.0 N Na2C03 (0.500 mL) aqueous solution was heated in μW at 100 °C for 30 min. The reaction was cooled to room temperature, added a small portion of Si-THIOL to get rid of Palladium. The mixture was filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 7.100 min; 1H NMR (400 MHz, DMSO- g) δ ppm 11.33 (s, 1 H), 10.52 (s, 1 H), 8.50 (d, J=8.2 Hz, 1 H), 7.93 (dd, J=7.8, 2.0 Hz, 1 H), 7.71 - 7.80 (m, 2 H), 7.59 - 7.64 (m, 1 H), 7.53 - 7.59 (m, 1 H), 7.51 (ddd, J=8.5, 7.1, 2.0 Hz, 1 H), 7.32 (t, J=7.8 Hz, 1 H), 7.25 (t, J=7.8 Hz, 1 H), 7.18 (d, J=8.6 Hz, 1 H), 7.00 - 7.10 (m, 2 H), 6.39 (dd, J=11.7, 2.3 Hz, 1 H), 5.60 - 5.92 (m, 1 H), 4.27 (q, J=6.9 Hz, 2 H), 1.86 (dd, J=7.4, 2.0 Hz, 3 H), 1.30 (t, J=6.8 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C25H25N203, 401.1860; found 401.1862. MPLE 186
[0550] This example illustrates a synthesis of N-(3-Cyanophenyl)-2-(2- ethoxybenzamido)benzamide (XJBl 1-080, NCGC00250133-01). The title compound was prepared according to general protocol A. LC-MS Retention Time: ti (Method 1) = 6.342 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.28 (s, 1 H), 10.83 (s, 1 H), 8.49 (d, J=7.8 Hz, 1 H), 8.22 (t, J=1.6 Hz, 1 H), 7.95 - 8.04 (m, 1 H), 7.93 (dd, J=7.8, 2.0 Hz, 1 H), 7.78 (dd, J=7.8, 2.0 Hz, 1 H), 7.54 - 7.63 (m, 3 H), 7.51 (ddd, J=8.5, 7.1 , 2.0 Hz, 1 H), 7.23 - 7.33 (m, 1 H), 7.19 (d, J=8.2 Hz, 1 H), 7.00 - 7.13 (m, 1 H), 4.29 (q, J=7.0 Hz, 2 H), 1.30 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C23H20N3O3, 386.1499; found 386.1515.
EXAMPLE 187
[0552] This example illustrates a synthesis of Methyl 2-amino-3-(2- ethoxybenzamido)benzoate (XJB 11-082). A solution of 2, 3-diaminobenzoate (100 mg, 0.602 mmol) in dichloro methane (5.00 mL) and TEA (0.252 mL, 1.81 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (11 1 mg, 0.602 mmol). The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was concentrated in vacuo and the crude material was used directly in the next reaction.
EXAMPLE 188
[0554] This example illustrates a synthesis of Methyl 2-(2-ethoxyphenyl)-lH- benzo[d]imidazole-4-carboxylate (XJB 11-083). A solution of methyl crude 2-amino-3-(2- ethoxybenzamido)benzoate (189 mg, 0.602 mmol) in glacial acetic acid (3.00 mL) was heated at 70 °C for 24 h. The reaction mixture was concentrated in vacuo; and the crude residue was purified via silica gel chromatography using a gradient of 0-20% of MeOH in dichloromethane to give 165 mg (92%) of the title compound as a white solid. LC-MS Retention Time: t2 (Method 2) = 3.088 min; m/z (M+H)+ 297.1.
PLE 189
[0556] This example illustrates a synthesis of 2-(2-Ethoxyphenyl)-N-(3- ((trifluoromethyl)sulfonyl)phenyl)-lH-benzo[d]imidazole-4-carboxamide (XJBl 1-086, NCGC00250115-01). The title compound was prepared according to general protocol A. LC- MS Retention Time: ti (Method 1) = 6.265 min; HRMS (ESI) m/z (M+H)+ calcd. for
C23H19F3N3O4S, 490.1043; found 490.1049.
EXAMPLE 190
[0558] This example illustrates a synthesis of tert-Butyl (2-formylphenyl)carbamate (XJBl 1-088). A solution of tert-butyl 2-(hydroxymethyl)phenylcarbamate (0.370 g, 1.66 mmol) and Dess-Martin Periodinane (0.914 g, 2.15 mmol) in dichloromethane (15.0 mL) was stirred at 0 °C for 1 h. The reaction mixture was concentrated and the crude residue was purified via silica gel chromatography using 10% of EtOAc in hexanes to give 300 mg (82%) of the title compound as a colorless oil. XAMPLE 191
[0560] This example illustrates a synthesis of tert-Butyl (2-(((3-
((trifluoromethyl)sulfonyl)phenyl)amino)methyl)phenyl)carbamate (XJB 11-090). A mixture of tert-butyl 2-formylphenylcarbamate (80.0 mg, 0.362 mmol) and 3- (trifluoromethylsulfonyl)aniline (122 mg, 0.542 mmol) in MeOH (2.00 ml) was treated with ΤΪ(0'ΡΓ)4 (0.212 mL, 0.723 mmol). The reaction was stirred at room temperature for 6 h, then treated with NaBH4 (20.5 mg, 0.542 mmol) and stirred overnight at room temperature. The reaction mixture was poured into 2N NH4OH aqueous solution, the resulting inorganic precipitate was filtered off, and the filtrate was extracted with EtOAc. The organic layer was separated, dried and concentrated to give the final product as a colorless oil which was used directly in the next reaction. LC-MS Retention Time: t2 (Method 2) = 3.869 min; m/z (M+H)+ 431.1. XAMPLE 192
[0562] This example illustrates a synthesis of N-(2-Aminobenzyl)-3- ((trifluoromethyl)sulfonyl)aniline (XJB11-091). A solution of tert-butyl 2-((3- (trifluoromethylsulfonyl)phenylamino)methyl)phenylcarbamate (0.156 g, 0.362 mmol) in dichloro methane (2.00 mL) was treated at 0 °C with TFA (2.00 mL, 26.0 mmol). The reaction mixture was stirred at room temperature for 1 h. The mixture was concentrated to give the final product which was used directly in the next reaction. LE 193
[0564] This example illustrates a synthesis of 2-Ethoxy-N-(2-(((3- ((trifluoromethyl)sulfonyl)phenyl)amino)methyl)phenyl)benzamide (XJB 11 -097,
NCGC00250112-01). A solution of N-(2-aminobenzyl)-3-(trifluoromethylsulfonyl)aniline (0.060 g, 0.181 mmol) in dichloromethane (2.00 mL) and TEA (0.075 mL, 0.535 mmol) was treated at 0 °C with 2-ethoxybenzoyl chloride (0.033 g, 0.181 mmol). The reaction mixture was stirred overnight at room temperature for 2 h. The mixture was concentrated, re- dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 6.813 min; HRMS (ESI) m/z (M+H)+ calcd. for C23H22F3N2O4S, 479.1247; found 479.1249.
EXAMPLE 194
[0566] This example illustrates a synthesis of 7-Amino-2-(3-
(trifluoromethyl)phenyl)isoindolin-l-one (XJB 11-098). A mixture of 7-aminoisoindolin-l- one (80.0 mg, 0.540 mmol), l-iodo-3-(trifluoromethyl)benzene (176 mg, 0.648 mmol), (15,2iS)-M^-dimethylcyclohexane ,2-diaimne (0.017 mL, 0.108 mmol), Cul (5.1 mg, 0.027 mmol) and K2CO3 (149 mg, 1.08 mmol) in toluene (3.00 mL) was stirred overnight at 110 °C. The reaction mixture was concentrated and the crude residue was purified via silica gel chromatography using a gradient of 0-100% of EtOAc in hexanes to give 39.0 mg (25%) of the title compound as a white solid. LC-MS Retention Time: t2 (Method 2) = 3.736 min; m/z (M+H)+ 293.1.
EXAMPLE 195
[0568] This example illustrates a synthesis of 2-Ethoxy-N-(3-oxo-2-(3- (trifiuoromethyl)phenyl)isoindolin-4-yl)benzamide (XJB12-002, NCGC00250113-01). A solution of 7-amino-2-(3-(trifluoromethyl)phenyl)isoindolin-l-one (18.0 mg, 0.062 mmol) in dichloromethane (1.00 mL) and TEA (0.026 mL, 0.185 mmol) was treated at 0 °C with 2- ethoxybenzoyl chloride (17.1 mg, 0.092 mmol). The reaction mixture was stirred overnight at room temperature for 2 h. The mixture was concentrated, re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 7.538 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 12.04 (s, 1 H), 8.98 (d, J=8.2 Hz, 1 H), 8.76 (s, 1 H), 8.35 (dd, J=8.2, 2.7 Hz, 1 H), 8.27 (dd, J=7.8, 2.0 Hz, 1 H), 7.93 - 8.05 (m, 2 H), 7.79 - 7.92 (m, 2 H), 7.65 (d, J=7.8 Hz, 1 H), 7.57 (d, J=8.2 Hz, 1 H), 7.35 - 7.50 (m, 1 H), 5.41 (s, 2 H), 4.72 (q, J=6.8 Hz, 2 H), 1.68 - 1.82 (t, J=7.2 Hz, 3 H); 19F NMR (376 MHz, DMSO-d6) δ ppm -61.34 (s, 3 F); HRMS (ESI) m/z (M+H)+ calcd. for C24H20F3N2O3, 441.1421; found 441.1429. PLE 196
[0570] This example illustrates a synthesis of N-(3-(lH-tetrazol-5-yl)phenyl)-2-(2- ethoxybenzamido)benzamide (XJB12-006, NCGC00250114-01). A solution of N-(3- cyanophenyl)-2-(2-ethoxybenzamido)benzamide (0.066 g, 0.171 mmol) in water (1.00 mL) was treated at room temperature with ZnBr2 (0.058 g, 0.257 mmol) and NaN3 (0.033 g, 0.513 mmol). The pH value of the solution was adjusted to ~ 7 by several drops of 1 N NaOH aqueous solution. The reaction mixture was heated at 120 °C for 60 hours. Another aliquot of reagents was added and the mixture was heated at 120 °C for an additional 24 h. The reaction mixture filtered and purified via C18 reverse phase HPLC to give two products
NCGC00250114-01 and NCGC00250134-01. LC-MS Retention Time: ti (Method 1) = 5.547 min; 1H NMR (400 MHz, DMSO- 6) δ ppm 11.36 (s, 1 H), 10.77 (s, 1 H), 8.61 (t, J=2.0 Hz,
1 H), 8.52 (d, J=8.2 Hz, 1 H), 7.93 (dd, J=7.8, 2.0 Hz, 1 H), 7.85 - 7.91 (m, 1 H), 7.81 (dd, J=7.8, 1.6 Hz, 1 H), 7.74 (d, J=7.8 Hz, 1 H), 7.53 - 7.63 (m, 2 H), 7.50 (ddd, J=8.6, 7.0, 2.0 Hz, 1 H), 7.23 - 7.31 (m, 1 H), 7.18 (d, J=8.2 Hz, 1 H), 7.01 - 7.10 (m, 1 H), 4.30 (q, J=7.0 Hz, 2 H), 1.28 (t, J=7.0 Hz, 3 H); HRMS (ESI) m/z (M+H)+ calcd. for C23H21N6O3, 429.1670; found 429.1673. PLE 197
[0572] This example illustrates a synthesis of N-(3-Carbamimidoylphenyl)-2-(2- ethoxybenzamido)benzamide (XJB12-008, NCGC00250116-01). A suspension of ammonium chloride (267 mg, 5.00 mmol) in benzene (5.00 mL) at 5 °C, was slowly added a trimethylaluminum (2.0 M in toluene, 2.50 mL, 5.00 mmol). After the addition was completed, the reaction mixture was allowed to warm to room temperature and was stirred for 1-2 hours until gas evolution has ceased. The solution was ready to use. 0.394 mL of above in situ solution was added to another solution of N-(3-cyanophenyl)-2-(2- ethoxybenzamido)benzamide (50.0 mg, 0.130 mmol) in toluene (1.00 mL) at room
temperature. The reaction mixture was heated under argon at 80 °C for 4 h. The reaction mixture was filtered through a pad of celite and concentrated as a yellow oil. The crude material was re-dissolved in 2.00 mL of DMSO, filtered and purified via C18 reverse phase HPLC to give the final product. LC-MS Retention Time: ti (Method 1) = 4.349 min; 1H NMR
(400 MHz, DMSO- g) δ ppm 11.36 (s, 1 H), 10.78 (s, 1 H), 8.58 - 8.64 (m, 1 H), 8.52 (d, J=8.2 Hz, 1 H), 7.93 (dd, J=7.6, 2.2 Hz, 1 H), 7.87 (dd, J=8.2, 2.7 Hz, 1 H), 7.81 (dd, J=7.8, 2.0 Hz, 1 H), 7.74 (d, J=7.4 Hz, 1 H), 7.53 - 7.62 (m, 2 H), 7.50 (ddd, J=8.6, 7.0, 2.0 Hz, 1 H), 7.24 - 7.32 (m, 1 H), 7.18 (d, J=8.2 Hz, 1 H), 7.06 (t, J=7.6 Hz, 1 H), 4.30 (q, J=7.0 Hz, 2 H), 1.28 (t, J=6.8 Hz, 3 H) (3 N-H protons didnffi show up); HRMS (ESI) m/z (M+H)+ calcd. for C23H23N4O3, 403.1765; found 403.1766.
[0574] This example illustrates a synthesis of 3-(4-(lH-Tetrazol-5-yl)phenyl)-2-(2- ethoxyphenyl)quinazolin-4(3H)-one (XJB12-010, NCGC00250134-01). The title compound was prepared as a by-product of synthesizing N-(3-(lH-tetrazol-5-yl)phenyl)-2-(2- ethoxybenzamido)benzamide (XJB12-006, NCGC00250114-01). LC-MS Retention Time: ti (Method 1) = 5.100 min; HRMS (ESI) m/z (M+H)+ calcd. for C23H19N6O2, 411.1564; found 411.1569.
EXAMPLE 199
[0575] This example demonstrates activation of the RXFPl receptor resulting in stimulation of cAMP production by several embodiments of the disclosure in the RXFPl cAMP assay in HE K293 -RXFPl cells
[0576] The RXFPl receptor couples to the Gs protein, and activation of the receptor results in stimulation of cAMP production. To screen for agonists of the receptor, RXFPl was stably expressed in human embryonic kidney cells (HE K293 -RXFPl), which have previously been show to constitute a functional cell-based model for RXFPl -cAMP signaling pathway.16'17 Cyclic AMP levels were detected using the HTRF cAMP assay kit.18 This assay uses a europium cryptate labeled anti-cAMP antibody (K-a-cAMP) and d2 dye labeled cAMP (cAMP-d2) as a tracer in a time-resolved fluorescence energy transfer (TR-FRET) detection system. The TR-FRET between the K-a-cAMP and cAMP-d2 is disrupted by cAMP in the cell lysates, thus allowing TR-FRET detection in a homogenous format that is suitable for HTS. The assay was carried out in the presence of a phosphodiesterase 4 (PDE4) inhibitor, Ro 20-1724, to amplify cAMP signal. The primary screen was carried out in 1536-
well format, however, because of a more robust signal to background ratio, all subsequent follow-up experiments were carried out in 384-well format.
[0577] For the primary screen, HEK293-RXFP1 cells were seeded at 2,000 cells/well in 3 μίΛνεΙΙ media with a MultiDrop Combi dispenser (Thermo Scientific, Logan, UT), and allowed to attach overnight at 37 °C, 5% C02. Next, 1 uL/well of 400 μΜ Ro 20-1724 in PBS was added, followed by addition of 23 nL/well of compound solution in DMSO with a pintool transfer (Kalypsys, San Diego, CA). The cells were allowed to be stimulated with the compounds for 30 minutes at 37 °C, 5% C02, after which, 1 μΙ,ΛνεΙΙ of each HTRF detection reagent was dispensed with a BioRAPTR FRD dispenser. The detection reagents were diluted before addition as follows: K-a-cAMP antibody at 1 :20 and cAMP-d2 at 1 : 18 in HTRF lysis buffer (supplied by the assay kit). The plates were incubated for 30 minute at room temperature, and then the signal was read on a ViewLux plate reader (PerkinElmer, Waltham, MA).
[0578] The assay was run according to the following protocol:
[0579] The results are set forth in Tables 1-7, wherein AC50 (μΜ) indicates the potency of the compound in micromolar, or more specifically the concentration at which the compound activates the functional activity of the receptor by its half-maximal amount. Max Response indicates what the maximal amount of functional activity induced by the compound is, as a percentage of the maximal receptor activation induced by high concentrations of forskolin.
inactive N/A
160
RXFP1 Max
RXFP1 Max AC50 (μΜ) Response
121 f^N^^\ 59.3 63%
H
Table 6
171
153 inactive N/A
Table 7
RXFP1 Max
AC50 (μΜ) Response
ı74
EXAMPLE 200
[0580] This example illustrates the activation of VEGF expression in THP1 cells by several embodiments of the disclosure.
[0581] THP1 cells (human acute monocytic leukemia cell line) were used to analyze the stimulation of VEGF gene expression after treatment with relaxin or compounds. The VEGF stimulation in these cultured endometrial cells is a well-established property of relaxin.19 This effect is most probably responsible for the observed angiogenic and neovascularization properties of relaxin in various settings.20 400,000 THP1 cells (0.4 mL at l x lO6 cells/mL) in test media (RPMI-1640 without phenol red, 0.5% FBS, lx Pen/Strep, 0.05 mM of 2- mercaptoethanol) were seeded in each well on a 24-well plate. After 24 hours incubation at 37 °C, 5% C02, relaxin or compounds were added for 2 hours. The cells were harvested and R A was extracted by the Trizol (Invitrogen, Carlsbad, CA) method according to manufacturers instructions. cDNA was synthesized by using Verso cDNA kit (Thermo Scientific, Waltham, MA) according to manufacturers protocol. Quantitative real time RT- PCR for VEGF and GAPDH gene expression was done using a Roche LightCycler 480 (Roche Diagnostics, Indianapolis, IN) with the appropriate set of primers and probes spanning different exons. The relative fold change in VEGF mRNA level was calculated by the comparative Ct (2ϋΔΔα) method using GAPDH expression for normalization of RNA.
[0582] The results are set forth in Table 8 as relative VEGF gene expression relative to control.
Table 8
Compound Relative VEGF gene expression (control = 1.0)
Relaxin 2.5
158 1.2
177 1.3
179 1.5
180 1.6
99 1.9
174 2.3
178 2.8
159 1.4
[0583] As is apparent from the results set forth, all of the compounds with the possible exception of compound 158 exhibited a significant upregulation of VEGF expression.
Compound 178 exhibited a greater upregulation of VEGF expression than did relaxin.
EXAMPLE 201
[0584] It was previously shown that relaxin increases cell impedance in RXFP1 transfected cells. Cell-substrate impedance was measured using a Roche DP RTCA xCELLigence Analyzer (Roche Diagnostics, Indianapolis, IN) on E-Plates. Real Time Cell Analyzer (RTCA) allows for continuous time-resolved measurement of cellular index without additional labeling. Cell number, cellular adherence to the plate, and intracellular
interactions all contribute to the total cellular impedance. The effect of the compound treatment is only measured within the first hour, changes in cellular density are unlikely to contribute to the overall effect, and therefore cellular impedance is most likely caused by intercellular interactions, or signaling.
[0585] Cell Index (CI) was calculated by subtracting impedance at the beginning of experiment Zo from impedance at each individual time point Zt, divided by 15Ω [CIt=( Z0- Zt)/15 Ω]. Delta Cellular Indices were calculated as the change of impedance at a given time t, from the time of compound addition (CIcomp0und)
Impedance at each time point was then normalized to the average of quadruplicate CI of cells treated with vehicle (VI, V2, V3, and V4), to calculate normalized delta Cell Index NACI= (CL- CIcompound)/Average[ACIvi, ΔΟν2, ΔΟν3, ΔΟν4]. Maximal relaxin activity was assigned a value of 100% and all other values adjusted proportionally.
[0586] The cell line stably transfected with RXFP 1 receptor HEK293-RXFP 1 was used for cell impedance assay to confirm relaxin-like properties of the compounds. To equilibrate the plates, 100 μΕ of test media (DMEM, 1% FBS, 1 x Pen/Strep) was added to each well of E-Plate (Roche Diagnostics, Indianapolis, IN) and the plate was incubated at room
temperature for 30 minutes at which point baseline impedance was measures. Then 20,000 HEK293-RXFP1 cell or HEK293 cells (parental control cell line) were added per well in a volume of 100 test media and allowed to sediment at room temperature for 30 minutes. The plate was placed into xCELLigence RTCA DP Instrument in the C02 incubator
overnight to allow the cells to attach. Relaxin (10 ng/mL), vehicle, or compounds at different concentrations (250, 500, and 750 nM) were added to the wells and the cellular impedance was measured every 10-30 seconds for 1 hour. The protocol was as follows:
[0587] The results are set forth in Figure 8.
EXAMPLE 202
[0588] This Example illustrates the cyclic AMP assay in THP-1 cells. THP-1 cells were propagated in RPMI-1640 supplemented with 20% FBS, 0.05 mM β-mercaptoethanol, 100
U/mL penicillin and 100 μg/mL streptomycin at 37 C in 5% C02. Before assaying for cAMP response, cells were serum starved in RPMI-1640 supplemented with 0.05 mM β- mercaptoethanol, 100 U/mL penicillin and 100 μg/mL streptomycin at 37 C in 5% C02 for
16 firs. For 384-well format assays, cells were seeded as 30,000 cells/well in 30 μΕΛνεΙΙ media with a MultiDrop Combi dispenser (Thermo Scientific, Waltham, MA). Subsequently,
2 μΕ/well of 1.6 mM Ro 20-1724 and 160 uM forskolin in PBS+ (DPBS, 1 mM CaCl2, 0.5 mM MgCl2, 0.05% BSA, 0.005% Tween 20) was dispensed using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). Immediately after, 0.25 μΕΛνεΙΙ of compound solutions in DMSO was dispensed with CyBi-well dispenser (CyBio, Jena, Germany). The cells were allowed to be stimulated with compounds for 30 min at 37 C in 5% C02, after which, 8 μίΛνεΙΙ of each HTRF cAMP HiRange kit (CisBio, Bedford, MA) detection reagent was dispensed with a BioRAPTR FRD dispenser. The detection reagents were diluted as such: K-a-cAMP antibody at 1 :20 and cAMP-d2 at 1 : 18 in HTRF lysis buffer (supplied by the assay kit). The plates were incubated for 30 min at room temperature before the signal
was read on an Envision plate reader (PerkinElmer, Waltham, MA). The EC50 values for selected embodiments are set forth in Table 9.
Table 9
EXAMPLE 203
[0589] This example demonstrates the RXFP2 cAMP assay in HEK293 -RXFP2 cells. HEK293 cells stably transfected with RXFP2, the cognate receptor for another relaxin family peptide, insulin-like 3, (HEK293-RXFP2) was used to test compound specificity towards the RXFP1 receptor. For this assay, cells were seeded at 8,000 cells/well in 30 μΕ/well of media with a MultiDrop Combi dispenser (Thermo Scientific), and allowed to attach overnight at 37 °C, 5% C02. Next, 2 μΕ/well of 1.6 mM Ro 20-1724 solution in PBS+ (DPBS, 1 mM CaCl2, 0.5 mM MgCl2, 0.05% BSA, 0.005% Tween 20) were dispensed using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA), followed addition of 0.25 μΕΛνεΙΙ of compound solution in DMSO with CyBi-well dispenser (CyBio, Jena, Germany). The cells were allowed to be stimulated with the compounds for 30 minutes at 37 °C, 5%> C02, after which, 8 μΕΛνεΙΙ of each HTRF detection reagent (diluted according to assay kit directions in HTRF lysis buffer) was dispensed with a BioRAPTR FRD dispenser. The plates were incubated for 30 minute at 37 °C, and then the signal was read on a ViewLux plate reader (PerkinElmer, Waltham, MA). The protocol was as follows:
Sequence Parameter Value Description
1 Cells 30 μΐ. 8,000 cells/well
2 Time 16-24 h Incubate at 37 °C and 5% C02
3 Reagent 2 μΐ. 1600 μΜ Ro 20-1724 in PBS
4 Reagent 2.5 μΐ. Compounds in DMSO, forskolin as control
5 Time 30 min Incubate at 37 °C and 5% C02
6 Reagent 8 μΐ. cAMP-d2 diluted 1 : 18 in lysis buffer
7 Reagent 8 μΐ. K-a-cAMP diluted 1 :20 in lysis buffer
8 Time 30 min Room temperature incubation
EXAMPLE 204
[0590] This example demonstrates the Vlb cAMP assay in HEK293-Vlb cells. HEK293 stably trans fected with a nonrelated G protein coupled receptor, vasopressin receptor lb (HEK293-Vlb), were used as an additional counter screen to eliminate compounds that increase cAMP HTRF signal through non-RXFPl dependent mechanisms. For this assay, cells were seeded at 8,000 cells/well in 30 μΕΛνεΙΙ media with a MultiDrop Combi dispenser (Thermo Scientific, Logan, UT), and allowed to attach overnight at 37 °C, 5% C02. Next, 2 μΕ/well of 1.6 mM Ro 20-1724 solution in PBS+ (DPBS, 1 mM CaCl2, 0.5 mM MgCl2, 0.05% BSA, 0.005% Tween 20) was dispensed using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA), followed by additional of 0.25 μΕΛνεΙΙ of compound solution in DMSO with CyBi-well dispenser (CyBio, Jena, Germany). The cells were allowed to be stimulated with the compounds for 30 minutes at 37 °C, 5% C02, after which, 8 μΕΛνεΙΙ of each HTRF detection reagent (diluted according to assay kit directions in HTRF lysis buffer) was dispensed with a BioRAPTR FRD dispenser. The plates were incubated for 30 minute at room temperature, and then the signal was read on a ViewLux plate reader (PerkinElmer,
Waltham, MA). The protocol was as follows:
Sequence Parameter Value Description
1 Cells 30 μΕ 8,000 cells/well
2 Time 16-24 h Incubate at 37 °C and 5% C02
3 Reagent 2 μΕ 1,600 μΜ Ro 20-1724 in PBS
4 Reagent 2.5 μΕ Compounds in DMSO, forskolin as control
5 Time 30 min Incubate at 37 °C and 5% C02
6 Reagent 8 μΕ cAMP-d2 diluted 1 : 18 in lysis buffer
7 Reagent 8 μΕ K-a-cAMP diluted 1 :20 in lysis buffer
8 Time 30 min Room temperature incubation
9 Detector TR-FRET EnVision plate reader
EXAMPLE 205
[0591] This example demonstrates the ATP Cytotoxicity assay in HEK293-RXFP1 cells. This follow-up assay was conducted to measure the effect of compounds on cell viability by measuring ATP levels (ATPLite™). ATPLite™ is an Adenosine Triphosphate (ATP) monitoring system based on firefly (Photinus pyralis) luciferase. The level of ATP in a metabolically active cell is a general marker for its viability. ATP levels are often reduced during necrosis or apoptosis. In this assay, the luciferase enzyme catalyzes the conversion of the added substrate D-luciferin to oxyluciferin and light with ATP. Thus, the emitted light is proportional to the ATP concentration. To evaluate the cytotoxic properties of the compounds, HEK293-RXFP1 cells were incubated with compounds for 72 hours in growth media (DMEM 10% FBS, lx Pen/Strep, 0.5 mg/mL of G418) in 384-well format. After compound incubation, the levels of ATP in each well were measured with the addition of the ATPLite assay reagent. The protocol was as follows:
EXAMPLE 206
[0592] This example illustrates the activity of several embodiments of the disclosure in the RXFPl assay (Example 199), the RXFP2 assay (Example 203), the Vlb assay (Example 204), and the ATP toxicity (Example 202), as well as the PBS solubility and the mouse liver microsome (MLM) stability. The results are set forth in Table 10.
Table 10
RXFP1 AC50 RXFP2 AC50 V1b AC50 ATP Tox. EC50 PBS Solubility MLM Stability
Entry Internal ID
(μΜ, Max. Resp.) (μΜ, Max. Resp.) (μΜ, Max. Resp.) (μΜ, Max. Resp.) (μΜ) (t,/2 In mln.)
37 99 0.297 (95%) 9.40 (47%) inactive3 inactive3 1.7 N/A
61 158 0.297 (99%) 3.34 (54%) inactive3 3.74 (-31%) 2.9 N/A
62 159 0.188 (99%) inactive3 inactive3 29.7 (-76%) 6.3 N/A
63 174 0.188 (99%) 7.47 (38%) inactive3 18.8 (-73%) < 1.1 1732
65 177 0.067 (97%) inactive3 inactive3 29.7 (-78%) 3.3 100
66
178
ML290 0.094 (98%) inactive3 inactive3 9.4 (-85%) 7.0 122
67 179 0.052 (98%) inactive3 inactive3 9.4 (-83%) 17.0 133
68 180 0.047 (98%) inactive3 inactive3 59.3 (-53%) 5.3 178
Maximum response less than 30%.
EXAMPLE 207
[0593] Referring to Figure 9, 1-3ECL are extracellular loops of transmembrane domains of RXFPl . This example demonstrates the ability of compound to activate human but not mouse relaxin receptor transfected in HEK293 cells as measured by cAMP accumulation. The compound was inactive against related to RXFPl mouse relaxin family receptor 2, RXFP2. The chimeric mouse/human RXFPl receptors were activated by compounds only if they contained the region encoded by human exon 17 plus two humanized codons from exon 18. The 3 Eend of mouse and human exon 17 encodes the 3 rd ECL. There are 4 amino acid differences between human and mouse 3EXL. Two mouse site-specific mutants were tested, one where iso leucine 646 and leucine 647 were substituted by two valines specific for human sequence (M10), and the other one where aspartic acid (position 659) and serine (660) were substituted by glycine and threonine (Ml 1). Both did not respond to the compound stimulation.
n = 1-6 n = 1 -6
[0595] Example 209 provides a method for preparing tritium 3H labeled analogs of the Relaxin Receptor 1 modulators disclosed herein.
[0596] Example 210 provides a method for preparing fluorine-18 (18F) labeled analogs of the Relaxin Receptor 1 modulators disclosed herein.
EXAMPLE 211
[0597] Synthesiso of tert-Butyl (2-((3-((trifluoromethyl)thio)phenyl)carbamoyl) phenyl)carbamate. A mixture of 2-((fert-butoxycarbonyl)amino)benzoic acid (2.50 g, 10.5 mmol) and 3-((trifluoromethyl)thio)aniline (2.44 g, 12.6 mmol) in DMF (40.0 mL) was treated at room temperature with HATU (4.01 g, 10.5 mmol) and DIPEA (5.52 mL, 31.6 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water and extracted with EtOAc. The organic layer was separated, dried and concentrated as a brown oil. The crude material was purified on silica gel with a gradient of 0-100% EtOAc in hexanes to give 3.20 g (yield 74%) of the title product as a white solid.
EXAMPLE 212
[0598] Synthesis of tert-Butyl (2-((3-((trifluoromethyl)sulfonyl)phenyl)carbamoyl) phenyl)carbamate. A solution of tert-butyl (2-((3-((trifluoromethyl)thio)phenyl)carbamoyl) phenyl)carbamate (400 mg, 0.970 mmol) in mixed solvents of DCM (2.00 mL), acetonitrile (2.00 mL) and water (4.00 mL) was treated at room temperature with sodium periodate (622 mg, 2.91 mmol). To this suspension was added RuCl3 (0.2 mg, 0.970 μιηοΐ). The reaction mixture was stirred at room temperature overnight. The mixture was concentrated and re- disolved in water and DCM. The organic layer was separated, dried and concentrated to give a grey powder which was used directly in the next reaction without further purification.
EXAMPLE 213
[0599] Synthesis of 2-Amino-N-(3-((trifluoromethyl)sulfonyl)phenyl)benzamide. A solution of crude tert-butyl (2-((3-((trifluoromethyl)sulfonyl)phenyl)carbamoyl)phenyl) carbamate (0.430 g, 0.970 mmol) in DCM (10.0 mL) was treated with TFA (5.00 mL) at room temperature. The reaction mixture was stirred at room temperature for 30 minutes. The
reaction mixture was concentrated and purified using ISCO on reverse phase column to give the desired product as a TFA salt.
EXAMPLE 214
[0600] Synthesis of Ethyl 2-(but-3-en-l-yloxy)benzoate. A solution of ethyl 2- hydroxybenzoate (0.442 mL, 3.01 mmol) and 4-bromobut-l-ene (1.22 g, 9.03 mmol) in DMF (30.0 mL) was treated at room temperature with K2C03 (4.16 g, 30.1 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and concentrated to give a yellow oil which was used directly in the next reaction without further purification.
EXAMPLE 215
[0601] Synthesis of 2-(But-3-en-l-yloxy)benzoic acid. A solution of ethyl 2-(but-3-en-l- yloxy)benzoate (0.66 g, 3.01 mmol) in MeOH (15.0 mL) and water (15.0 mL) was treated at room temperature with LiOH (0.72 g, 30.1 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was cooled to 0 °C and acidified with 1 N HC1 until pH = 1. The reaction mixture was extracted with DCM and the organic layer was separated, dried and concentrated to give a colorless oil. The crude product was purified on silica gel with a gradient of 5-20% MeOH in DCM to give a colorless oil.
EXAMPLE 216
[0602] Synthesis of 2-(Allyloxy)-N-(2-((3-((trifluoromethyl)sulfonyl)phenyl)carbamoyl )phenyl)benzamide. A solution of 2-amino-N-(3-((trifluoromethyl)sulfonyl)phenyl) benzamide, TFA salt (30.5 mg, 0.067 mmol) in DMF (2.00 mL) was treated at room temperature with 2-(allyloxy)benzoic acid (23.7 mg, 0.13 mmol), HATU (25.3 mg, 0.067 mmol) and DIPEA (0.058 mL, 0.33 mmol). The reaction mixture was stirred at room temperature for 2 days. The crude mixture was purified on ISCO under reverse phase column to give the title product as a grey solid.
EXAMPLE 217
[0603] Synthesis of 2-(But-3-en-l-yloxy)-N-(2-((3-((trifluoromethyl)sulfonyl)phenyl) carbamoyl)phenyl)benzamide. A solution of 2-amino-N-(3-((trifluoromethyl)sulfonyl) phenyl)benzamide, TFA salt (10.0 mg, 0.022 mmol) in DMF (2.00 mL) was treated at room temperature with 2-(but-3-en-l-yloxy)benzoic acid (8.4 mg, 0.044 mmol), HATU (8.3 mg, 0.022 mmol) and DIPEA (0.019 mL, 0.109 mmol). The reaction mixture was stirred at room temperature for 2 days. The crude mixture was purified on ISCO under reverse phase column to give the title product as a grey solid.
EXAMPLE 218
[0604] Synthesis of 2-Butoxy-N-(2-((3-((trifluoromethyl)sulfonyl)phenyl)
carbamoyl)phenyl)benzamide. A solution of 2-(but-3-en-l-yloxy)-N-(2-((3-((trifluoromethyl) sulfonyl)phenyl)carbamoyl)phenyl)benzamide (1.8 mg, 3.47 μηιοΐ) in a mixed solvents of THF (0.60 mL) and water (0.20 mL) was treated at 0 °C with ruthenium (III) chloride (1.0 mg, 4.8 μιηοΐ). NaBH4 (2.0 mg, 15.2 μmol) was added slowly into the mixture. The reaction mixture was stirred at room temperature for 15 minutes. The reaction mixture was filtered through a pad of celite and purified using reverse phase column to give the desired product as a white powder. In the scaled up reaction, ruthenium (III) chloride can be catalytic and NaBH4 will be 2 equivalents.
EXAMPLE 219
[0605] Identification of a human RXFP1 region responsible for activation by compound 178 (Figure 11). Human RXFP1 (hRXFPl) is fully activated (100%) after treatment with relaxin or compound 178. Mouse RXFP1 (mRXFPl) does not respond to compound 178 (marked as 0%) at 66 μΜ. The RXFP1 contains the extracellular, 7 transmembrane, and intracellular (ICD) domains. Using chimeric mouse-human receptors (m/hRXFPl) the region responsible for RXFP1 activation by compound 178 was mapped to the part containing extracellular loop 3 (ECL3) of 7 transmembrane domain. Alignment of hRXFPl and mRXFPl shows two pairs of diverse amino acids within ECL3. The N- terminal IL to VV substitution in mRXFPl (mRXFPl-MlO) did not change mouse receptor response, whereas C-terminal GT to DS substitution in hRXFPl (hRXFPl -Ml 1) abolished its compound 178 dependent activation. The mRXFPl -Ml 1 mutant was partially active and the mouse receptor with humanized ECL3 (mRXFPl -M10/M1 1) was fully active after stimulation with compound 178. The cAMP response to compound 178 (66 μΜ) in cells transfected with a specific construct was normalized to the response of the same cells to relaxin (15nM). The
results represent the average of 3 independent experiments ± s.e.m. repeated in quadruplicates. ** P<0.01 vs hRXFPl by Students t-test.
EXAMPLE 220
[0606] Pharmacokinetics of compound 178 (NCGC00250135). The pharmacokinectics of compound 178 (NCGC00250135) were determined in male C57/B16 mice after a single intravenous (IV) administration of 3 mg/kg and oral (PO) administration of 30 mg/kg of compound 178. The data is present in TABLE 11.
[0607] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0608] The use of the terms HCand HnCand IheCand similar referents in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms Bomprising, DtLaving, DShcluding, Cand
BontainingCare to be construed as open-ended terms (i.e., meaning [including, but not limited to, [J unless otherwise noted. Recitation of ranges of values herein are merely
intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., Huch as provided herein, is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
[0609] Embodiments of this disclosure are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is
encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
CLAIM(S):
wherein A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, or -CH2CH2-, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, and 1,2-heterocyclyl are optionally substituted with one or more substituents selected from halo, CF3, alkyl, alkyloxy,haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and S02CF3,
Ri is -NHCOR3, R4, -NHR5, or -OR6,
R2 is alkyl, cycloalkyl, heteroarylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, trihalo C1-C10 alkyl, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, aryl, haloalkylaryl, heterocyclylalkyl, -SR7, -SOR7, -S02R7, -SCF3, -N02, -CN, and -S02CF3,
R3 is alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, aryl, heteroaryl, arylalkyl, or phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, Ci-Ciohaloalkyl, Ci- Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, -N02,-CN, and -S02CF3,
R4 is phenyl optionally substituted with alkyloxy, haloalkyloxy, arylalkyl, or arylalkyloxy,
R5 is hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, or cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl,
Re is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
and R7 is C1-C10 alkyl or C1-C10 haloalkyl,
with the provisos that:
(i) when R3 is methyl, chloromethyl, or dichloromethyl, and A is 1 ,2-phenylenyl, then R2 is not methyl, phenyl, 2-methylphenyl, 2-methoxyphenyl, or 4-methoxyphenyl; and
(ii) when R3 is phenyl, and A is 1 ,2-phenylenyl, then R2 is not halophenyl, methoxyphenyl, 2,6-dimethylphenyl, or 2,4,6-trimethylphenyl; and
(iii) when R3 is phenyl substituted with alkyl, and A is 1 ,2-phenylenyl, then R2 is not methoxyphenyl;
or a pharmaceutically acceptable salt thereof.
2. The compound or salt of claim 1, wherein R2 is phenyl substituted with a substituent selected from the group consisting of -S02CF3, -SCF3, and -CF3.
3. The compound or salt of claim 1 or 2, wherein A is 1 ,2-phenylene optionally substituted with one or more substituents independently selected from hydrogen, halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
4. The compound or salt of claim 3, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from the group consisting of -CF3, Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, alkyloxyalkyloxy,
dimethylaminoalkyloxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
5. The compound or salt of claim 3 or 4, wherein R3 is
2-(Ci-Cio)alkyloxyphenyl.
6. The compound or salt of any one of claims 1-5, wherein R2 is phenyl substituted with a substituent selected from -CF3, Ci-Cio alkyl, Ci-Cio alkyloxy, , Ci- Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
7. The compound or salt of any one of claims 3-6, wherein the compound is selected from the group consisting of:
8. The compound or salt of claim 3, wherein Ri is R4, wherein R4 Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
9. The compound or salt of claim 3, wherein Ri is -NHR5, wherein R5 is aryl optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl.
10. The compound or salt of claim 3, wherein Ri is -OR5, wherein 5 is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl.
11. The compound or salt of claim 1 or 2, wherein A is 1 ,2-heteroarylenyl optionally substituted with one or more subsitutents independently selected from halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
13. The compound or salt of claim 11 or 12, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3, C1-C10 alkyl, C1-C10 alkyloxy,Ci- C10 haloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
14. The compound or salt of any one of claims 11-13, wherein R3 is
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
15. The compound or salt of any one of claims 11-14, wherein the compound is selected from the group consisting of:
16. The compound or salt of claim 1 or 2, wherein A is -CH2CH2-
17. The compound or salt of claim 16, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3 C1-C10 alkyl, C1-C10 alkyloxy, C1-C10 haloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
18. The compound or salt of claiml7, wherein R3 is 2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkoxyphenyl.
19. The compound or salt of any one of claims 16-18, wherein the compound is:
20. A pharmaceutical composition comprising a compound or salt according to any of claims 1-19, and a pharmaceutically acceptable carrier.
21. A method for therapeutic intervention in a facet of mammalian health that is mediated by a mammalian relaxin receptor 1, the method comprising administering to a mammal in need thereof an effective amount of a compound of the formula (I):
wherein A is 1 ,2-phenylenyl, 1,2-heteroarylenyl, 1,2-heterocyclyl, and -CH2CH2-, wherein the 1 ,2-phenylenyl, 1,2-heteroarylenyl, or 1,2-heterocyclyl, each of which are optionally substituted with one or more substituents independently selected from halo, CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and S02CF3,
Ri is selected from -NHCOR3, R4, -NHR5, and -ORe,
R2 is selected from alkyl, cycloalkyl, heteroarylalkyl, and phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, C1-C10 haloalkyl, Ci-Ciohaloalkoxy, aryl, haloalkylaryl, heterocyclylalkyl, -SR7, -SOR7, -S02R7, -SCF3, -N02, -CN, and -S02CF3,
R3 is selected from the group consisting of alkyl, cycloalkyl, bicycloalkyl,
tricycloalkyl, aryl, heteroaryl, arylalkyl, and phenyl, which are optionally substituted with one or more substituents independently selected from halo, CF3, C1-C10 alkyl, C2-Cio alkenyl, C1-C10 alkyloxy, C1-C10 haloalkyl, Ci-Ciohaloalkoxy, - SR7, -SOR7, -S02R7, -SCF3, -N02,-CN, and -S02CF3,
R4 is phenyl optionally substituted with alkyloxy, haloalkoxy, arylalkyl, or
arylalkyloxy,
R5 is selected from hydrogen, alkyl, alkylaryl, aryl, alkylcycloalkyl, and
cycloalkylalkyl which are optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl,
Re is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl,
and R7 is C1-C10 alkyl, C1-C10 haloalkyl, or haloalkoxy,
or a pharmaceutically acceptable salt thereof.
22. The method of claim 21, wherein R2 is phenyl substituted with a substituent selected from -S02CF3, -SCF3, and -CF3.
23. The method of claim 21 or 22, wherein A is 1 ,2-phenylene optionally substituted with one or more substituents independently selected from hydrogen, halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
24. The method of claim 23, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent independently selected from -CF3, Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Ciohalo alkyl, Ci-Ciohaloalkoxy„ alkyloxyalkyloxy, dimethylammoalkyloxy, - SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
25. The method of claim 23 or 24, wherein R3 is 2-(Ci-Cio)alkyloxyphenyl.
26. The method of any one of claims 21-25, wherein R2 is phenyl substituted with a substituent selected from Ci-Cio alkyl, Ci-Cio alkyloxy, Ci-Cio haloalkyl, Ci- Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
27. The method of any one of claims 23-26, wherein the compound is selected from the group consisting of:
28. Themethod of claim 23, wherein Ri is R4, wherein R4 is
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
29. The method of claim 23, wherein Ri is -NHR5, wherein R5 is aryl optionally substituted with one or more substituents independently selected from alkyloxy and trifluoromethyl.
30. The method of claim 23, wherein Ri is -OR6, wherein R^ is alkyl optionally substituted with alkylamino, dialkylamino, alkyloxy, and heteroaryl
31. The method of claim 21 or 22, wherein A is 1 ,2-heteroarylenyl optionally substituted with one or more subsitutents independently selected from halo, -CF3, alkyl, alkyloxy, haloalkyl, haloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
33. The method of claim 31 or 32, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3, C1-C10 alkyl, C1-C10 alkyloxy, trihalo C1-C10 alkyl, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
34. The method of any one of claims 31-33, wherein R3 is
2-(Ci-Cio)alkyloxyphenyl or 2-(Ci-Cio)haloalkyloxyphenyl.
35. The method of any one of claims 31-34, wherein the compound is selected from the group consisting of:
36. The method of claim 1 or 2, wherein A is -CH2CH2-
37. The method of claim 36, wherein Ri is -NHCOR3, wherein R3 is phenyl substituted with a substituent selected from -CF3, C1-C10 alkyl, C1-C10 alkyloxy, Ci- Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, -S02R7, -SCF3, and -S02CF3.
38. The method of claim 37, wherein R3 is 2-(Ci-Cio)alkyloxyphenyl or
2-(C 1 -C 1 o)haloalkyloxyphenyl.
39. The method of any one of claims 36-38, wherein the compound is:
40. The method of any one of claims 21-39, wherein the facet of mammalian health is cardiovascular disease.
41. The method of claim 40, wherein the cardiovascular disease is selected from myocardial ischemia-reperfusion injury, cardiac fibrosis, acute congestive heart failure, cerebrovascular disease and stroke, post-infarction heart, cardiac anaphylaxis, cerebral ischemia (stroke), intestinal ischemia-reperfusion injury, systemic and pulmonary
hypertension, vascular inflammation, hypertension, high blood pressure; left ventricular hypertrophy (LVH); vasodilation; renal hypertension; diuresis; nephritis; natriuresis;
scleroderma renal crisis; angina pectoris (stable and unstable); myocardial infarction; heart attack; coronary artery disease; coronary heart disease; cardiac arrhythmias; atrial fibrillation; portal hypertension; raised intraocular pressure; vascular restenosis; chronic hypertension; valvular disease; myocardial ischemia; acute pulmonary edema; acute coronary syndrome; hypertensive retinopathy; hypertensive pregnancy sickness; Raynaud's phenomenon; erectile dysfunction, glaucoma, and preeclampsia.
42. The method of any one of claims 21-39, wherein the facet of mammalian health is dyspnea associated with acute heart failure in a mammal, wherein the mammal has dyspnea associated with acute heart failure and is in a hypertensive or normotensive state at the onset of said administering.
43. The method of any one of claims 21-39, wherein the facet of mammalian health is acute decompensated heart failure, wherein the method is effective to reduce in- hospital worsening of said acute decompensated heart failure in the mammal.
44. The method of claim 43, wherein said in-hospital worsening of said acute decompensated heart failure comprises one or more of worsening dyspnea, need for additional therapy to treat said heart failure, need for mechanical support of breathing, and need for mechanical support of blood pressure.
45. The method of claim 43, further comprising a reduction in the risk of death or rehospitalization of the mammal.
46 The method of any one of claims 21-39, wherein the facet of mammalian health is fibrotic disease.
47. The method of claim 46, wherein the fibrotic disease is selected from pulmonary fibrosis, renal tubulo interstitial fibrosis, mesangial proliferative nephritis, hepatic fibrosis (cirrhosis) alcohol and non-alcohol related (including viral infection such as HAV, HBV and HCV); fibromatosis; granulomatous lung disease; glomerulonephritis, myocardial scarring following infarction; endometrial fibrosis and endometriosis, polycystic kidney disease, scleroderma and systemic sclerosis, keloids, arthritis, autoimmune disorder, inflammatory condition associated with infection, skeletal muscle injuries, conditions involving tissue remodeling following inflammation or ischemia-reperfusion injury and is selected from the group consisting of endomyocardial and cardiac fibrosis; mediastinal fibrosis; retroperitoneal fibrosis; fibrosis of the spleen; fibrosis of the pancreas; wound healing whether by injury or surgical procedures, diabetes related wound fibrosis.
48. The method of any one of claims 21-39, wherein the facet of mammalian health is respiratory disease selected from asthma, bronchial disease, lung diseases, chronic obstructive pulmonary disease (COPD), Acute Respiratory Distress Syndrome (ARDS), severe acute respiratory syndrome (SARS), Fibrosis related Asthma, and cystic fibrosis.
49. The method of any one of claims 21-39, wherein the facet of mammalian health is skin disease selected from dermal repair, wound healing; burns, erythemas, lesions, wound healing following surgical procedures; skin or tissue lesions including lesions induced by Psoriasis, Lupus and Kaposhi Sarcoma; Scleroderma, and collagenous diseases of the skin and skin tumors.
50. The method of any one of claims 21-39, wherein the facet of mammalian health is female reproduction.
51. The method of claim 50, wherein the facet of female reproduction is selected from in vitro fertilization, abnormal implantation, pre-term birth and induction of labor, mammary functions and lactation disorders;, plasma osmolarity during pregnancy, uterine fibroids, abnormal endometrial angiogenesis; placental development defects; cervical ripening (softening); nipple development and disfunction; pregnancy related remodeling of the uterine tissue; endometriosis; preeclampsia; estrogenic and non-estrogenic related hormonal disorders; pre-term labor; post term labor; and labor complications.
52. The method of any one of claims 21-39, wherein the facet of mammalian health is male reproduction.
53. The method of claim 52, wherein the facet of male reproduction is selected from sperm function and fertilization.
54. The method of any one of claims 21-39, wherein the facet of mammalian health is surgical transplantation of a liver.
55. The method of any one of claims 21-39, wherein the facet of mammalian health is a cancer selected from colon cancer, lung cancer, breast cancer, prostate cancer,
brain cancer, pancreatic cancer, ovarian cancer, kidney cancer, testicular cancer, bone cancer, osteosarcoma, liver cancer, melanoma, glioma, sarcoma, leukemia, or lymphoma, and wherein the cancer is invasive or metastatic.
56. The method of any one of claims 21-39, wherein the facet of mammalian health is enhancement of drug delivery in the treatment of a solid cancer, in combination with a chemotherapeutic treatment or radiation treatment of the cancer.
57. The method of any one of claims 21-39, wherein the facet of mammalian health is orthodontic tooth movement.
58. The method of any one of claims 21-39, wherein the facet of mammalian health is bone joint disease.
59. The method of any one of claims 21-39, wherein the facet of mammalian health is selected from osteoporosis; osteoarthritis; osteopetrosis; bone inconsistency;
osteosarcoma; and cancer metastasis to the bone.
60. The method of any one of claims 21-39, wherein the facet of mammalian health is diabetes mellitus.
61. The method of any one of claims 21-39, wherein the facet of mammalian health is ischemia-reperfusion injury associated with ischemic and post-ischemic events in organs and tissues and in a group of patients with thrombotic stroke; myocardial infarction; angina pectoris; embolic vascular occlusions; peripheral vascular insufficiency; splanchnic artery occlusion; arterial occlusion by thrombi or embolisms, arterial occlusion by non- occlusive processes such as following low mesenteric flow or sepsis; mesenteric arterial occlusion; mesenteric vein occlusion; ischemia-reperfusion injury to the mesenteric microcirculation; ischemic acute renal failure; ischemia-reperfusion injury to the cerebral tissue; intestinal intussusception; hemodynamic shock; tissue dysfunction; organ failure; restenosis; atherosclerosis; thrombosis; platelet aggregation, ischemia-reperfusion injury following cardiac surgery; organ surgery; organ transplantation; angiography;
cardiopulmonary and cerebral resuscitation.
62. The method of any one of claims 21-39, wherein the facet of mammalian health is an inflammatory condition associated with an infection, wherein the infection is selected from a viral infection caused by human immunodeficiency virus I (HIV-1) or HIV-2, acquired immune deficiency (AIDS), West Nile encephalitis virus, coronavirus, rhinovirus, influenza virus, dengue virus, HCV, HBV, HAV, hemorrhagic fever; an otological infection; severe acute respiratory syndrome (SARS), sepsis and sinusitis.
63. The method of any one of claims 21-39, wherein the facet of mammalian health is kidney diseases selected from diabetic nephropathy; glomerulosclerosis;
nephropathies; renal impairment; scleroderma renal crisis and chronic renal failure.
64. The method of any one of claims 21-39, wherein the facet of mammalian health is an angiogenesis related condition selected from retinal angiogenesis in a number of human ocular diseases such as diabetes mellitus, retinopathy of prematury, and age-related macular degeneration, or cancer associated angiogenesis in primary or metastatic cancer, including but not limited to cancer of the prostate, brain, breast, colorectal, lung, ovarian, pancreatic, renal, cervical, melanoma, soft tissue sarcomas, lymphomas, head-and-neck, and glioblastomas.
65. The method of any one of claims 21-39, wherein the facet of mammalian health is an inflammatory disorder selected from of gastritis, gout, gouty arthritis, arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ulcers, chronic bronchitis, asthma, allergy, acute lung injury, pulmonary inflammation, airway hyper-responsiveness, vasculitis, septic shock and inflammatory skin disorders, including but not limited to psoriasis, atopic dermatitis, eczema.
66. The method of any one of claims 21-39, wherein the facet of mammalian health is an autoimmune disorder is selected from f multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, transplant rejection, immune disorders associated with graft transplantation rejection, benign
lymphocytic angiitis, lupus erythematosus, Hashimoto's thyroiditis, primary myxedema,
Graves' disease, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, insulin dependent diabetes mellitis, Good pasture's syndrome, myasthenia gravis, pemphigus, sympathetic ophthalmia, autoimmune uveitis, autoimmune hemolytic anemia, idiopathic thrombocytopenia, primary biliary cirrhosis, chronic action hepatitis, ulceratis colitis, Sjogren's syndrome, rheumatic disease, polymyositis, scleroderma, mixed connective tissue disease, inflammatory rheumatism, degenerative rheumatism, extra-articular rheumatism, collagen diseases, chronic polyarthritis, psoriasis arthropathica, ankylosing spondylitis, juvenile rheumatoid arthritis, periarthritis humeroscapularis, panarteriitis nodosa, progressive systemic scleroderma, arthritis uratica, dermatomyositis, muscular rheumatism, myositis, myogelosis, and chondrocalcinosis.
67. The method of any one of claims 21-39, wherein the facet of mammalian health is an behavioral abnormality or disease.
68. The method of any one of claims 21-67, wherein the facet of mammalian health is a facet of human health.
69. The method of any one of claims 21-68, wherein the mammalian relaxin receptor 1 is a human relaxin receptor 1.
70. The method of any one of claims 21-69, wherein the mammal is a human.
71. A com ound or pharmaceutically acceptable salt thereof, having the formula
where
is a 3- to 8-membered carbocyclic ring or a 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, each of which A ring is optionally fused to a 3- to 8-membered carbocyclic ring or a 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, to form a bicylic ring system; and the A ring and 3 - to 8--membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with R10; m, n, o, and p are integers independently chosen from 0, 1, and 2 and each
W n , W 0 , and W P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy;
X and Y are independently chosen from O and S;
Rs and R9 are independently chosen from hydrogen and Ci-C4alkyl;
Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is NO2, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
A compound or salt of Claim 71, wherein
is a group of formula
each of which is substituted with R 10·
73. A compound or salt of Claim 71 or 72, wherein m, n, o, and p are all 0 and X and Y are both O. 4. A compound or salt thereof of Claim 71 , having the formula
Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is NO2, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
75. A compound or salt of Claim 74, wherein R2o is Ci-Cehaloalkyl, -S(Ci- C6haloalkyl), or -S02(Ci-C6haloalkyl).
76. A compound or salt therof of Claim 74, wherein Rio, R21, and R31 are each 0 substituents.
77. A compound or salt thereof of claim 74, wherein Rio, R21, and R3i are each 0 substituents; R20 is CF3, SCF3, or S02CF3i and R3o is C2-C6alkoxy or C2-C6alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and -CF3.
A compound or salt thereof of any one of Claims 74 to 77, wherein R20
A compound or pharmaceutically acceptable salt thereof, having the formula
Rio and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy; and
R2 is (phenyl)Co-C2alkyl- or (5- or 6-membered heteroaryl)Co-C2alkyl, each of which is substituted with 0 or 1 or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7Cycloalkyl)Co-C2alkyl, 5- and 6-membered heterocycloalkyl, thienyl, phenyl, phenyl substituted with CF3, mono- and di-Ci-Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy, -SR7, -SOR7, and -SO2R7, where R7 is Ci-Ciocarbhydryl or Ci-Ciohaloalkyl; or
R2 is dihydroindenyl, benzo[<i][l,3]dioxolyl, or indolyl, each of which is substituted with 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- or di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci- C2haloalkoxy.
80. A compound or salt thereof of Claim 79, wherein Rio and R31 are both 0 substituents.
81. A compound or salt thereof of Claim 79 or 80, wherein
R2 is phenyl substituted with one or two substituents independently chosen from hydroxyl, halogen, nitro, SCF3, SC>2CF3, Ci-Cealkyl, C2-C6alkenyl, C2-C6alkynyl, 5- and 6- membered heterocycloalkyl, thienyl, phenyl, phenyl substituted with CF3, mono- and di-Ci- Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci-C4alkoxy, Ci-C2haloalkyl, and Ci- C2haloalkoxy.
82. A compound or salt thereof of Claim 79 or 80, wherein R2 is phenyl substituted in the meta position with CF3, SCF3, or S02CF3.
83. A compound or salt thereof of Claim 79 or 80, wherein
R2 is 2,3-dihydro-lH-indenyl, benzo[<i][l,3]dioxolyl, or indolyl, each of which is unsubstituted.
84. A compound or pharmaceutically acceptable salt thereof, having the formula
Rio and R2i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbhydryl or Ci-Ciohaloalkyl;; and
R3 is cyclohexyl; or
R3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF3, S02CF3, Ci-Cealkyl, C2-C6alkenyl, C2- C6alkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-C6alkylthio, Ci-C6alkylsulfonyl Ci- C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
85. A compound or salt of Claim 84, wherein R10 and R2i are both 0 substituents and R3 is phenyl substituted with one meta-position substituent.
86. A compound or salt of Claim 84 or 85, wherein Rio and R2i are both 0 substituents and R2o is CF3, SCF3, or S02CF3.
87. A compound or salt of Claim 84, wherein R2o is CF3; and
R3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF3, SO2CF3, Ci-Cealkyl, C2-C6alkenyl, C2- C6alkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-C6alkylthio, Ci-Cealkylsulfonyl Ci- C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
88. A compound or salt of Claim 84, wherein R2o is SO2CF3; and
R3 is phenyl substituted with one or more substituents independently chosen from hydroxyl, halogen, nitro, cyano, amino, SCF3, SO2CF3, Ci-Cealkyl, C2-Cealkenyl, C2- Cealkynyl, phenyl mono- and di-Ci-Cealkylamino, Ci-Cealkylthio, Ci-Cealkylsulfonyl Ci- C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy. 9. A compound or salt thereof of Claim 71, wherein
90. A compound or salt of Claim 89, wherein R10, R21, and R31 are each 0 substituents.
91. A compound or salt of Claim 89 or 90, wherein each of m, n, o, and p are 0 and X and Y are both O.
92. A compound or salt of any one of Claims 89 to 91, wherein
R20 is NO2, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl; and
R30 is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
93. A compound or salt of Claim 92, wherein R2o is Ci-Cehaloalkyl, -S(Ci- C6haloalkyl), or -S02(Ci-C6haloalkyl).
94. A compound or salt thereof of Claim 93, wherein R10, R21, and R31 are each 0 substituents; R20 is CF3, SCF3, or S02CF3i and R3o is C2-C6alkoxy or C2-C6alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and -CF3.
95. A compound or salt thereof of any one of Claims 89 to 94, wherein R20 is S02CF3.
96. A compound or pharmaceutically acceptable salt thereof, having the formula
m
, n, o, and p are integers independently chosen from 0, 1, and 2 and each of n , 0 , and P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy;
X and Y are independently chosen from O and S;
Rs and R9 are independently chosen from hydrogen and Ci-C4alkyl;
Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is N02, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
97. A compound or salt of Claim 96, wherein m, n, o, and p are all 0 and X and Y are both O.
98. A compound or salt thereof of Claim 97, having the formula
Rio, R21 , and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is NO2, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
R3o is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
Rio, R21, and R31 are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is NO2, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Cioalkyl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Csalkoxy or Ci-Csalkylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci- C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
100. A compound or salt of Claim 98 or 99, wherein R2o is Ci-Cehaloalkyl, -S(Ci- C6haloalkyl), or -S02(Ci-C6haloalkyl).
101. A compound or salt therof of any one of Claims 98 to 100, wherein R21, and R31 are both 0 substituents.
102. A compound or salt thereof of any one of Claims 98 to 100, wherein R21 and R3i are both 0 substituents; R20 is CF3, SCF3, or S02CF3i and R3o is C2-C6alkoxy or C2- C6alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and -CF3.
103. A compound or salt thereof of any one of Claims 98 to 102, wherein R20 is S02CF3..
A compound or pharmaceutically acceptable salt thereof, having the formula
membered carbocyclic ring and a 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, each of which A ring is optionally fused to a 3- to 8-membered carbocyclic ring or a 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, to form a bicylic ring system; the A ring and 3 - to 8--membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with R10;
the B ring and 3 - to 8— membered carbocyclic or heterocyclic ring to which B is optionally fused are each substituted with R3i;
the C ring and 3 - to 8— membered carbocyclic or heterocyclic ring to which C is optionally fused are each substituted with R2i; m, n, o, and p are integers independently chosen from 0, 1, and 2 and each of
, n , 0 , and P , is unsubstituted or substituted with one or more substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy;
X and Y are independently chosen from O and S;
Rs and R9 are independently chosen from hydrogen and Ci-C4alkyl;
Rio, R21, and R3i are each 0 to 3 substitutents independently chosen from hydroxyl, halogen, nitro, cyano, amino, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-(Ci-C2alkyl)amino-, Ci-C2haloalkyl, and Ci-C2haloalkoxy;
R20 is NO2, CN, Ci-Ciohaloalkyl, Ci-Ciohaloalkoxy, -SR7, -SOR7, or -S02R7, where R7 is Ci-Ciocarbyhdryl or Ci-Ciohaloalkyl;
R30 is hydrogen or R30 is Ci-Cscarbhydryloxy or Ci-Cscarbhydrylthio- each or which is substituted with 0 to 3 substituents independently chosen from hydroxyl, halogen, nitro, cyano, Ci-C4alkyl, Ci-C4alkoxy, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
105. A compound or salt of Claim 104, wherein
where
each independently chosen from phenyl and a 5- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, each of which A ring is optionally fused to a 5 - to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, to form a bicylic ring system;
the A ring and 5 - to 6--membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with Ri0;
the B ring and 5 - to 6— membered carbocyclic or heterocyclic ring to which B is optionally fused are each substituted with R31; and
the C ring and 5 - to 6— membered carbocyclic or heterocyclic ring to which C is optionally fused are each substituted with R2i .
is substituted with R10.
107. A compound or salt of any one of Claims 104 to 106, wherein m, n, o, and p are all 0, X and Y are both O; and Rs and Rgare both hydrogen. compound or salt of any one of Claims 104 to 107, wherein
is cyclohexyl, pyridyl, or phenyl, each of which is substituted with R30 and optionally substituted with R3i. pound or salt of any one of Claims 104 to 108 wherein
is a pyridyl, phenyl, or indolyl, each of which is substituted with R2o and optionally substituted with R2i.
110. A compound or salt of any one of Claims 104 to 109, wherein R2o is Ci- Cehaloalkyl, -S(Ci-C6haloalkyl), or -S02(Ci-C6haloalkyl).
111. A compound or salt therof of Claim 110 wherein Rio, R21, and R3i are each 0 substituents.
112. A compound or salt thereof of any one of Claims 104 to 110, wherein Rio, R2i, and R3i are each 0 substituents; R2o is CF3, SCF3, or S02CF3i and R3o is C2-C6alkoxy or C2- C6alkylthio-, each of which is substituted with 0 to 2 substituents independently chosen from halogen and -CF3.
113. A mpound or salt of Claim 71 , wherein
wherein
is phenyl or a 5-to 6-membered heteroaryl ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, each of which A ring is optionally fused
to a 5- to 6-membered carbocyclic ring or a 5-to 6—membered heterocyclic ring containing 1 to 3 heteroatoms independently chosen from N, O, and S, to form a bicylic ring system; and the A ring and 5- to 6-membered carbocyclic or heterocyclic ring to which A is optionally fused are each substituted with R10.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES13715054T ES2929283T3 (en) | 2012-05-04 | 2013-03-15 | Relaxin 1 receptor modulators |
US14/398,830 US9452973B2 (en) | 2012-05-04 | 2013-03-15 | Modulators of the relaxin receptor 1 |
EP13715054.6A EP2844345B1 (en) | 2012-05-04 | 2013-03-15 | Modulators of the relaxin receptor 1 |
US15/247,438 US10125112B2 (en) | 2012-05-04 | 2016-08-25 | Modulators of the relaxin receptor 1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642986P | 2012-05-04 | 2012-05-04 | |
US61/642,986 | 2012-05-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/398,830 A-371-Of-International US9452973B2 (en) | 2012-05-04 | 2013-03-15 | Modulators of the relaxin receptor 1 |
US15/247,438 Division US10125112B2 (en) | 2012-05-04 | 2016-08-25 | Modulators of the relaxin receptor 1 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013165606A1 true WO2013165606A1 (en) | 2013-11-07 |
Family
ID=48050923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/032231 WO2013165606A1 (en) | 2012-05-04 | 2013-03-15 | Modulators of the relaxin receptor 1 |
Country Status (4)
Country | Link |
---|---|
US (2) | US9452973B2 (en) |
EP (1) | EP2844345B1 (en) |
ES (1) | ES2929283T3 (en) |
WO (1) | WO2013165606A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016016728A3 (en) * | 2014-07-31 | 2016-08-11 | University College Cardiff Consultants Limited | Bcl-3 inhibitors |
CN106349244A (en) * | 2015-07-13 | 2017-01-25 | 首都医科大学 | Benzo imidazo quinazoline dimethyl oxygen benzene oxygen acetyl-AA-OBzl, as well as synthesis, activity and application thereof |
JP2017109982A (en) * | 2015-12-11 | 2017-06-22 | ロート製薬株式会社 | Anthranilamide derivative and tlr3-associated disease therapeutic agent comprising the same |
CN107417565A (en) * | 2017-07-26 | 2017-12-01 | 温州医科大学 | Act on the FGFR1 dimethoxy benzene yl-benzamide derivatives of 4 bromine N 3,5 and its preparation and application |
CN108531447A (en) * | 2018-04-13 | 2018-09-14 | 上海市计划生育科学研究所 | Adjust the compound and application thereof of Sperm Motility and supplementary reproduction |
WO2018183122A1 (en) * | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
US10258636B2 (en) | 2013-11-06 | 2019-04-16 | Aeromics, Inc. | Prodrug salts |
WO2019179436A1 (en) * | 2018-03-20 | 2019-09-26 | 成都海创药业有限公司 | Acid amide compound and use thereof in treatment of cancers |
CN111825585A (en) * | 2019-09-23 | 2020-10-27 | 山东康乔生物科技有限公司 | Aryl sulfide containing benzylamine structure and synthesis method and application thereof |
IT201900006543A1 (en) * | 2019-05-06 | 2020-11-06 | Isagro Spa | Compounds with fungicidal activity, relative agronomic compositions and use for the control of phytopathogenic fungi |
CN111909053A (en) * | 2020-08-06 | 2020-11-10 | 湖北省生物农药工程研究中心 | Diarylamine unit-based amide derivative and preparation method and application thereof |
US11084778B2 (en) | 2012-05-08 | 2021-08-10 | Aeromics, Inc. | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia |
WO2022076565A1 (en) * | 2020-10-07 | 2022-04-14 | Sorrento Therapeutics, Inc. | Salicylanilide analogs for use in the treatment of coronavirus |
WO2022122773A1 (en) | 2020-12-08 | 2022-06-16 | Astrazeneca Ab | 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure |
WO2023077070A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 agonists |
WO2023077041A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 modulators for the treatment of heart failure |
WO2023077040A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 agonists |
WO2023076626A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 agonists |
WO2023114823A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Benzothiophene derivatives as rxfp1 agonists |
WO2023114818A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Naphthalene and quinoline analogs as rxfp1 agonists |
WO2023114824A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Bicyclo [3.2.0] heptane bis(amide) rxfp1 agonists |
WO2023114822A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Benzothiazole, benzoisoxazole and benzodioxole analogs as rxfp1 receptor agonists |
WO2023114819A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Tetraline, phenylcyclobutane, and phenylcyclopentane analogs as rxfp1 agonists |
EP3984534A4 (en) * | 2019-06-19 | 2023-07-19 | Sunshine Lake Pharma Co., Ltd. | Diarylamide compound and application thereof |
WO2023237512A1 (en) | 2022-06-07 | 2023-12-14 | Astrazeneca Ab | Combinations of rxfp1 modulators and sglt2 inhibitors |
WO2023237511A1 (en) | 2022-06-07 | 2023-12-14 | Astrazeneca Ab | Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension |
WO2023237510A1 (en) | 2022-06-07 | 2023-12-14 | Astrazeneca Ab | Solid forms of rxfp1 modulators |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2929283T3 (en) | 2012-05-04 | 2022-11-28 | Us Health | Relaxin 1 receptor modulators |
MX2017000135A (en) | 2014-06-27 | 2017-04-10 | Nogra Pharma Ltd | Aryl receptor modulators and methods of making and using the same. |
JP2019131470A (en) * | 2016-05-20 | 2019-08-08 | 石原産業株式会社 | Pest control agent containing n-(4-pyridyl) benzamide compound or salt thereof as active ingredient |
US20220211614A1 (en) * | 2019-05-24 | 2022-07-07 | Commonwealth Scientific And Industrial Research Organisation | Compositions and implantable devices |
CN111646933B (en) * | 2020-06-04 | 2021-06-08 | 广州市朝利良生物科技有限公司 | Application of micromolecular compound in preparation of anti-tumor metastasis medicine |
US11235033B1 (en) * | 2020-11-06 | 2022-02-01 | The Florida International University Board Of Trustees | Materials and methods for the treatment of vascular calcification |
CN113651768A (en) * | 2021-03-24 | 2021-11-16 | 南华大学 | N-aryl anthranilamide compound and preparation and application thereof |
CN115108931A (en) * | 2022-04-02 | 2022-09-27 | 南华大学附属第一医院 | Tofenamic acid derivative and preparation and application thereof |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
US20020120007A1 (en) * | 1997-06-26 | 2002-08-29 | Beight Douglas Wade | Antithrombotic agents |
US20030195223A1 (en) * | 1997-06-26 | 2003-10-16 | Beight Douglas Wade | Antithrombotic agents |
EP1839655A1 (en) * | 2005-01-20 | 2007-10-03 | Shionogi Co., Ltd. | Ctgf expression inhibitor |
US20080206287A1 (en) * | 2006-09-18 | 2008-08-28 | Reed John C | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands |
US20110144135A1 (en) * | 2005-11-04 | 2011-06-16 | Hydra Biosciences, Inc. | Compounds for Modulating TRPV3 Function |
US20110177998A1 (en) | 2007-07-12 | 2011-07-21 | Ronen Shemesh | Bioactive peptides and methods of using same |
US8053411B2 (en) | 2008-05-16 | 2011-11-08 | Corthera, Inc. | Method of treating dyspnea associated with acute heart failure |
US20110294807A1 (en) * | 2009-01-08 | 2011-12-01 | Hansen Henrik C | Compounds for the prevention and treatment of cardiovascular disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0934068A1 (en) | 1996-09-09 | 1999-08-11 | Smithkline Beecham Corporation | Compounds and methods |
WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
ES2929283T3 (en) | 2012-05-04 | 2022-11-28 | Us Health | Relaxin 1 receptor modulators |
-
2013
- 2013-03-15 ES ES13715054T patent/ES2929283T3/en active Active
- 2013-03-15 EP EP13715054.6A patent/EP2844345B1/en active Active
- 2013-03-15 US US14/398,830 patent/US9452973B2/en active Active
- 2013-03-15 WO PCT/US2013/032231 patent/WO2013165606A1/en active Application Filing
-
2016
- 2016-08-25 US US15/247,438 patent/US10125112B2/en active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
US20030195223A1 (en) * | 1997-06-26 | 2003-10-16 | Beight Douglas Wade | Antithrombotic agents |
US20020120007A1 (en) * | 1997-06-26 | 2002-08-29 | Beight Douglas Wade | Antithrombotic agents |
EP1839655A1 (en) * | 2005-01-20 | 2007-10-03 | Shionogi Co., Ltd. | Ctgf expression inhibitor |
US20110144135A1 (en) * | 2005-11-04 | 2011-06-16 | Hydra Biosciences, Inc. | Compounds for Modulating TRPV3 Function |
US20080206287A1 (en) * | 2006-09-18 | 2008-08-28 | Reed John C | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands |
US20110177998A1 (en) | 2007-07-12 | 2011-07-21 | Ronen Shemesh | Bioactive peptides and methods of using same |
US8053411B2 (en) | 2008-05-16 | 2011-11-08 | Corthera, Inc. | Method of treating dyspnea associated with acute heart failure |
US20110294807A1 (en) * | 2009-01-08 | 2011-12-01 | Hansen Henrik C | Compounds for the prevention and treatment of cardiovascular disease |
Non-Patent Citations (19)
Title |
---|
"Pharmaceutics and Pharmacy Practice", 1982, J. B. LIPPINCOTT COMPANY, pages: 238 - 250 |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, pages: 1445 |
ANNE J. RÜGER ET AL: "Synthesis of tetra-substituted pyrazoles", TETRAHEDRON, vol. 68, no. 42, 1 October 2012 (2012-10-01), pages 8823 - 8829, XP055068966, ISSN: 0040-4020, DOI: 10.1016/j.tet.2012.07.069 * |
BAYLIS. C., AM. J. KIDNEY DIS., vol. 34, 1999, pages 1142 - 4 |
E.T. VAN DER WESTHUIZEN ET AL., CURRENT DRUG TARGETS, vol. 8, 2007, pages 91 - 104 |
FEVOLD. H.L. ET AL., J AM. CHEM. SOC., vol. 52, no. 8, 1930, pages 3340 - 3348 |
HIROKI KAKUTA ET AL: "Cyclooxygenase-1-Selective Inhibitors Are Attractive Candidates for Analgesics That Do Not Cause Gastric Damage. Design and in Vitro/in Vivo Evaluation of a Benzamide-Type Cyclooxygenase-1 Selective Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 8, 1 April 2008 (2008-04-01), pages 2400 - 2411, XP055068730, ISSN: 0022-2623, DOI: 10.1021/jm701191z * |
HISAW, F.L., PROC. SOC. EXP. BIOL. MED., vol. 23, no. 8, 1926, pages 661 - 663 |
I. R. GELLING ET AL: "Pyridopyrimidines. Part V. Syntheses and properties of pyrido[3,4-d]-pyrimidin-4(3H)-ones and -pyrimidine-2,4-(1H,3H)-diones", JOURNAL OF THE CHEMICAL SOCIETY C: ORGANIC, no. 6, 1 January 1969 (1969-01-01), pages 931, XP055068943, ISSN: 0022-4952, DOI: 10.1039/j39690000931 * |
JÁN KOZIC ET AL: "Synthesis and in vitro antimycobacterial activity of 2-methoxybenzanilides and their thioxo analogues", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, 1 October 2012 (2012-10-01), pages 387 - 395, XP055068727, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2012.07.044 * |
JOUMALOFPHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2 - 19 |
LINDA M. HAUGAARD-KEDSTROM ET AL: "Design, Synthesis, and Characterization of a Single-Chain Peptide Antagonist for the Relaxin-3 Receptor RXFP3", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, no. 13, 6 April 2011 (2011-04-06), pages 4965 - 4974, XP055069073, ISSN: 0002-7863, DOI: 10.1021/ja110567j * |
MENDEL ET AL: "Anthranilamide inhibitors of factor Xa", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 17, 4 August 2007 (2007-08-04), pages 4832 - 4836, XP022184918, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2007.06.051 * |
ROGER, V L ET AL., CIRCULATION, vol. 123, no. 4, 2011, pages 459 - 463 |
SCHRIER, R. W. ET AL., AM. J. KIDNEY DIS., vol. 9, 1987, pages 284 - 9 |
SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467 |
TEICHMAN S.L. ET AL., CURR. HEART FAILURE REP., vol. 7, 2010, pages 75 - 82 |
TOISSEL: "ASHP Handbook on Injectable Drugs 4th ed.,", 1986, pages: 622 - 630 |
WILEY M R ET AL: "Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 1,43, no. 5, 9 March 2000 (2000-03-09), pages 883 - 899, XP002373089, ISSN: 0022-2623, DOI: 10.1021/JM9903287 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11873266B2 (en) | 2012-05-08 | 2024-01-16 | Aeromics, Inc. | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke |
US11084778B2 (en) | 2012-05-08 | 2021-08-10 | Aeromics, Inc. | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia |
US10894055B2 (en) | 2013-11-06 | 2021-01-19 | Aeromics, Inc. | Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate |
US11801254B2 (en) | 2013-11-06 | 2023-10-31 | Aeromics, Inc. | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate |
US10258636B2 (en) | 2013-11-06 | 2019-04-16 | Aeromics, Inc. | Prodrug salts |
US11071744B2 (en) | 2013-11-06 | 2021-07-27 | Aeromics, Inc. | Prodrug salts |
WO2016016728A3 (en) * | 2014-07-31 | 2016-08-11 | University College Cardiff Consultants Limited | Bcl-3 inhibitors |
US10273218B2 (en) | 2014-07-31 | 2019-04-30 | University College Cardiff Consultants Limited | BCL-3 inhibitors |
CN106349244A (en) * | 2015-07-13 | 2017-01-25 | 首都医科大学 | Benzo imidazo quinazoline dimethyl oxygen benzene oxygen acetyl-AA-OBzl, as well as synthesis, activity and application thereof |
JP2017109982A (en) * | 2015-12-11 | 2017-06-22 | ロート製薬株式会社 | Anthranilamide derivative and tlr3-associated disease therapeutic agent comprising the same |
US11345676B2 (en) | 2017-03-27 | 2022-05-31 | Pharmakea, Inc. | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds |
WO2018183122A1 (en) * | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
CN107417565B (en) * | 2017-07-26 | 2020-02-14 | 温州医科大学 | 4-bromo-N-3, 5-dimethoxyphenylbenzamide derivative acting on FGFR1 and preparation and application thereof |
CN107417565A (en) * | 2017-07-26 | 2017-12-01 | 温州医科大学 | Act on the FGFR1 dimethoxy benzene yl-benzamide derivatives of 4 bromine N 3,5 and its preparation and application |
CN110305045A (en) * | 2018-03-20 | 2019-10-08 | 成都海创药业有限公司 | A kind of amides compound and its purposes in treating cancer |
WO2019179436A1 (en) * | 2018-03-20 | 2019-09-26 | 成都海创药业有限公司 | Acid amide compound and use thereof in treatment of cancers |
CN108531447A (en) * | 2018-04-13 | 2018-09-14 | 上海市计划生育科学研究所 | Adjust the compound and application thereof of Sperm Motility and supplementary reproduction |
IT201900006543A1 (en) * | 2019-05-06 | 2020-11-06 | Isagro Spa | Compounds with fungicidal activity, relative agronomic compositions and use for the control of phytopathogenic fungi |
WO2020225700A1 (en) * | 2019-05-06 | 2020-11-12 | Isagro S.P.A. | Compounds having a fungicidal activity, their agronomic compositions and use thereof for the control of phytopathogenic fungi |
EP3984534A4 (en) * | 2019-06-19 | 2023-07-19 | Sunshine Lake Pharma Co., Ltd. | Diarylamide compound and application thereof |
WO2021056922A1 (en) * | 2019-09-23 | 2021-04-01 | 山东康乔生物科技有限公司 | Aryl sulfide containing benzylamine structure, synthesis method therefor and application thereof |
EP4050000A4 (en) * | 2019-09-23 | 2023-06-28 | Shandong Kangqiao Bio-Technology Co., Ltd. | Aryl sulfide containing benzylamine structure, synthesis method therefor and application thereof |
JP2022531823A (en) * | 2019-09-23 | 2022-07-12 | 山東康喬生物科技有限公司 | Aryl sulfides containing a benzylamine structure and their synthetic methods and applications |
KR102644920B1 (en) * | 2019-09-23 | 2024-03-06 | 산둥 캉차오 바이오-테크놀로지 컴퍼니 리미티드 | Aryl group sulfide with benzylamine-containing structure and its synthesis method and application |
KR20210124389A (en) * | 2019-09-23 | 2021-10-14 | 산둥 캉차오 바이오-테크놀로지 컴퍼니 리미티드 | Aryl group sulfide with benzylamine-containing structure and its synthesis method and application |
CN111825585A (en) * | 2019-09-23 | 2020-10-27 | 山东康乔生物科技有限公司 | Aryl sulfide containing benzylamine structure and synthesis method and application thereof |
TWI801961B (en) * | 2019-09-23 | 2023-05-11 | 大陸商山東康喬生物科技有限公司 | Aryl sulfide containing benzylamine structure and its synthesis method and application |
JP7303893B2 (en) | 2019-09-23 | 2023-07-05 | 山東康喬生物科技有限公司 | Aryl sulfide containing benzylamine structure and its synthesis method and application |
CN111909053B (en) * | 2020-08-06 | 2022-12-06 | 湖北省生物农药工程研究中心 | Diarylamine unit-based amide derivative and preparation method and application thereof |
CN111909053A (en) * | 2020-08-06 | 2020-11-10 | 湖北省生物农药工程研究中心 | Diarylamine unit-based amide derivative and preparation method and application thereof |
WO2022076565A1 (en) * | 2020-10-07 | 2022-04-14 | Sorrento Therapeutics, Inc. | Salicylanilide analogs for use in the treatment of coronavirus |
WO2022122773A1 (en) | 2020-12-08 | 2022-06-16 | Astrazeneca Ab | 4-(2-fluoro-4-methoxy-5-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as rxfp1 modulators for the treatment of heart failure |
US11667602B2 (en) | 2020-12-08 | 2023-06-06 | Astrazeneca Ab | Compounds and their use |
WO2023077070A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 agonists |
WO2023077041A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 modulators for the treatment of heart failure |
WO2023077040A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 agonists |
WO2023076626A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Rxfp1 agonists |
WO2023114819A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Tetraline, phenylcyclobutane, and phenylcyclopentane analogs as rxfp1 agonists |
WO2023114823A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Benzothiophene derivatives as rxfp1 agonists |
WO2023114818A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Naphthalene and quinoline analogs as rxfp1 agonists |
WO2023114822A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Benzothiazole, benzoisoxazole and benzodioxole analogs as rxfp1 receptor agonists |
WO2023114824A1 (en) * | 2021-12-15 | 2023-06-22 | Bristol-Myers Squibb Company | Bicyclo [3.2.0] heptane bis(amide) rxfp1 agonists |
WO2023237512A1 (en) | 2022-06-07 | 2023-12-14 | Astrazeneca Ab | Combinations of rxfp1 modulators and sglt2 inhibitors |
WO2023237511A1 (en) | 2022-06-07 | 2023-12-14 | Astrazeneca Ab | Rxfp1 modulators for treating resistant hypertension or heart failure with pulmonary hypertension |
WO2023237510A1 (en) | 2022-06-07 | 2023-12-14 | Astrazeneca Ab | Solid forms of rxfp1 modulators |
Also Published As
Publication number | Publication date |
---|---|
EP2844345B1 (en) | 2022-08-03 |
US10125112B2 (en) | 2018-11-13 |
ES2929283T3 (en) | 2022-11-28 |
US20170144984A1 (en) | 2017-05-25 |
US9452973B2 (en) | 2016-09-27 |
US20150119426A1 (en) | 2015-04-30 |
EP2844345A1 (en) | 2015-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10125112B2 (en) | Modulators of the relaxin receptor 1 | |
AU2008321577B2 (en) | Bis-(sulfonylamino) derivatives in therapy 066 | |
KR102240101B1 (en) | Heterocyclyl compounds | |
AU2008248201A1 (en) | Compounds as CRTH2 and/or PGD2 receptors modulators and their use for treating asthma and allergic inflammation | |
WO2011120327A1 (en) | Anti-tumor medicament of structure of diarylurea or thiourea kind based on indazole or aza-indazole | |
CA2929562A1 (en) | Dimethylbenzoic acid compounds | |
EP1959944A1 (en) | A pharmaceutical composition comprising an amide derivative | |
WO2016035008A1 (en) | Pyridopyrimidine derivatives as mek inhibitors | |
TW201902885A (en) | Liver x receptor (lxr) modulators | |
WO2016009306A1 (en) | Heterocyclyl compounds as mek inhibitors | |
JP2019528262A (en) | Sulfonamides as GPR40-agonists and GPR120-agonists | |
CA2721576A1 (en) | Compound having npy y5 receptor antagonist activity | |
CA2921742A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
US8563557B2 (en) | Pyrimidine derivatives and their pharmaceutical use | |
CA2910255A1 (en) | Inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof | |
CA3104956C (en) | Novel lxr modulators with bicyclic core moiety | |
JP2008517930A (en) | Bissulfonamide compounds, compositions, and methods of use as agonists of GalR1 | |
EP3802498A1 (en) | Mitogen-activated protein kinase kinase 7 inhibitors | |
WO2021188728A1 (en) | Selective non-cyclic nucleotide activators for the camp sensor epac1 | |
CN113045488A (en) | Indoleamine 2, 3-dioxygenase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13715054 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14398830 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013715054 Country of ref document: EP |